0001213900-23-017302.txt : 20230303 0001213900-23-017302.hdr.sgml : 20230303 20230303170558 ACCESSION NUMBER: 0001213900-23-017302 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 44 CONFORMED PERIOD OF REPORT: 20221130 FILED AS OF DATE: 20230303 DATE AS OF CHANGE: 20230303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Better For You Wellness, Inc. CENTRAL INDEX KEY: 0001852707 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56262 FILM NUMBER: 23705516 BUSINESS ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 BUSINESS PHONE: 6143689898 MAIL ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 FORMER COMPANY: FORMER CONFORMED NAME: Fast Track Solutions, Inc. DATE OF NAME CHANGE: 20210322 10-Q 1 f10q1122_betterforyou.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended November 30, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to ______________

 

Commission File Number: 000-56262

 

BETTER FOR YOU WELLNESS, INC.

 

(Exact name of registrant as specified in its charter)

 

Nevada   87-2903933
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

c/o Ian James

1349 East Broad Street

Columbus, OH

  43205
(Address of principal executive offices)   (Zip Code)

 

1 (614) 368-9898

 

(Registrant’s telephone number, including area code)

 

N/A

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
 None   None    None 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒ No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒ No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ☐ Accelerated filer  ☐
Non-accelerated filer  ☐ Smaller reporting company  
  Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes  ☒ No  ☐

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of March 3, 2023, there were 404,014,987 shares of Common Stock, and 700,000 shares of Series A Preferred Stock issued and outstanding.

 

 

 

 

 

INDEX

 

    Page
PART I - FINANCIAL INFORMATION  
     
ITEM 1 FINANCIAL STATEMENTS – UNAUDITED
  CONSOLIDATED Balance Sheets as of November 30, 2022 (UNAUDITED) and February 28, 2022 1
  CONSOLIDATED Statements of Operations for the Three and Nine Months ended November 30, 2022 (UNAUDITED) and November 30, 2021 2
  STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) for the Three and Nine Months Ended November 30, 2022 (UNAUDITED) and November 30, 2021 3
  CONSOLIDATED Statement of Cash Flows for the Nine Months Ended November 30, 2022 (UNAUDITED) and November 30, 2021 4
  Notes to Condensed Consolidated Financial Statements (UNAUDITED) 5
     
ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS 15
ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 27
ITEM 4 CONTROLS AND PROCEDURES 27
     
PART II - OTHER INFORMATION  
     
ITEM 1 LEGAL PROCEEDINGS 29
ITEM 1A RISK FACTORS 29
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 29
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 29
ITEM 4 MINE SAFETY DISCLOSURES 29
ITEM 5 OTHER INFORMATION 29
ITEM 6 EXHIBITS 29
     
SIGNATURES 30

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Better For You Wellness, Inc.

Condensed Consolidated Balance Sheet (unaudited)

As of November 30, 2022 and February 28, 2022

 

   Consolidated     
   November 30,   February 28, 
   2022   2022 
ASSETS        
Current Asset:        
Cash and cash equivalents  $3,154   $9,642 
Accounts Receivable   1,495    - 
Related Party Receivable   108,301    - 
Prepaid expenses   23,425    - 
Inventory   1,657    - 
Prepaids and other assets    78,072    - 
Total Current assets   216,104    9,642 
Equipment, net   1,741    - 
Goodwill   583,484    - 
TOTAL ASSETS  $801,329   $9,642 
           
LIABILITIES AND STOCKHOLDER EQUITY (DEFICIT)          
Current Liabilities:          
Accounts Payable  $311,541   $375,408 
Deferred Compensation   284,499    - 
Clearbanc Debit Card   895    - 
Illinois Department of Revenue Payable   128    - 
Out Of Scope Agency Payable   414    - 
Related Party Notes Payable   202,000    - 
Total Current Liabilities  $799,478   $375,408 
Long-Term Liabilities          
Notes Payable - PayPal Capital   2,216    - 
Notes Payable Shopify Capital   166    - 
Convertible notes payable, net accumulated interest   599,111    - 
Total Liabilities  $1,400,970   $375,408 
           
STOCKHOLDERS’ EQUITY (DEFICIT):          
Preferred Stock ( $.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of November 30, 2022 and February 28, 2022)  $70   $70 
Common stock ($.0001 par value, 500,000,000 shares authorized, 389,995,988 and 370,747,042 issued and outstanding as of November 30, 2022 and February 28, 2022, respectively)   39,001    37,075 
Additional Paid in Capital   3,319,048    1,485,364 
Shares Cancelable   -    (250,000)
Accumulated Deficit   (3,957,760)   (1,638,275)
Total Stockholders’ Equity (Deficit)   (599,641)   (365,766)
TOTAL LIABILITIES & EQUITY (DEFICIT)  $801,329   $9,642 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

1

 

 

Better For You Wellness, Inc.

Condensed Consolidated Statements of Operations (Unaudited)

For the three and nine months ended November 30, 2022 and 2021

 

   Three Months Ended   Nine Months Ended 
   November 30,   November 30,   November 30,   November 30, 
   2022   2021   2022   2021 
Revenue                
Merchandise Sales  $6,986   $
-
   $9,008   $
-
 
Cost of Good Sold   5,823    
-
    15,381    
-
 
Gross Profit  $1,163   $
-
   $(6,373)  $
-
 
Operating Expenses                    
Share Based expense   346,762    532,243    1,332,475    609,243 
Selling, General and Administrative   258,401    533,854    852,184    542,910 
Total Operating Expenses   605,163    1,066,097    2,184,659    1,152,153 
                     
Operating Income/(Loss)   (604,000)   (1,066,097)   (2,191,032)   (1,152,153)
                     
Other Income/(Expense)                    
Interest Expense   (55,935)   
-
    (128,453)   
-
 
Other Expense   
-
    
-
    
-
    
-
 
Total Other Income   (55,935)   
-
    (128,453)   
-
 
                     
Net income/(loss)  $(659,936)  $(1,066,097)  $(2,319,485)  $(1,152,153)
                     
Loss per share  $(0.00)  $(0.00)  $(0.01)  $(0.00)
                     
Weighted average number of common shares outstanding   372,031,446    361,664,351    372,031,446    287,241,405 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

2

 

 

Better For You Wellness, Inc.
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit) (Unaudited)
For the three and nine months ended November 30, 2022 and 2021 (unaudited)

 

   Common Shares   Par Value Common Shares   Series A Preferred Shares   Par Value Series A Preferred Shares   Additional Paid-in Capital   Shares Cancelable   Accumulated Deficit   Total 
                                 
Balances, February 28, 2022   370,747,042   $37,075    700,000   $70   $1,485,364   $(250,000)  $(1,638,275)  $(365,766)
Common shares canceled and returned to the Company   (7,048,873)   (705)             (249,295)   250,000         0 
Common shares issued for cash previously received   325,000    33              (33)             
-
 
Common shares issued for services   5,085,000    509              272,226              272,735 
Common shares issued for purchase of subsidiary   11,000,000    1,100              548,900              550,000 
Stock option expense                       411,315              411,315 
Warrant Issuance                       78,072              78,072 
Warrant Issuance                       13,514              13,514 
Debt Forgiveness                       49,686              49,686 
Net loss                                 (891,872)   (891,872)
Balances, May 31, 2022   380,108,169   $38,012    700,000   $70   $2,609,749   $
-
   $(2,530,147)  $117,684 
Common shares issued for services   5,060,000    506              250,192              250,698 
Common shares issued for cash received   30,282    3              3,747              3,750 
Stock option expense                       274,025              274,025 
Warrant Issuance                       17,188              17,188 
Forfeiture of stock compensation                       (223,060)             (223,060)
Net loss                                 (767,677)   (767,677)
Balance August 31, 2022   385,198,451   $38,521    700,000   $70   $2,931,841   $
-
   $(3,297,824)  $(327,392)
Common shares issued for services   1,350,000    135              31,815              31,950 
Stock option expense                       274,025              274,025 
Common shares issued for notes payable extension   2,686,667    269              63,943              64,211 
Common shares issued for Debt settlement   760,870    76              17,424              17,500 
Net loss                                 (659,936)   (659,936)
Balance November 30, 2022   389,995,988   $39,001    700,000   $70   $3,319,048   $
-
   $(3,957,760)  $(599,641)

 

   Common Shares   Par Value Common Shares   Series A Preferred Shares   Par Value Series A Preferred Shares   Additional
Paid-in
Capital
    Accumulated Deficit    Total   
                             
Balances, December 1, 2020   
-
   $
-
    
-
   $
-
   $
-
   $
-
   $
-
 
                                    
Expenses paid on behalf of the Company and contributed to capital   -    
-
    -    
-
    1,185    
-
    1,185 
Net loss   -    
-
    -    
-
    
-
    (4,935)   (4,935)
Balances, February 28, 2021   
-
   $
-
    
-
   $
-
   $1,185   $(4,935)  $(3,750)
Common shares issued after reorganization   359,996,332    36,000    -    
-
    (36,000)   
-
    
-
 
Preferred shares issued after reorganization   -    
-
    700,000    70    69,930    
-
    70,000 
Expenses paid on behalf of the Company and contributed to capital   -    
-
    -    
-
    3,951    
-
    3,951 
Net loss   -    
-
    -    
-
    
-
    (72,051)   (72,051)
Balance, May 31, 2021  $359,996,332   $36,000    700,000   $70   $39,607   $(76,986)  $(1,850)
Common shares issued for services   50,000    5    -    
-
    6,995    
-
    7,000 
                                    
Expenses paid on behalf of the Company and contributed to capital   -    
-
    -    
-
    2,990    
-
    2,990 
Net loss   -    
-
    -    
-
    
-
    (14,005)   (14,005)
Balances, August 31, 2021  $360,046,332   $36,005    700,000   $70   $49,052   $(90,992)  $(5,865)
Common share issued for services to the Company   2,977,740    298    -    
-
    531,945    
-
    532,243 
Stock options expense   -    
-
    -    
-
    265,946    
-
    265,946 
Net loss   -    
-
    -    
-
    
-
    (1,066,097)   (1,066,097)
Balances, November 30, 2021  $363,024,072   $36,302    700,000   $70   $846,943   $(1,157,088)  $(273,773)

 

The accompanying notes are an integral part of these unaudited financial statements.

 

3

 

 

Better For You Wellness, Inc.

Condensed Consolidated Statement of Cash Flows (Unaudited)

For the nine months ended November 30, 2022 and 2021

 

   November 30,
2022
   November 30,
2021
 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net (loss)  $(2,319,485)  $(1,152,153)
Adjustments to reconcile Net Loss to net cash provided by (used in) operating activities:          
Share based expenses   1,332,475    875,189 
Amortized debt discount and debt issuance costs   86,810    
-
 
Depreciation   582    
-
 
Changes in current assets and liabilities:          
Accounts receivable   (1,495)   
-
 
Related party receivable   (108,301)   
-
 
Prepaid expenses and other assets   (23,588)   
-
 
Inventory   11,440    
-
 
Accounts payable   (63,866)   113,267 
Accrued Interest   41,643    
-
 
Deferred compensation   284,499    
-
 
Other liabilities   (1,675)     
Related party notes payable   -    156,756 
Net cash provided by (used in) Operating Activities   (760,961)   (6,941)
CASH FLOWS FROM INVESTING ACTIVITIES:          
Fixed Assets   (2,323)   
-
 
Net cash used in Investing Activities   (2,323)   
-
 
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payment of debt issuance costs   (56,640)     
Proceeds from Convertible loan, net of original issue discount   558,000    
-
 
Proceed from related party note payable   202,000    
 
 
Proceeds from Common Stock Issuance   3,750    - 
Expenses contributed to capital   49,686    6,941 
Net cash provided by Financing Activities   756,796    6,941 
           
Net Change in Cash  $(6,488)  $
-
 
           
Cash at beginning of period:  $9,642   $
-
 
Cash at end of period:  $3,154   $
-
 
           
NON-CASH FINANCING TRANSACTIONS:          
Discount on notes payable for warrants   30,702    
-
 
Warrants issued and extended for common stock issuance costs   78,072    
-
 

  

The accompanying notes are an integral part of these unaudited financial statements.

 

4

 

  

Better For You Wellness, Inc.

Notes to Condensed Consolidated Financial Statements (Unaudited)

 

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

5

 

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time.

 

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

 

On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.

 

On August 18, 2021, we filed an amendment to the Company’s Articles of Incorporation with the Nevada Secretary of State to change our name to Better For You Wellness, Inc. On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company. On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders.

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

 

6

 

 

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

Significant Accounting Policies and Use of Estimates:

 

There were no material changes in the Company’s significant accounting policies for the three and nine months ended November 30, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.

 

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of November 30, 2022, the Company had no deferred revenues. 

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2022 was $3,154 and $9,642 for February 28, 2022.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

7

 

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2022.

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of November 30, 2022 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of November 30, 2022 and February 28, 2022.

 

8

 

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

 

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

Note 4 - Business Combinations

 

On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.

 

The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:

 

Assets acquired:    
Cash   $913 
Inventory    12,995 

Total Assets Acquired

   13,908 
Liabilities assumed:      
Clearbanc Debit Card    2,365 
Notes Payable - PayPal Capital    2454 
Notes Payable Shopify Capital    537 
Sales Tax Payable    138 

Total Liabilities Assumed

   5,494 
      
Total identifiable net assets    8,414 
Purchase price    592,000 
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date   $583,586 

 

The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.

 

9

 

 

As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.

 

The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.

 

   For the Three months ended 
   (unaudited)   (unaudited) 
   November 30, 2022   November 30, 2021 
Total revenues  $6,986   $17,022
           
Net (loss) income  $(659,935)  $(1,087,775)
           
Loss per share  $
-
   $
-
 

 

   For the Nine months ended 
   (unaudited)   (unaudited) 
   November 30, 2022   November 30, 2021 
Total revenues  $15,676   $52,496 
           
Net (loss) income  $(2,319,485)  $(1,200,616)
           
Loss per share  $
-
   $
-
 

 

The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.

 

The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.

 

   For the
three months ended
November 30,
   For the
nine months ended
November 30,
 
   2022   2022 
Mango Moi:        
Total revenues  $1,163   $(51)
Net income  $(657)  $(9,757)

 

Note 5 - Income Taxes

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of November 30, 2022, the Company has incurred a net loss of approximately $4,105,379 which resulted in a net operating loss for income tax purposes. The loss results in a deferred tax asset of approximately $862,130 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2022, we have completed only two taxable fiscal years.

 

10

 

 

Note 6 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of November 30, 2022 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On October 12, 2022, the Company renewed its Agreement with SRAX to retain access to the platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, issued 1,250,000 restricted Common Shares in lieu of the fee of $30,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Note 7 - Shareholder Equity

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 and 0 shares issued and outstanding as of November 30, 2022 and February 28, 2022, respectively.

 

11

 

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 389,995,988 and 370,747,042 shares of common stock issued and outstanding as of November 30, 2022 and February 28, 2022, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.

 

On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.

 

On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.

 

On April 12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date of $0.0535, as listed on the OTC Markets, which totaled approximately $6,687.

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the "Note"). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, and interest of 12% per year and mature on April 12, 2023 (the "Maturity Date"). The Note is convertible into shares of the Company's common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company's common stock (the "Commitment Shares") as a condition to closing.

 

12

 

 

On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC. The shares were valued at the closing share price on the day prior to close was $0.05, as listed on the OTC Markets, which totaled approximately $550,000.

 

On July 12, 2022, 100,000 shares of Restricted Common Stock were issued to four Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price of on that date of $0.0399, as listed on the OTC Markets, which totaled $3,990.

 

On July 27, 2022 the Company filed its Pre-14-C notice and accompanying Information Statement and furnished this information to the holders of shares of common stock, par value $0.0001 per share, of Better For You Wellness, Inc., a Nevada corporation (the “Company”), pursuant to Section 78.320 of the Nevada General Corporation Law, Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulation 14C and Schedule 14C thereunder, in connection with the approval of the following actions taken by the Company’s Board of Directors (the “Board”) and by written consent of the holders of a majority of the voting power of the issued and outstanding capital stock of the Company, to amend our certificate of incorporation, as amended (the “Certificate”), to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (the “Authorized Share Increase” or “Corporate Action”).

 

During the period ended August 31, 2022, a total of 30,282 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $3,750.

 

On October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of $64,211 for the extension of the April 12, 2022 Registration Rights Agreement.

 

On October 12, 2022, the Board of Directors authorized the issuance of 760,780 Common Shares to Joseph Gushy to whom the Company had a $35,000 debt in relation to the Mango Moi acquisition. The Issuance of Common Shares retired half of the Debt (i.e., $17,500). The Company shall pay Holder the balance of $17,500 in the First Quarter of 2023.

 

On October 12, 2022, the Board of Directors authorized the issuance of 1,250,000 to SRAX pursuant to its Platform Account Contract with an Effective Date of October 12, 2022 for consideration of $30,000.00 for access to the Platform for a 12-month period from the Effective Date.

 

Shares Cancelable

 

No shares were cancelled during this period.

 

Stock Options

 

During the nine months ended November 30, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 10,500,000 fully vested on November 30, 2022. The remaining 7,000,000 shares vest over the next 2 years. During the nine months ended November 30, 2022, 2,500,000 shares were forfeited. The outstanding options have an exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options was zero as of November 30, 2022.

 

The Company fair valued the options on the grant date at $2,787,028 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 per share (based on the quoted trading price on the date of grant), volatility of 151.08%, expected term of 5 years, and a risk-free interest rate range of ..98%. The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ending November 30, 2022 was $274,025. The total unamortized stock option expense for the period ending November 30, 2022 was $1,853,540.

 

Additional Paid-In Capital

 

During the quarterly period ended November 30, 2022, a total of $3,319,048 was posted as additional paid-in capital.

 

This includes Common Shares issued for services for the Company including $31,815 SRAX, $274,025 of share option vestment/expense for the Board of Directors, $63,943 for Mast Hill notes payable extension, $17,424 in Common shares issued for Debt settlement for purchase of Subsidiary/No subsidiary acquired this quarterly filing.

 

13

 

 

Note 8 - Related-Party Transactions

 

Loan to Company

 

During the period ended November 30, 2022, Mr. James loaned the Company $39,500 last quarter. Our Audit Chairman, David Deming loaned the Company $145,000 in the three months ending November 30, 2022, and Mr. Deming plans to convert his loan into equity. The Company has recognized $284,499 in deferred compensation related to the Employment Agreements for Ian James, Stephen Letourneau and Jacob Ellman. These are non-interest bearing and unsecured and payable on demand. Both James and Letourneau will seek to convert at least 66% of their deferred compensation into restricted Common Shares at a $0.037 per share price to be consistent with the Mast Hill per share pricing. In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary. On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.

 

Note 9 - Goodwill

 

While changes in circumstances requiring an interim goodwill impairment test have not been identified for the three and nine months ended November 30, 2022. The Company will continue to monitor circumstances, such as disposition activity, stock price declines or changes in forecasted cash flows in future periods. If the fair value of the Company’s reporting unit declines below the carrying value in the future, goodwill impairment charges may be incurred.

 

Note 10 - Subsequent Events

 

On November 30, 2022, Mango Moi founder, Amanda Cayemitte voluntarily agreed to be furloughed as a cost savings measure while the Company focused on the reformulation and re-packaging of the Mango Moi product lines.

 

On December 8, 2022, the Company issued 13,918,999 Common Shares to SRAX pursuant to section 4(d) Share Adjustment of the Platform Account Contract, which was executed September 17, 2021.

 

Pursuant to their Employment Agreements, Ian James, Stephen Letourneau and Jacob Ellman have deferred compensation. Accordingly, the following represents each individual’s deferred compensation since March 1, 2022:

 

Ian James has deferred $141,197, Stephen Letourneau has deferred $106,810, and Jacob Ellman has deferred $36,492. Both Mr. James and Mr. Letourneau have stipulated that they will seek to convert at least 66% of their deferred compensation into restricted Common Shares at a $0.037 per share price to be consistent with the Mast Hill per share pricing.

 

On January 9, 2023, Anthony L.G., PLLC replaced Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case-by-case basis. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel is important to the company’s growth going forward. The Company seeks to retire the debt owed to Carter Ledyard Milburn by August 31, 2023.

 

On January 31, 2023, the Company appointed Dr. Pratibha Chaurasia, CPA, CA, Ph.D. as Fractional Chief Financial Officer (“CFO”). Pratibha offers over 24 years of diverse professional experience in financial reporting and auditing under GAAP and IFRS, with expertise in PCAOB audits and more. Chaurasia is the founder of Aprari Solutions and was formerly a Professor of International Finance and Management at the Daly College Business School and a Manager of Operations at Max Life Insurance Company Limited, formerly known as Max New York Life Insurance Company Limited.

 

On January 31, 2023, the Company entered into an agreement with Aprari Solutions for accounting and audit-related services (the “Engagement Letter”). Established in 2018, Aprari Solutions is a leading audit and accounting firm in India with a team consisting of qualified CPAs, Chartered Accountants, CFAs, Ph.D. and MBAs from top institutions, and experienced professionals well-trained in US GAAP and PCAOB audit standards and procedures. Aprari Solutions will be paid $25,000 over 12 months for accounting services, and for fractional CFO services, $30,000 in cash and $10,000 in stock over 12 months.

 

14

 

 

ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.”

 

These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

 

Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

 

Company Overview

 

Business Overview

 

We are a sustainable brands and services company headquartered in Columbus, Ohio. We are evaluating opportunities targeting six goals-based wellness categories within the rapidly growing wellness industry to create a leading global wellness conglomerate.

 

Through our dual buy and build model, we evaluate the wellness industry in the following six goals-based categories:

 

Better Health
   
Better Fitness
   
Better Nutrition
   
Better Appearance
   
Better Sleep
   
Better Mindfulness 

 

As an early-stage company, our Company generated $6,986 and $0 in revenue for the three months ended November 30, 2022, and 2021 respectively. Our Company generated $9,008 and $0 in revenue for the nine months ended November 30, 2022, and 2021 respectively. Our strategy is designed to offer wellness consumers a diverse synergistic portfolio of brands and products that will allow them to live a life of intention and improve their quality of life.

 

We believe wellness consumers purchase with intention and specifically seek out the brands and products that improve their quality of life. Furthermore, we believe wellness consumers pursue these six goals-based dimensions of wellness and are positioning the Company to capitalize on this demand. With skin being humans’ largest organ, we have initially prioritized skincare and haircare to help wellness consumers look and feel better with clean and natural products. We intend to expand into additional wellness categories with functional foods, beverages, supplements, and more.

 

Our management team brings deep expertise in heavily regulated industries, operating, brand identity, genetics, and services, and raising capital to the public market. We seek synergistic and complementary mergers and acquisition opportunities, implementing operational efficiencies to eliminate duplicative measures and centralize administrative operations to achieve more significant revenues and profitability. Additionally, we expect to leverage our network of retail relationships and acquire and manage brands and services cultivated in the beauty and wellness industry to secure sales in major retailers in the United States and globally.

 

Our management team monitors various trends and factors that follow, which could impact our operating performance.

 

As an early-stage company, the Company has relatively few transactions to date.

 

15

 

 

Trends and Other Factors Affecting Our Operating Performance

 

Our management team monitors various trends and factors that could impact our operating performance.

 

Revenue Strategy — Our revenue growth strategy follows a dual buy-and-build business model in which we acquire brands and related infrastructure and develop brands and related infrastructure in-house. In addition to scaling the Company’s wholly-owned subsidiary, Glow Market LLC, which currently owns and operates our Better Suds soap brand, we have executed multiple non-binding letters of intent to acquire companies within the skincare sector, including a vertically-integrated skincare manufacturer and multiple brands. The closing of these respective transactions depends on numerous factors, including but not limited to the satisfactory completion of due diligence, capital constraints, and more. Furthermore, any of these contemplated transactions would likely have a material impact on the Company’s operating performance. On May 26, 2022, our Company closed its first acquisition of the right, title and interest in, including all of the outstanding membership interests of Mango Moi, LLC, a hair and skincare business located in Chicago, Illinois.

 

Market Opportunity

 

We aim to become a major participant in the $1.5 trillion global wellness industry. We believe our innovative wellness-related offerings converge with wellness consumer trends and demands for “Better-For-You” brands and products that can satisfy all pricing points. We expect consumer trends towards the adoption of these healthier lifestyles to continue.

 

Competition 

 

We will compete with companies that operate in the plant-based and science-focused wellness market. Many of our competitors will have substantially greater financial resources, a broader market presence, longer-standing relationships with distributors, retailers, and suppliers, longer operating histories, more extensive production and distribution capabilities, robust brand recognition, and significant marketing resources, and more comprehensive product lines than us. We believe that principal competitive factors in this category include, among others, quality ingredients, wellness profile, cost, convenience, branding, and marketing.

 

Sales and Marketing Costs 

 

As we continue to grow our “BFYW” product portfolio, we expect to expand our sales and marketing team by adding dedicated personnel to service additional retail customers. Outside sales representatives and brokers may be added to expand our sales efforts. We further envision engaging, developing, and possibly acquiring a subscription box retail operation. Marketing expenditures are expected to begin primarily online and in product fees (as we engage retail store expansion), as well as other similar in-store marketing costs. These expenses will be categorized as net deductions to revenue under GAAP instead of marketing expenses. We plan to hire a national marketing firm to implement digital video and display campaigns, connected television, social media, and search engine marketing. As we expand and grow revenue, we will build a brand management team (to support Management, who oversees all “BFYW” marketing efforts) to focus on digital marketing, social media, and other marketing functions.

 

Operating Costs 

 

Our operating costs include raw materials, labor, related benefits, manufacturing overhead, marketing, sales, distribution, shipping, and other general and administrative expenses. We attempt to manage the impact of our operating costs through fixed hourly rate agreements with legal counsel and certain consultants. We have begun to reduce our labor force to right size the operations costs, as we reformulate the Mango Moi line of products for commercial scaling.

 

Fluctuations in Costs 

 

Our costs are subject to fluctuations, particularly due to changes in commodity prices, transportation costs, and our productivity efforts. If we are unable to manage cost fluctuations through pricing actions, cost savings projects, sourcing decisions, and consistent productivity improvements, it may adversely impact our gross margin, operating margin, and net earnings. Sales can also be adversely impacted following pricing actions if there is a negative impact on the consumption of our products. We strive to implement, achieve, and sustain cost improvement plans, including supply chain optimization, general overhead, workforce optimization, and outsourcing projects as deemed appropriate.

 

16

 

 

Commodities

 

In the future, our profitability could depend on our ability to anticipate and react to raw material costs, among other things. Raw materials can be sourced from various parts of the globe, and the prices of raw goods are subject to many factors beyond our control. These factors include variables in world economic conditions, political events, tariffs, trade wars, or other events.

 

Acquisitions 

 

The Company follows a dual buy-and-build business model for growth through acquisitions and in-house development of brands. We have executed multiple non-binding letters of intent to acquire companies within the skincare sector and functional beverage, women’s wellness and pet care. The closing of these respective transactions depends on numerous factors including but not limited to the satisfactory completion of due diligence, capital constraints, and more. Furthermore, any of these contemplated transactions would likely have a material impact on the Company’s operating performance.

 

Strategic Advisory Committee

 

To assist in the expansion of the Company, management sought and received unanimous consent from the Board of Directors to create and seat a Strategic Advisory Committee composed of respected industry leaders who bring relevant experience, networks, and leadership to the Company’s various initiatives.

 

Discussion of Financial Statement

 

As an Early-Stage Company with few transactions, the Company’s expenditures were heavily Selling General, and Administrative (“SG&A”). The Company engaged Anthony L.G., PLLC as legal counsel, to be consulted on a case-by-case basis as may be necessary for corporate legal services and securities counsel. Payroll expenses, including deferred compensation, were the single largest category of cash expenditures for the quarter. Pursuant to their Employment Agreements, Ian James, Stephen Letourneau and Jacob Ellman have deferred compensation. Accordingly, the following represents each individual’s deferred compensation since March 1, 2022: Ian James has deferred $141,197, Stephen Letourneau has deferred $106,810, and Jacob Ellman has deferred $36,492. Both Mr. James and Mr. Letourneau have stipulated that they will seek to convert at least 66% of their deferred compensation into restricted Common Shares at a $0.037 per share price to be consistent with the Mast Hill per share pricing. Management expects legal costs to taper as a percentage of overall SG&A as the company grows. The Company’s SG&A further includes the cost of EDGAR and news release filing services, payroll of a single person, website development and publishing, professional services such as accounting, SRAX for regular updates of NOBO data for the shareholder lists for ongoing shareholder communications, Governmental filing fees including business licensing.

 

Systems and Controls

 

As an early-stage company, the Company has very few transactions to date. The Company’s Board of Directors comprises 6 members, 4 of which are non-executive independent directors. The Board of Directors’ reviews transactions, and the CEO signs off on transactions. The Company is developing revenue recognition processes and procedures for the business, including revenue streams, point of performance obligation discharged, etc., to comply with applicable State, Provincial, Federal, and International Laws and Regulations.

 

Critical Accounting Policies and Estimates

 

We prepare our unaudited condensed consolidated financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Under Note 2 – Summary of Significant Accounting Policies, the unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of November 30, 2022, the Company had no deferred revenues. 

 

17

 

 

Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

COVID-19

 

An outbreak of infectious respiratory illness caused by a novel coronavirus known as COVID-19 spread globally in 2020. This outbreak resulted in travel restrictions, closed international borders, enhanced health screenings at ports of entry and elsewhere, disruption of and delays in healthcare service preparation and delivery, prolonged quarantines, cancellations, supply chain disruptions, lower consumer demand, layoffs, defaults, and other significant economic impacts, as well as general concern and uncertainty.

 

The pandemic has not materially impacted our operations in 2021 or 2022 thus far.  

 

Financial Statements and Exhibits

 

The Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination. The Company’s business purpose is to seek the acquisition of or merger with an existing company.

 

The Company is an “emerging growth company” (“EGC”) that is exempt from certain financial disclosure and governance requirements for up to five years as defined in the Jumpstart Our Business Startups Act (the JOBS Act), which eases restrictions on the sale of securities; and increases the number of shareholders a company must have before becoming subject to the U.S. Securities and Exchange Commissions (SEC’s) reporting and disclosure rules (See Emerging Growth Companies Section Below).

 

The Company has elected February 28th as its fiscal year-end.

 

18

 

 

Results of Operations

 

The following table sets forth selected items in our unaudited condensed consolidated financial data in dollar amounts and as a percentage of revenue for the period represented:

 

   For the
three months
   For the
three months
    For the
nine months
    For the
nine months
 
   Ended
November 30,
2022
   Ended
November 30,
2021
   Ended
November 30,
2022
   Ended
November 30,
2021
 
                 
Revenues   6,986    -    9,008    - 
Cost of Goods   5,823    -    15,381    - 
Gross Profit and Gross Margin   1,163    -    (6,373)   - 
Operating Expenses   605,163    1,066,097    2,184,659    1,152,153 
Net (Loss) Income   (659,935)   (1,066,097)   (2,191,032)   (1,152,153)

 

Revenues 

 

The company generated $6,986 and $0 for the three months ended November 30, 2022, and 2021 respectively, a increase of $6,986. The company generated $9,008 and $0 for the nine months ended November 30, 2022, and 2021 respectively, a increase of $9,008. The increase was due to the Company having sales from its Mango Moi operation.

 

Cost of Goods Sold

 

We recorded $5,823 and $0 for Cost of Goods Sold for the three months ended November 30, 2022, and 2021 respectively, an increase of $5,823. We recorded $15,381 and $0 for Cost of Goods Sold for the nine months ended November 30, 2022, and 2021 respectively, an increase of $15,381.

 

Gross Profit and Gross Margin

 

We recorded $1,163 and $0 in Gross Profit for the three months ended November 30, 2022, and 2021 respectively, a increase of $1,163. The increase was due to the increase in sales and the streamlining of manufacturing. We recorded a negative $6,373 and $0 in Gross Profit for the nine months ended November 30, 2022, and 2021 respectively, a decrease of $6,373. The decrease was due to the reformulating and reconfiguring Mango Moi production over the period.

 

Operating Expenses

 

We recorded $605,163 and $1,066,097 in Operating Expenses for the three months ended November 30, 2022, and 2021 respectively. We recorded $2,184,659 and $1,152,153 in Operating Expenses for the nine months ended November 30, 2022, and 2021 respectively.

 

We incurred $460,934 in lower Operating Expenses for the three months ended November 30, 2022 due to approximately $346,762 in share-based expenses, and approximately $258,401 in general and administrative expenses, compared to $532,243 and $533,854 in share-based expenses, and general administrative expenses, respectively, for the three months ended November 30, 2021. The decrease in general expenses and administrative expenses was due to reduced stock option expenses for Independent Directors with the vacancy of one Independent Board member, and reduction in legal fees, marketing expenses, membership subscriptions, licenses, and software and applications.

 

Income Taxes 

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. As of November 30, 2022, the Company has incurred a net loss of approximately $4,105,379 resulting in a net operating loss for income tax purposes.  The loss results in a deferred tax asset of approximately $862,130 the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our Company’s inception date of December 1, 2020, and our fiscal year end of February 28, 2022, we have completed only two taxable fiscal years.

 

Net (Loss) Income 

 

We recorded a loss of $659,935 and $1,066,097 for the three months ended November 30, 2022, and 2021 respectively. We recorded a lower net loss during this period compared to the same quarter of the prior year due to an reduced Operating Expenses during the period. We recorded a loss of $2,191,032 and $1,152,153 for the nine months ended November 30, 2022, and 2021 respectively. We recorded a greater net loss for our third quarter for the nine months ended November 30, 2022, compared to the same quarter of the prior year due to an increase in Operating Expenses.

 

19

 

 

Liquidity and Capital Resources 

 

Our cash balance was $3,154 and $0 as of November 30, 2022, and 2021 respectively. We received $0 and $0 from the sale of shares of Common Stock for the nine months ended November 30, 2022, and 2021 respectively. We presently are largely reliant on capital contributions towards expenses from Mr. Ian James, the Company’s Chief Executive Officer, President, Treasurer, and Chairman of the Board of Directors. Mr. James loaned the Company $39,500 last quarter. Our Audit Chairman, David Deming loaned the Company $145,000 in the three months ending November 30, 2022. Mr. Deming has indicated that he plans to convert the loan into equity.

 

Mr. Ian James has not guaranteed that he will continue to support our capital needs. Therefore, we may not be able to continue as a going concern. We may require further funding to implement our operations plan for the next twelve months. Being a start-up stage company, we have a very limited operating history. After a twelve-month period, we may need additional financing but currently do not have any arrangements for such financing with the exception of the Standby Equity Commitment Agreement with MacRab LLC.

 

If we need additional cash and cannot raise it, we will either have to suspend operations until our Company raises the necessary financing or cease operations entirely. 

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements including special purpose entities.

 

Corporate History

 

Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”), was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On January 28, 2021, as a result of an Application for Custodianship granted by the Eighth Judicial District Court, Clark County, Nevada, styled as “In the matter of Sauer Energy, Inc., a Nevada corporation, Case Number: A-20-826848-P”, Jeffrey DeNunzio was appointed Custodian of Sauer Energy, Inc. (the “Predecessor”).

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230, and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Jeffrey DeNunzio was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor, and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021 at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until trading under the new ticker symbol “FTRK” for the Company began on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc. resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

20

 

 

On July 19, 2021, Fast Track Solutions entered into a Share Purchase Agreement by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021, CRS sold 700,000 shares of the Fast Track Solutions’ Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of Fast Track Solutions; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000). The consummation of the transactions contemplated by this Share Purchase Agreement resulted in a change in control of Fast Track Solutions, with Ian James, Stephen Letourneau, and GOHV becoming the largest controlling stockholders.

 

Ian James and Stephen Letourneau retained a majority of the membership interests (collectively constituting approximately 84.12%) of GOVH.

 

On July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Chief Executive Officer, Chief Financial Officer, President, Secretary, and Treasurer. In addition, Mr. DeNunzio resigned as Director on July 30, 2021. Mr. Ian James was appointed as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors. Mr. Stephen Letourneau was appointed Director. The resignation of Mr. DeNunzio was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On August 18, 2021, a Certificate of Amendment to change our name to “Better For You Wellness, Inc.” was filed with the Nevada Secretary of State.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 17, 2021, we entered into a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, allowing WVH to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. According to the aforementioned term sheet, any future proceeds from the sale of shares are to go towards the Company to be used for working capital. According to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, we entered into an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Under the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

On September 17, 2021, we entered into another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On September 17, 2021, Mr. David H. Deming was appointed Secretary of the Company’s Board of Directors.

 

On September 17, 2021, we engaged Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case-by-case basis. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel is important to the company’s growth going forward.

 

On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock is 08771B105.

 

On October 1, 2021, our Board of Directors unanimously approved the establishment of an Audit Committee and appointed Montel Williams, David Deming, and Joseph Watson to the newly formed Audit Committee. Our Board of Directors also unanimously approved the establishment of a Compensation Committee and appointed Leslie Bumgarner, Montel Williams, and Joseph Watson to the newly formed Compensation Committee.

 

On November 18, 2021, Ms. Leslie Bumgarner advised the Company’s Board of Directors that she would resign as a director and Compensation Committee member of the Company effective upon December 31, 2021. The resignation of Ms. Bumgarner was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

21

 

 

On December 3, 2021, the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s Common Stock as reported by the OTC Markets Group. The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s Common Stock at a 15% discount to the last closing price of the Company’s Common Stock as reported by the OTC Markets Group.

 

On December 3, 2021, the Company also executed the Registration Rights Agreement with WVH. Under the terms and conditions of the Registration Rights Agreement, and to induce WVH to enter into the Equity Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act. The Registration Rights agreement provides that the Company shall, on or before the one hundred and eightieth (180th) day after December 3, 2021, file with the SEC a prospectus supplement on effective Form S-1 covering the maximum number of Registrable Securities (as defined therein) as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the WVH, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the WVH (the “Initial Registration Statement”). The Initial Registration Statement shall register only registrable securities. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment thereto declared effective by the SEC at the earliest possible date (in any event, within ninety (90) calendar days after the filing date of the Initial Registration Statement). The Registration Rights Agreement also provides that the Company is obligated to file additional registration statements under certain circumstances.

 

On December 6, 2021, we announced that the Company had formed a wholly-owned subsidiary, Glow Market LLC, an Ohio Limited Liability Company, to build and operate digitally-native, mission-driven brands within the clean beauty sector in multiple consumer product categories. Glow Market, LLC, launched its first brand, Better Suds, an impact-driven brand that sells cruelty-free natural soap. Better Suds is committed to positively impacting the environment by removing 1 pound of plastic from the ocean for every soap sold through donations to Ocean Blue Project Inc., a 501(c)(3) organization that removes plastics from oceans and waterways. With the Company’s launch of Glow Market LLC, we ceased to be a shell company, as defined in Rule 12b-2 under the Exchange Act, and are no longer a blank-check company.

 

On December 9, 2021, we announced that the Company had submitted an application to the OTC Markets Group to up-list its common stock for trading on the OTC Markets Venture Market, or the OTCQB, and pending the completion of the application process and its acceptance by the OTC Markets Group, the Company expects that its common stock will begin trading on the OTCQB under the Company’s current ticker symbol “BFYW”.

 

On December 14, 2021, we appointed Christina Jefferson to the Board as an Independent Director, effective January 1, 2022, in order to replace Leslie Bumgarner whose resignation became effective December 31, 2021.

 

On December 15, 2021, we reported on a phased fundraising of up to $1,000,000 USD in a Private Placement of restricted Common Stock to investors who qualify as “accredited investors”.

 

On February 2, 2022, we received approval from OTC Markets Group to up-list our common stock for trading to the OTC Markets Venture Market, or the OTCQB, as of February 3, 2022 under the Company’s current ticker symbol “BFYW”.

 

On February 5, 2022, our Board of Directors unanimously approved the Establishment of a Strategic Advisory Committee tasked with providing acceleration, reach and guidance to further enhance the Company’s value proposition and portfolio. Our Board of Directors appointed six initial Committee Members by unanimous consent including: David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.

 

Also on February 5, 2022, by unanimous consent of the five non-executive independent members of our Board of Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, and Christina Jefferson was appointed to the Company’s Compensation Committee filling the vacancy left by former director Leslie Bumgarner, and Joseph Watson was appointed as Chairperson of the Company’s Compensation Committee.

 

22

 

 

On February 11, 2022, we entered into a non-binding Letter of Intent with Amanda Cayemitte, Yapo M’Be, and Mango Moi, LLC setting forth the contemplated terms for a transaction in which the Company would acquire 100% ownership interest in Mango Moi, LLC and substantially all of the property and assets of Mango Moi including without limitation inventory, formulas, packaging, intellectual property, customer lists, websites, domain names, and social media accounts.

 

On March 15, 2022, we entered into a Finder’s Fee Agreement with JH Darbie & Co., Inc. Pursuant to which JH Darbie & Co., Inc. would introduce the Issuer to third-party investors.

 

On April 12, 2022, we entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership, pursuant to which Mast Hill Fund, L.P. purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 bearing an original issue discount of $31,000, interest of 12% per year and a maturity date of April 12, 2023. The promissory note is convertible into shares of our common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. We have the right to prepay the promissory note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. Pursuant to the Securities Purchase Agreement, we issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock as a condition to closing. In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with Mast Hill Fund, L.P. pursuant to which we are obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the commitment shares and the shares of our common stock that may be issued to Mast Hill Fund, L.P. pursuant to the conversion of the promissory note. Pursuant to the Finder’s Fee Agreement, we entered into on March 15, 2022, with JH Darbie & Co., Inc., fees of approximately $22,320.00 were paid to JH Darbie & Co., Inc. in addition to non-callable warrants expiring 5 years after the date of issuance equal to 8% warrant coverage of the amount raised, entitling JH Darbie & Co., Inc. thereof to purchase our common stock at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of our common stock on the date of the transaction, whichever is lower.

 

Also on April 12, 2022, we entered into an Agreement to Terminate Amended and Corrected Equity Purchase Agreement (the “Agreement to Terminate”) with WVH to terminate the aforementioned Equity Purchase Agreement, whereby WVH agreed to forfeit the 7,048,873 shares of our common stock that were previously issued to WVH as commitment shares pursuant to the Equity Purchase Agreement.

 

On April 15, 2022, we entered into a Placement Agent Agreement with JH Darbie & Co., Inc. pursuant to which JH Darbie would possibly participate as a sales agent in the private placement of a $5,000,000 Equity Line of Credit.

 

On April 18, 2022, we entered into a Standby Equity Commitment Agreement with MacRab LLC, a Florida limited liability company providing us with an option to sell up to $5,000,000 worth of our common stock, par value $0.0001, to MacRab LLC, in increments, over the period ending 24 months after the date that the Company’s registration statement is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. Additionally, we issued MacRab LLC a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock as a commitment fee in connection with the execution of the Standby Equity Commitment Agreement. We also entered into a Registration Rights Agreement with the Investor requiring the Company to file a registration statement providing for the registration of the common stock issuable to MacRab LLC under the Standby Equity Commitment Agreement and their common stock purchase warrant and the subsequent resale by MacRab LLC of such common stock. Pursuant to the Placement Agent Agreement entered into on April 15, 2022, with JH Darbie & Co., Inc., the Company will pay Darbie a fee equal to 3% of the gross proceeds raised from the sale of the securities, including all amounts placed in an escrow account or payable in the future and all amounts paid or payable upon exercise, conversion or exchange of such securities received or receivable directly by the Company. Such consideration paid in cash shall be paid directly to Darbie out of escrow, as and when such consideration is paid to the Company.

 

On April 29, 2022, we entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (the “Sellers”) to acquire the right, title, and interest in, including all of the outstanding membership interests of Mango Moi, LLC, for the consideration and on the terms set forth in the MIPA. Additionally, in accordance with the terms of the MIPA, we entered into an Employment Agreement with Mango Moi, LLC founder Amanda Cayemitte, and a Consulting Agreement with Yapo M’be, respectively.

 

On May 26, 2022 closed on the Membership Interest Purchase Agreement (the “MIPA”) and acquired Mango Moi, LLC with a purchase price of $597,726.57 worth of shares of the Company’s common stock, which consisted of 11,000,000 shares of common stock, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be. In accordance with the terms of the MIPA, we entered into an Employment Agreement with Mango Moi, LLC founder Amanda Cayemitte, and a Consulting Agreement with Yapo M’be, respectively.

 

23

 

 

On June 7, 2022, we entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership, pursuant to which Mast Hill Fund, L.P. purchased a promissory note with a principal amount of $310,000 for a purchase price of $279,000 bearing an original issue discount of $31,000, the interest of 12% per year and a maturity date of June 7, 2023. The promissory note is convertible into shares of our common stock at a conversion price of $0.037 per share, subject to adjustment as provided therein. We have the right to prepay the promissory note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. Pursuant to the Securities Purchase Agreement, we issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock as a condition to closing. In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with Mast Hill Fund, L.P. pursuant to which we are obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the commitment shares and the shares of our common stock that may be issued to Mast Hill Fund, L.P. pursuant to the conversion of the promissory note. Pursuant to the Finder’s Fee Agreement, we entered into on March 15, 2022, with JH Darbie & Co., Inc., fees of approximately $22,320.00 were paid to JH Darbie & Co., Inc. in addition to non-callable warrants expiring 5 years after the date of issuance equal to 8% warrant coverage of the amount raised, entitling JH Darbie & Co., Inc. thereof to purchase our common stock at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of our common stock on the date of the transaction, whichever is lower.

 

On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021. The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

On July 19, 2022, the Company’s Board of Directors approved and adopted a Code of Business Conduct and Ethics and Compliance Program designed to deter wrongdoing and to promote the types of conduct by directors, executives, and employees to uphold a strong sense of ethics and integrity.

 

On July 21, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer, and the Company entered into the Agreement with Mr. James as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Mr. James will earn a Base Salary in the amount of $199,196 per annum and shall also be eligible to earn an additional payment (Bonus) of $68,328.

 

Also on July 21, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer, and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Mr. Letourneau will earn a Base Salary in the amount of $152,787 per annum and shall also be eligible to earn an additional payment (Bonus) of $70,632.

 

On August 15, 2022, Melisse Gelula advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Melisse Gelula was not compensated by the Company for her services as a director since June 20, 2022. Melisse Gelula is to remain a member of the Company’s Strategic Advisory Committee as previously announced and filed on February 10, 2022.

 

The resignation of Melisse Gelula as a director was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On August 31, 2022, BF Borgers CPA PC (“BF Borgers”) furnished a letter addressed to the Securities and Exchange Commission stating whether BF Borgers agrees with following statements:

 

The Audit Committee (the “Committee”) of the Company had conducted a competitive selection process to determine the Company’s independent registered public accounting firm for the fiscal year ending February 28, 2023. The Committee evaluated several public accounting firms in this process, including BF Borgers, the Company’s independent registered public accounting firm for the fiscal year ended February 28, 2022. As a result of this process, the Committee approved the appointment of GBQ Partners LLC (“GBQ”) as the Company’s independent registered public accounting firm for the fiscal year ending February 28, 2023. This action effectively dismissed BF Borgers as the Company’s independent registered public accounting firm as of August 31, 2022.

 

24

 

 

The reports of BF Borgers on the Company’s condensed consolidated financial statements for the fiscal years ended February 28, 2022 and 2021 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. In connection with the audits of the Company’s condensed consolidated financial statements for the fiscal years ended February 28, 2022 and 2021, and in the subsequent interim periods through August 31, 2022, there were no disagreements with BF Borgers on any matters of accounting principles or practices, financial statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of BF Borgers, would have caused BF Borgers to make reference to the matter in their reports. There were no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K) during the two fiscal years ended February 28, 2022 and 2021, or in the subsequent periods through August 31, 2022.

 

A copy of BF Borgers’ letter, dated August 31, 2022, is filed as Exhibit 16.1 to a Current Report on Form 8-K filed with the Securities and Exchange Commission on August 31, 2022.

 

During the two most recent fiscal years and in the subsequent interim periods through August 31, 2022, the Company has not consulted with GBQ with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that would have been rendered on the Company’s unaudited condensed consolidated financial statements, or any other matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-K.

 

On September 20, 2022, the Company entered into a Manufacturing Agreement with Ironwood Clay Company (ICCI) to develop commercially scaled Personal Care Products for Mango Moi and other products in the Company’s portfolio. The Company agreed to pay a non-refundable deposit of $10,000 USD for up to 8 Product Formula. This includes three formulation revisions and samples per Product Formula (each iteration of sampling of up to 500gr./ml.). Additional revisions to the Formula(s) will be charges to the Client at a rate of $500 USD per revision.

 

Once the Company has approved the final Formula(s) and places a Purchase Order exceeding $10,000 USD, the non-refundable deposit will be applied to the total amount of the Purchase Order. Upon ordering at least Twenty Five Thousand US Dollars ($25,000 USD) of each Product Formula, the exclusivity granted to ICCI herein in respect of such Product and Formula shall cease, the Company shall no longer be obligated to purchase Products from ICCI, and the Client shall be free to engage any other manufacturer for such purpose.

 

On September 22, 2022, the Company announced the cancelation of the Letter of Intent (LOI) to acquire Ironwood Clay Company (ICCI) because ICCI was unable to have its Clay Mining Operation adequately meet SEC reporting requirements related to the mining of a natural resource. Additionally, ICCI owners were unwilling to bifurcate the Mining Operation from the Personal Care Manufacturing.

 

On September 22, 2022, the Company announced the Letter of Intent (LOI) to acquire The Ideation Lab and its functional beverage division, The Jordre Well.

 

The Ideation Lab is a brand solutions incubator and accelerator focused on the plant-based wellness and hemp-infused industry. The Ideation Lab has been developing plant-based wellness brands since 2020, including Garrett and Emmett’s Pet Treats, a pet lifestyle brand, E.J. Well Co, a women’s wellness brand, and others.

 

The Jordre Well is a functional beverage company that is 49% owned by Coffee Holding Co., Inc. (NASDAQ: JVA), a leading integrated wholesale coffee roaster and dealer in the United States. Earlier this week, The Jordre Well announced its portfolio of products from Stephen James Curated Coffee Collection (“SJCCC”), the Company’s premium coffee brand, which is now being sold through Amazon.com and is in discussion with major national retailers. The e-commerce giant carries 8 of SJCCC’s premium coffee products and ships to more than 100 countries around the globe. Additionally, the deal contemplates Coffee Holding Company continuing its global purchase of coffee beans, manufacturing, distribution, and licensure of its Cafe Caribe and Harmony Bay to The Jordre Well for Hemp infusion.

 

On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 270 calendar days to file the initial Registration Statement and 360 calendar days to have it declared effective. This extension follows the July 11, 2022 extension in which Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 180 calendar days to file the initial Registration Statement and 270 calendar days to have it declared effective. In consideration of the extension, on October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of the extension of the 4/12/2022 Registration Rights Agreement.

 

25

 

 

On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.

 

On October 12, 2022, our Board of Directors approved to renew an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies.” In exchange for twelve months of access to the Sequire Platform, we paid SRAX $30,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Pursuant to the Company’s Compensation Committee approval of July 21, 2022, the Company entered a formal Employment Agreement with Jacob Ellman, the Company’s Chief Business Development Officer and the Company entered into the Agreement with Mr. Ellman as of October 14, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Mr. Ellman will earn a Base Salary in the amount of $128,656 per annum and shall also be eligible to earn an additional payment (Bonus) of $41,140.

 

On December 7, 13,918,999 restricted Common Shares were issued to SRAX as a part of the September 17, 2021 contract with SRAX, Inc. in which payment in the amount of $380,000 for services was made in securities. The share issuance addresses the “Dilutive Issuance” of securities pursuant to section 4(d) Share Adjustment of the contract.

 

On January 9, 2023, Anthony L.G., PLLC replaced Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case-by-case basis. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel is important to the company’s growth going forward. The Company seeks to retire the debt owed to Carter Ledyard Milburn by August 31, 2023.

 

On January 31, 2023, the Company appointed Dr. Pratibha Chaurasia, CPA, CA, Ph.D. as Fractional Chief Financial Officer (“CFO”). Pratibha offers over 24 years of diverse professional experience in financial reporting and auditing under GAAP and IFRS, with expertise in PCAOB audits and more. Chaurasia is the founder of Aprari Solutions and was formerly a Professor of International Finance and Management at the Daly College Business School and a Manager of Operations at Max Life Insurance Company Limited, formerly known as Max New York Life Insurance Company Limited.

 

On January 31, 2023, the Company entered into an agreement with Aprari Solutions for accounting and audit-related services (the “Engagement Letter”). Established in 2018, Aprari Solutions is a leading audit and accounting firm in India with a team consisting of qualified CPAs, Chartered Accountants, CFAs, Ph.D. and MBAs from top institutions, and experienced professionals well-trained in US GAAP and PCAOB audit standards and procedures. Aprari Solutions will be paid $25,000 over 12 months for accounting and auditing assistance services, and for fractional CFO services, $30,000 in cash and $10,000 in stock over 12 months.

 

26

 

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

ITEM 4 CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures 

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our fractional Chief Financial Officer to allow for timely decisions regarding required disclosure. 

 

As of November 30, 2022, our management, with the participation of, and under the supervision of, our Chief Executive Officer and fractional Chief Financial Officer, evaluated the effectiveness of the design and the operation of our disclosure controls and procedures. Based upon that evaluation, management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of November 30, 2022, due to the identification of a material weakness in the Company’s internal control over financial reporting as of November 30, 2022.

 

As disclosed in the Company’s Current Report on Form 8-K filed on March 3, 2023 with the SEC, on February 5, 2023, the Company’s management concluded that the following financial statements should be restated and should no longer be relied upon:

 

  (i) The Company’s unaudited consolidated financial statements for the three months ended May 31, 2022 included in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2022 (the “Q1 2022 10-Q”); and

 

  (ii) The Company’s unaudited consolidated financial statements for the three and six months ended August 31, 2022 included in the Company’s Quarterly Report on Form 10-Q, filed with the SEC on October 21, 2022 (the “Q2 2022 10-Q” and together with the Q1 2022 10-Q, the “Filings”).

 

The following errors impacted the Filings:

 

  (i) Incorrect itemization of accounts payable to reflect certain itemized expenses;

 

  (ii) Failure to include the rounding up of shares to reflect the correct total number of issued common stock;

 

  (iii) Failure to include certain accrued expenses to the accounts payable section;

 

  (iv) Incorrect calculation of closing dates regarding the reporting period for goods sold;

 

  (v) Incorrect calculation of closing dates regarding the reporting period for costs of goods sold;

 

  (vi) Incorrect statement of impaired expenses of $577,473 related to the acquisition of Mango Moi;

 

  (vii) Incorrect calculation of stock option agreements with Mast Hill and members of the Company’s Board of Directors;

 

  (viii) Incorrect calculation of selling, general and administrative operating expenses, which have been retranslated to comply with reporting standards under GAAP;

 

27

 

 

  (ix) Incorrect itemization of stock warrant expenses, reflected in the reitemization of $36,366;

 

  (x) Portions of the cash flow section of the financials did not meet GAAP standards;

 

  (xi) Omission of unaccounted depreciation in the financial statements; and

 

  (xii) Certain other incorrect calculations.

 

The Company has determined that the reporting effects of the above errors had a material impact to the Company’s unaudited consolidated financial statements of the Company for the three months ended May 31, 2022, as reported in the Q1 2022 10-Q, and for the three and six months ended August 31, 2022, as reported in the Q2 2022 10-Q. As a result, the unaudited consolidated financial statements for the three months ended May 31, 2022 and the unaudited consolidated financial statements for the three and six months ended August 31, 2022 will be restated, and the Company will file an amendment to each of the Q1 2022 10-Q and the Q2 2022 10-Q with the SEC.

 

Remediation of Material Weakness

 

We are in the process of implementing improvements and remedial measures in response to the material weakness, including the hiring of a fractional Chief Financial Officer with over 24 years of diverse professional experience in financial reporting and auditing under GAAP and IFRS, with expertise in PCAOB audits. Additionally, we entered into an agreement with Aprari Solutions for accounting and audit-related services. Established in 2018, Aprari Solutions is a leading audit and accounting firm in India with a team consisting of qualified CPAs, Chartered Accountants, CFAs, Ph.D. and MBAs from top institutions, and experienced professionals well-trained in GAAP and PCAOB audit standards and procedures. 

 

Changes in Internal Control over Financial Reporting  

 

Since September 1, 2022, and in connection with the evaluation required by Rule 13a-15 under the Exchange Act as of November 30, 2022, the Company has made changes to its internal control over financial reporting that materially affected or are reasonably likely to affect our internal control over financial reporting, including those changes set forth under “—Remediation of Material Weakness.” 

 

Limitations on the effectiveness of internal controls

 

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its desired objectives. In addition, the design of disclosure controls and procedures must reflect resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Our management does not expect the Company’s disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding internal controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. 

 

 

28

 

 

PART II-OTHER INFORMATION

 

ITEM 1 LEGAL PROCEEDINGS

 

There are no legal proceedings against the Company and the Company is unaware of such proceedings contemplated against it.

 

ITEM 1A RISK FACTORS

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4 MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5 OTHER INFORMATION

 

None.

 

ITEM 6 EXHIBITS

 

Exhibit No.   Description
     
31   Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-Q for the period ended November 30, 2022.(2)
   
32   Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(2)
     
101.INS   Inline XBRL Instance Document.(3)
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document.(3)
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.(3)
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.(3)
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.(3)
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.(3)
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

(1) Filed as an exhibit to the Company’s Form 10-12G, as filed with the SEC on March 23, 2021, and incorporated herein by this reference.
(2) Filed herewith.
(3) Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Annual Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

 

29

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

 

Better For You Wellness, Inc.  
(Registrant)  
   
By: /s/ Ian James  
Name:  Ian James  
  President and Chief Executive Officer  
     
Dated: March 3, 2023  

 

 

30

 

 

false --02-28 Q3 0001852707 0001852707 2022-03-01 2022-11-30 0001852707 2023-03-03 0001852707 2022-11-30 0001852707 2022-02-28 0001852707 2022-09-01 2022-11-30 0001852707 2021-09-01 2021-11-30 0001852707 2021-03-01 2021-11-30 0001852707 us-gaap:CommonStockMember 2022-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001852707 bfyw:SharesCancelableMember 2022-02-28 0001852707 us-gaap:RetainedEarningsMember 2022-02-28 0001852707 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-03-01 2022-05-31 0001852707 2022-03-01 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001852707 us-gaap:CommonStockMember 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-05-31 0001852707 2022-05-31 0001852707 us-gaap:CommonStockMember 2022-06-01 2022-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-08-31 0001852707 2022-06-01 2022-08-31 0001852707 us-gaap:RetainedEarningsMember 2022-06-01 2022-08-31 0001852707 us-gaap:CommonStockMember 2022-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001852707 bfyw:SharesCancelableMember 2022-08-31 0001852707 us-gaap:RetainedEarningsMember 2022-08-31 0001852707 2022-08-31 0001852707 us-gaap:CommonStockMember 2022-09-01 2022-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-09-01 2022-11-30 0001852707 us-gaap:RetainedEarningsMember 2022-09-01 2022-11-30 0001852707 us-gaap:CommonStockMember 2022-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-11-30 0001852707 bfyw:SharesCancelableMember 2022-11-30 0001852707 us-gaap:RetainedEarningsMember 2022-11-30 0001852707 us-gaap:CommonStockMember 2020-12-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001852707 us-gaap:RetainedEarningsMember 2020-12-31 0001852707 2020-12-31 0001852707 us-gaap:CommonStockMember 2021-01-01 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-01-01 2021-02-28 0001852707 2021-01-01 2021-02-28 0001852707 us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-02-28 0001852707 2021-02-28 0001852707 us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-05-31 0001852707 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-06-01 2021-08-31 0001852707 2021-06-01 2021-08-31 0001852707 us-gaap:CommonStockMember 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-08-31 0001852707 2021-08-31 0001852707 us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-01 2021-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001852707 us-gaap:RetainedEarningsMember 2021-09-01 2021-11-30 0001852707 us-gaap:CommonStockMember 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001852707 us-gaap:RetainedEarningsMember 2021-11-30 0001852707 2021-11-30 0001852707 bfyw:PredecessorsMember 2022-11-30 0001852707 bfyw:FastTrackSolutionsIncMember 2022-11-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-01 2021-07-30 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-30 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:GreenOhioVenturesLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-30 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 2021-09-01 2021-09-01 0001852707 2022-12-31 0001852707 2021-09-17 0001852707 2021-09-01 2021-09-17 0001852707 2022-10-01 2022-10-12 0001852707 bfyw:SauerEnergyIncMember 2022-11-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 srt:BoardOfDirectorsChairmanMember 2021-11-01 2021-11-17 0001852707 srt:BoardOfDirectorsChairmanMember 2022-01-01 2022-01-03 0001852707 us-gaap:MajorityShareholderMember 2022-01-01 2022-01-13 0001852707 srt:BoardOfDirectorsChairmanMember 2022-04-01 2022-04-12 0001852707 2022-04-01 2022-04-12 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 srt:BoardOfDirectorsChairmanMember 2022-07-01 2022-07-12 0001852707 srt:BoardOfDirectorsChairmanMember 2022-07-12 0001852707 2022-07-01 2022-07-27 0001852707 bfyw:NevadaCorporationMember 2022-07-27 0001852707 2022-07-27 0001852707 srt:MinimumMember 2022-07-27 0001852707 srt:MaximumMember 2022-07-27 0001852707 us-gaap:MajorityShareholderMember 2022-08-01 2022-08-31 0001852707 2022-08-01 2022-08-31 0001852707 2022-10-12 0001852707 srt:BoardOfDirectorsChairmanMember 2022-10-12 0001852707 2021-09-01 2021-09-30 0001852707 2022-02-01 2022-02-27 0001852707 us-gaap:StockOptionMember 2022-03-01 2022-11-30 0001852707 us-gaap:StockOptionMember 2022-11-30 0001852707 bfyw:BlackScholesOptionMember 2022-02-01 2022-02-27 0001852707 bfyw:SRAXIncMember 2022-03-01 2022-11-30 0001852707 srt:DirectorMember 2022-03-01 2022-11-30 0001852707 bfyw:MangoMoiLLMember 2022-03-01 2022-11-30 0001852707 2022-10-12 2022-10-12 0001852707 us-gaap:SubsequentEventMember 2022-12-08 0001852707 bfyw:IanJamesMember 2022-03-01 2022-11-30 0001852707 bfyw:StephenLetourneauMember 2022-03-01 2022-11-30 0001852707 bfyw:JacobEllmanMember 2022-03-01 2022-11-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31 2 f10q1122ex31_betterforyou.htm CERTIFICATION

Exhibit 31

 

CERTIFICATION

 

I, Ian James, Chairman of the Board and Chief Executive Officer, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q for the quarter ended November 30, 2022 of Better For You Wellness, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

IEvaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 3, 2023

 

/s/ Ian James  
Ian James  
Chairman of the Board and Chief Executive Officer    
(Principal Executive Officer)  
EX-32 3 f10q1122ex32_betterforyou.htm CERTIFICATION

Exhibit 32

 

CERTIFICATIONS

 

I, Pritabha Chaurasia, Fractional Chief Financial Officer, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q for the quarter ended November 30, 2022 of Better For You Wellness, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

/s/ Pritabha Chaurasia  
Fractional Chief Financial Officer    
(Principal Financial and Accounting Officer)  

EX-101.SCH 4 bfyw-20221130.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheet (unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheet (unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Business Combinations link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Shareholder Equity link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Related-Party Transactions link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Goodwill link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Business Combinations (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Business Combinations (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Business Combinations (Details) - Schedule of condensed consolidated results of operations link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Business Combinations (Details) - Schedule of revenue and earnings of Mango Moi link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Shareholder Equity (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 bfyw-20221130_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 bfyw-20221130_def.xml XBRL DEFINITION FILE EX-101.LAB 7 bfyw-20221130_lab.xml XBRL LABEL FILE EX-101.PRE 8 bfyw-20221130_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information - shares
9 Months Ended
Nov. 30, 2022
Mar. 03, 2023
Document Information Line Items    
Entity Registrant Name BETTER FOR YOU WELLNESS, INC.  
Document Type 10-Q  
Current Fiscal Year End Date --02-28  
Entity Common Stock, Shares Outstanding   404,014,987
Amendment Flag false  
Entity Central Index Key 0001852707  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Nov. 30, 2022  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-56262  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 87-2903933  
Entity Address, Address Line One 1349 East Broad Street  
Entity Address, City or Town Columbus  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43205  
City Area Code 1 (614)  
Local Phone Number 368-9898  
Entity Interactive Data Current Yes  
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Balance Sheet (unaudited) - USD ($)
Nov. 30, 2022
Feb. 28, 2022
Current Asset:    
Cash and cash equivalents $ 3,154 $ 9,642
Accounts Receivable 1,495
Related Party Receivable 108,301
Prepaid expenses 23,425
Inventory 1,657
Prepaids and other assets 78,072
Total Current assets 216,104 9,642
Equipment, net 1,741
Goodwill 583,484
TOTAL ASSETS 801,329 9,642
Current Liabilities:    
Accounts Payable 311,541 375,408
Deferred Compensation 284,499
Clearbanc Debit Card 895
Illinois Department of Revenue Payable 128
Out Of Scope Agency Payable 414
Related Party Notes Payable 202,000
Total Current Liabilities 799,478 375,408
Long-Term Liabilities    
Notes Payable - PayPal Capital 2,216
Notes Payable Shopify Capital 166
Convertible notes payable, net accumulated interest 599,111
Total Liabilities 1,400,970 375,408
STOCKHOLDERS’ EQUITY (DEFICIT):    
Preferred Stock ( $.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of November 30, 2022 and February 28, 2022) 70 70
Common stock ($.0001 par value, 500,000,000 shares authorized, 389,995,988 and 370,747,042 issued and outstanding as of November 30, 2022 and February 28, 2022, respectively) 39,001 37,075
Additional Paid in Capital 3,319,048 1,485,364
Shares Cancelable (250,000)
Accumulated Deficit (3,957,760) (1,638,275)
Total Stockholders’ Equity (Deficit) (599,641) (365,766)
TOTAL LIABILITIES & EQUITY (DEFICIT) $ 801,329 $ 9,642
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Balance Sheet (unaudited) (Parentheticals) - $ / shares
Nov. 30, 2022
Feb. 28, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued 700,000 700,000
Preferred stock, shares outstanding 700,000 700,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 389,995,988 370,747,042
Common stock, shares outstanding 389,995,988 370,747,042
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Revenue        
Merchandise Sales $ 6,986 $ 9,008
Cost of Good Sold 5,823 15,381
Gross Profit 1,163 (6,373)
Operating Expenses        
Share Based expense 346,762 532,243 1,332,475 609,243
Selling, General and Administrative 258,401 533,854 852,184 542,910
Total Operating Expenses 605,163 1,066,097 2,184,659 1,152,153
Operating Income/(Loss) (604,000) (1,066,097) (2,191,032) (1,152,153)
Other Income/(Expense)        
Interest Expense (55,935) (128,453)
Other Expense
Total Other Income (55,935) (128,453)
Net income/(loss) $ (659,936) $ (1,066,097) $ (2,319,485) $ (1,152,153)
Loss per share (in Dollars per share) $ 0 $ 0 $ (0.01) $ 0
Weighted average number of common shares outstanding (in Shares) 372,031,446 361,664,351 372,031,446 287,241,405
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
Series A
Preferred Shares
Common Shares
Additional Paid-in Capital
Shares Cancelable
Accumulated Deficit
Total
Balance at Dec. 31, 2020  
Balance (in Shares) at Dec. 31, 2020        
Expenses paid on behalf of the Company and contributed to capital 1,185   1,185
Net loss   (4,935) (4,935)
Balance at Feb. 28, 2021 1,185   (4,935) (3,750)
Balance (in Shares) at Feb. 28, 2021        
Common shares issued after reorganization $ 36,000 (36,000)  
Common shares issued after reorganization (in Shares)   359,996,332        
Preferred shares issued after reorganization $ 70 69,930   70,000
Preferred shares issued after reorganization (in Shares) 700,000          
Expenses paid on behalf of the Company and contributed to capital 3,951   3,951
Net loss   (72,051) (72,051)
Balance at May. 31, 2021 $ 70 $ 36,000 39,607   (76,986) (1,850)
Balance (in Shares) at May. 31, 2021 700,000 359,996,332        
Balance at Feb. 28, 2021 1,185   (4,935) (3,750)
Balance (in Shares) at Feb. 28, 2021        
Net loss           (1,152,153)
Balance at Nov. 30, 2021 $ 70 $ 36,302 846,943   (1,157,088) (273,773)
Balance (in Shares) at Nov. 30, 2021 700,000 363,024,072        
Balance at May. 31, 2021 $ 70 $ 36,000 39,607   (76,986) (1,850)
Balance (in Shares) at May. 31, 2021 700,000 359,996,332        
Common share issued for services to the Company $ 5 6,995   7,000
Common share issued for services to the Company (in Shares)   50,000        
Expenses paid on behalf of the Company and contributed to capital 2,990   2,990
Net loss   (14,005) (14,005)
Balance at Aug. 31, 2021 $ 70 $ 36,005 49,052   (90,992) (5,865)
Balance (in Shares) at Aug. 31, 2021 700,000 360,046,332        
Common share issued for services to the Company $ 298 531,945   532,243
Common share issued for services to the Company (in Shares)   2,977,740        
Stock option expense 265,946   265,946
Net loss   (1,066,097) (1,066,097)
Balance at Nov. 30, 2021 $ 70 $ 36,302 846,943   (1,157,088) (273,773)
Balance (in Shares) at Nov. 30, 2021 700,000 363,024,072        
Balance at Feb. 28, 2022 $ 70 $ 37,075 1,485,364 $ (250,000) (1,638,275) (365,766)
Balance (in Shares) at Feb. 28, 2022 700,000 370,747,042        
Common shares canceled and returned to the Company   $ (705) (249,295) 250,000   0
Common shares canceled and returned to the Company (in Shares)   (7,048,873)        
Common shares issued for cash received   $ 33 (33)    
Common shares issued for cash received (in Shares)   325,000        
Common share issued for services to the Company   $ 509 272,226     272,735
Common share issued for services to the Company (in Shares)   5,085,000        
Common shares issued for purchase of subsidiary   $ 1,100 548,900     550,000
Common shares issued for purchase of subsidiary (in Shares)   11,000,000        
Stock option expense     411,315     411,315
Warrant Issuance     78,072     78,072
Warrant Issuance     13,514     13,514
Debt Forgiveness     49,686     49,686
Net loss         (891,872) (891,872)
Balance at May. 31, 2022 $ 70 $ 38,012 2,609,749 (2,530,147) 117,684
Balance (in Shares) at May. 31, 2022 700,000 380,108,169        
Balance at Feb. 28, 2022 $ 70 $ 37,075 1,485,364 (250,000) (1,638,275) (365,766)
Balance (in Shares) at Feb. 28, 2022 700,000 370,747,042        
Net loss           (2,319,485)
Balance at Nov. 30, 2022 $ 70 $ 39,001 3,319,048 (3,957,760) (599,641)
Balance (in Shares) at Nov. 30, 2022 700,000 389,995,988        
Balance at May. 31, 2022 $ 70 $ 38,012 2,609,749 (2,530,147) 117,684
Balance (in Shares) at May. 31, 2022 700,000 380,108,169        
Common shares issued for cash received   $ 3 3,747     3,750
Common shares issued for cash received (in Shares)   30,282        
Common share issued for services to the Company   $ 506 250,192     250,698
Common share issued for services to the Company (in Shares)   5,060,000        
Stock option expense     274,025     274,025
Warrant Issuance     17,188     17,188
Forfeiture of stock compensation     (223,060)     (223,060)
Net loss         (767,677) (767,677)
Balance at Aug. 31, 2022 $ 70 $ 38,521 2,931,841 (3,297,824) (327,392)
Balance (in Shares) at Aug. 31, 2022 700,000 385,198,451        
Common share issued for services to the Company   $ 135 31,815     31,950
Common share issued for services to the Company (in Shares)   1,350,000        
Stock option expense     274,025     274,025
Common shares issued for notes payable extension   $ 269 63,943     64,211
Common shares issued for notes payable extension (in Shares)   2,686,667        
Common shares issued for Debt settlement   $ 76 17,424     17,500
Common shares issued for Debt settlement (in Shares)   760,870        
Net loss         (659,936) (659,936)
Balance at Nov. 30, 2022 $ 70 $ 39,001 $ 3,319,048 $ (3,957,760) $ (599,641)
Balance (in Shares) at Nov. 30, 2022 700,000 389,995,988        
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Nov. 30, 2022
Nov. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) $ (2,319,485) $ (1,152,153)
Adjustments to reconcile Net Loss to net cash provided by (used in) operating activities:    
Share based expenses 1,332,475 875,189
Amortized debt discount and debt issuance costs 86,810
Depreciation 582
Changes in current assets and liabilities:    
Accounts receivable (1,495)
Related party receivable (108,301)
Prepaid expenses and other assets (23,588)
Inventory 11,440
Accounts payable (63,866) 113,267
Accrued Interest 41,643
Deferred compensation 284,499
Other liabilities (1,675)  
Related party notes payable   156,756
Net cash provided by (used in) Operating Activities (760,961) (6,941)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Fixed Assets (2,323)
Net cash used in Investing Activities (2,323)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payment of debt issuance costs (56,640)  
Proceeds from Convertible loan, net of original issue discount 558,000
Proceed from related party note payable 202,000
Proceeds from Common Stock Issuance 3,750  
Expenses contributed to capital 49,686 6,941
Net cash provided by Financing Activities 756,796 6,941
Net Change in Cash (6,488)
Cash at beginning of period: 9,642
Cash at end of period: 3,154
NON-CASH FINANCING TRANSACTIONS:    
Discount on notes payable for warrants 30,702
Warrants issued and extended for common stock issuance costs $ 78,072
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Description of Business
9 Months Ended
Nov. 30, 2022
Organization and Description of Business [Abstract]  
Organization and Description of Business

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time.

 

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

 

On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.

 

On August 18, 2021, we filed an amendment to the Company’s Articles of Incorporation with the Nevada Secretary of State to change our name to Better For You Wellness, Inc. On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company. On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders.

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

XML 16 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
9 Months Ended
Nov. 30, 2022
Organization and Description of Business [Abstract]  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

Significant Accounting Policies and Use of Estimates:

 

There were no material changes in the Company’s significant accounting policies for the three and nine months ended November 30, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.

 

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of November 30, 2022, the Company had no deferred revenues. 

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2022 was $3,154 and $9,642 for February 28, 2022.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2022.

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of November 30, 2022 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of November 30, 2022 and February 28, 2022.

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

XML 17 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Going Concern
9 Months Ended
Nov. 30, 2022
Going Concern [Abstract]  
Going Concern

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

XML 18 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations
9 Months Ended
Nov. 30, 2022
Business Combinations [Abstract]  
Business Combinations

Note 4 - Business Combinations

 

On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.

 

The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:

 

Assets acquired:    
Cash   $913 
Inventory    12,995 

Total Assets Acquired

   13,908 
Liabilities assumed:      
Clearbanc Debit Card    2,365 
Notes Payable - PayPal Capital    2454 
Notes Payable Shopify Capital    537 
Sales Tax Payable    138 

Total Liabilities Assumed

   5,494 
      
Total identifiable net assets    8,414 
Purchase price    592,000 
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date   $583,586 

 

The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.

 

As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.

 

The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.

 

   For the Three months ended 
   (unaudited)   (unaudited) 
   November 30, 2022   November 30, 2021 
Total revenues  $6,986   $17,022
           
Net (loss) income  $(659,935)  $(1,087,775)
           
Loss per share  $
-
   $
-
 

 

   For the Nine months ended 
   (unaudited)   (unaudited) 
   November 30, 2022   November 30, 2021 
Total revenues  $15,676   $52,496 
           
Net (loss) income  $(2,319,485)  $(1,200,616)
           
Loss per share  $
-
   $
-
 

 

The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.

 

The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.

 

   For the
three months ended
November 30,
   For the
nine months ended
November 30,
 
   2022   2022 
Mango Moi:        
Total revenues  $1,163   $(51)
Net income  $(657)  $(9,757)
XML 19 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
9 Months Ended
Nov. 30, 2022
Income Taxes [Abstract]  
Income Taxes

Note 5 - Income Taxes

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of November 30, 2022, the Company has incurred a net loss of approximately $4,105,379 which resulted in a net operating loss for income tax purposes. The loss results in a deferred tax asset of approximately $862,130 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2022, we have completed only two taxable fiscal years.

XML 20 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
9 Months Ended
Nov. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 6 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of November 30, 2022 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On October 12, 2022, the Company renewed its Agreement with SRAX to retain access to the platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, issued 1,250,000 restricted Common Shares in lieu of the fee of $30,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

XML 21 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Shareholder Equity
9 Months Ended
Nov. 30, 2022
Shareholder Equity [Abstract]  
Shareholder Equity

Note 7 - Shareholder Equity

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 and 0 shares issued and outstanding as of November 30, 2022 and February 28, 2022, respectively.

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 389,995,988 and 370,747,042 shares of common stock issued and outstanding as of November 30, 2022 and February 28, 2022, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.

 

On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.

 

On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.

 

On April 12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date of $0.0535, as listed on the OTC Markets, which totaled approximately $6,687.

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the "Note"). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, and interest of 12% per year and mature on April 12, 2023 (the "Maturity Date"). The Note is convertible into shares of the Company's common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company's common stock (the "Commitment Shares") as a condition to closing.

 

On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC. The shares were valued at the closing share price on the day prior to close was $0.05, as listed on the OTC Markets, which totaled approximately $550,000.

 

On July 12, 2022, 100,000 shares of Restricted Common Stock were issued to four Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price of on that date of $0.0399, as listed on the OTC Markets, which totaled $3,990.

 

On July 27, 2022 the Company filed its Pre-14-C notice and accompanying Information Statement and furnished this information to the holders of shares of common stock, par value $0.0001 per share, of Better For You Wellness, Inc., a Nevada corporation (the “Company”), pursuant to Section 78.320 of the Nevada General Corporation Law, Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulation 14C and Schedule 14C thereunder, in connection with the approval of the following actions taken by the Company’s Board of Directors (the “Board”) and by written consent of the holders of a majority of the voting power of the issued and outstanding capital stock of the Company, to amend our certificate of incorporation, as amended (the “Certificate”), to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (the “Authorized Share Increase” or “Corporate Action”).

 

During the period ended August 31, 2022, a total of 30,282 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $3,750.

 

On October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of $64,211 for the extension of the April 12, 2022 Registration Rights Agreement.

 

On October 12, 2022, the Board of Directors authorized the issuance of 760,780 Common Shares to Joseph Gushy to whom the Company had a $35,000 debt in relation to the Mango Moi acquisition. The Issuance of Common Shares retired half of the Debt (i.e., $17,500). The Company shall pay Holder the balance of $17,500 in the First Quarter of 2023.

 

On October 12, 2022, the Board of Directors authorized the issuance of 1,250,000 to SRAX pursuant to its Platform Account Contract with an Effective Date of October 12, 2022 for consideration of $30,000.00 for access to the Platform for a 12-month period from the Effective Date.

 

Shares Cancelable

 

No shares were cancelled during this period.

 

Stock Options

 

During the nine months ended November 30, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 10,500,000 fully vested on November 30, 2022. The remaining 7,000,000 shares vest over the next 2 years. During the nine months ended November 30, 2022, 2,500,000 shares were forfeited. The outstanding options have an exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options was zero as of November 30, 2022.

 

The Company fair valued the options on the grant date at $2,787,028 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 per share (based on the quoted trading price on the date of grant), volatility of 151.08%, expected term of 5 years, and a risk-free interest rate range of ..98%. The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ending November 30, 2022 was $274,025. The total unamortized stock option expense for the period ending November 30, 2022 was $1,853,540.

 

Additional Paid-In Capital

 

During the quarterly period ended November 30, 2022, a total of $3,319,048 was posted as additional paid-in capital.

 

This includes Common Shares issued for services for the Company including $31,815 SRAX, $274,025 of share option vestment/expense for the Board of Directors, $63,943 for Mast Hill notes payable extension, $17,424 in Common shares issued for Debt settlement for purchase of Subsidiary/No subsidiary acquired this quarterly filing.

XML 22 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Related-Party Transactions
9 Months Ended
Nov. 30, 2022
Related Party Transactions [Abstract]  
Related-Party Transactions

Note 8 - Related-Party Transactions

 

Loan to Company

 

During the period ended November 30, 2022, Mr. James loaned the Company $39,500 last quarter. Our Audit Chairman, David Deming loaned the Company $145,000 in the three months ending November 30, 2022, and Mr. Deming plans to convert his loan into equity. The Company has recognized $284,499 in deferred compensation related to the Employment Agreements for Ian James, Stephen Letourneau and Jacob Ellman. These are non-interest bearing and unsecured and payable on demand. Both James and Letourneau will seek to convert at least 66% of their deferred compensation into restricted Common Shares at a $0.037 per share price to be consistent with the Mast Hill per share pricing. In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary. On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.

XML 23 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill
9 Months Ended
Nov. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill

Note 9 - Goodwill

 

While changes in circumstances requiring an interim goodwill impairment test have not been identified for the three and nine months ended November 30, 2022. The Company will continue to monitor circumstances, such as disposition activity, stock price declines or changes in forecasted cash flows in future periods. If the fair value of the Company’s reporting unit declines below the carrying value in the future, goodwill impairment charges may be incurred.

XML 24 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events
9 Months Ended
Nov. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 10 - Subsequent Events

 

On November 30, 2022, Mango Moi founder, Amanda Cayemitte voluntarily agreed to be furloughed as a cost savings measure while the Company focused on the reformulation and re-packaging of the Mango Moi product lines.

 

On December 8, 2022, the Company issued 13,918,999 Common Shares to SRAX pursuant to section 4(d) Share Adjustment of the Platform Account Contract, which was executed September 17, 2021.

 

Pursuant to their Employment Agreements, Ian James, Stephen Letourneau and Jacob Ellman have deferred compensation. Accordingly, the following represents each individual’s deferred compensation since March 1, 2022:

 

Ian James has deferred $141,197, Stephen Letourneau has deferred $106,810, and Jacob Ellman has deferred $36,492. Both Mr. James and Mr. Letourneau have stipulated that they will seek to convert at least 66% of their deferred compensation into restricted Common Shares at a $0.037 per share price to be consistent with the Mast Hill per share pricing.

 

On January 9, 2023, Anthony L.G., PLLC replaced Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case-by-case basis. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel is important to the company’s growth going forward. The Company seeks to retire the debt owed to Carter Ledyard Milburn by August 31, 2023.

 

On January 31, 2023, the Company appointed Dr. Pratibha Chaurasia, CPA, CA, Ph.D. as Fractional Chief Financial Officer (“CFO”). Pratibha offers over 24 years of diverse professional experience in financial reporting and auditing under GAAP and IFRS, with expertise in PCAOB audits and more. Chaurasia is the founder of Aprari Solutions and was formerly a Professor of International Finance and Management at the Daly College Business School and a Manager of Operations at Max Life Insurance Company Limited, formerly known as Max New York Life Insurance Company Limited.

 

On January 31, 2023, the Company entered into an agreement with Aprari Solutions for accounting and audit-related services (the “Engagement Letter”). Established in 2018, Aprari Solutions is a leading audit and accounting firm in India with a team consisting of qualified CPAs, Chartered Accountants, CFAs, Ph.D. and MBAs from top institutions, and experienced professionals well-trained in US GAAP and PCAOB audit standards and procedures. Aprari Solutions will be paid $25,000 over 12 months for accounting services, and for fractional CFO services, $30,000 in cash and $10,000 in stock over 12 months.

XML 25 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Accounting Policies, by Policy (Policies)
9 Months Ended
Nov. 30, 2022
Organization and Description of Business [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

Significant Accounting Policies and Use of Estimates

Significant Accounting Policies and Use of Estimates:

 

There were no material changes in the Company’s significant accounting policies for the three and nine months ended November 30, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.

 

Revenue Recognition

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of November 30, 2022, the Company had no deferred revenues. 

 

Basis of Presentation

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

Use of Estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2022 was $3,154 and $9,642 for February 28, 2022.

 

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2022.

 

Basic Earnings (Loss) Per Share

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company does not have any potentially dilutive instruments as of November 30, 2022 and, thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

 

Related Parties

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of November 30, 2022 and February 28, 2022.

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

Reclassification of Prior Year Presentation

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Tables)
9 Months Ended
Nov. 30, 2022
Business Combinations [Abstract]  
Schedule of fair value of such assets and liabilities
Assets acquired:    
Cash   $913 
Inventory    12,995 

Total Assets Acquired

   13,908 
Liabilities assumed:      
Clearbanc Debit Card    2,365 
Notes Payable - PayPal Capital    2454 
Notes Payable Shopify Capital    537 
Sales Tax Payable    138 

Total Liabilities Assumed

   5,494 
      
Total identifiable net assets    8,414 
Purchase price    592,000 
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date   $583,586 

 

Schedule of condensed consolidated results of operations
   For the Three months ended 
   (unaudited)   (unaudited) 
   November 30, 2022   November 30, 2021 
Total revenues  $6,986   $17,022
           
Net (loss) income  $(659,935)  $(1,087,775)
           
Loss per share  $
-
   $
-
 

 

   For the Nine months ended 
   (unaudited)   (unaudited) 
   November 30, 2022   November 30, 2021 
Total revenues  $15,676   $52,496 
           
Net (loss) income  $(2,319,485)  $(1,200,616)
           
Loss per share  $
-
   $
-
 

 

amounts of revenue and earnings of Mango Moi
   For the
three months ended
November 30,
   For the
nine months ended
November 30,
 
   2022   2022 
Mango Moi:        
Total revenues  $1,163   $(51)
Net income  $(657)  $(9,757)
XML 27 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Description of Business (Details) - USD ($)
1 Months Ended
Sep. 01, 2021
Aug. 25, 2021
Aug. 24, 2021
Jul. 30, 2021
Jul. 18, 2021
Nov. 30, 2022
Oct. 12, 2022
Organization and Description of Business (Details) [Line Items]              
Shares of common stock             2,686,667
Transfer of shares             1,250,000
Director agreement, description On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share.            
Fast Track Solutions, Inc. [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of common stock           1,000  
Series A Preferred Stock [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of restricted common stock         250,000,000    
Series of Individually Immaterial Business Acquisitions [Member]              
Organization and Description of Business (Details) [Line Items]              
Owning, percentage   5.00%          
Purchase Price [Member]              
Organization and Description of Business (Details) [Line Items]              
Voting, percentage       89.62%      
Paid consideration (in Dollars)       $ 335,000      
Predecessor [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of common stock           1,000  
CRS Consulting, LLC [Member] | Common Stock [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of common stock       250,000,000      
CRS Consulting, LLC [Member] | Series A Preferred Stock [Member]              
Organization and Description of Business (Details) [Line Items]              
Shareholder owning preferred stock         700,000    
Sale of shares       700,000      
CRS Consulting, LLC [Member] | Series of Individually Immaterial Business Acquisitions [Member]              
Organization and Description of Business (Details) [Line Items]              
Voting, percentage       89.62%      
Ian James [Member] | Series A Preferred Stock [Member]              
Organization and Description of Business (Details) [Line Items]              
Transfer of shares       350,000      
Stephen Letourneau [Member] | Series A Preferred Stock [Member]              
Organization and Description of Business (Details) [Line Items]              
Transfer of shares       350,000      
Green Ohio Ventures, LLC [Member] | Series A Preferred Stock [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of common stock       250,000,000      
MRKTS Group Inc [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of restricted common stock     17,963,817        
MRKTS Group Inc [Member] | Purchase Price [Member]              
Organization and Description of Business (Details) [Line Items]              
Owning, percentage     5.00%        
Better for You Wellness, Inc. [Member]              
Organization and Description of Business (Details) [Line Items]              
Shares of restricted common stock   24,137,499          
XML 28 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Details) - USD ($)
Nov. 30, 2022
Feb. 28, 2022
Organization and Description of Business [Abstract]    
Cash and cash equivalents $ 3,154 $ 9,642
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details)
9 Months Ended
Nov. 30, 2022
USD ($)
Business Combinations [Abstract]  
Purchase price of stock $ 592,000
Goodwill $ 583,586
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of fair value of such assets and liabilities
Dec. 31, 2022
USD ($)
Schedule Of Fair Value Of Such Assets And Liabilities [Abstract]  
Cash $ 913
Inventory 12,995
Total Assets Acquired 13,908
Clearbanc Debit Card 2,365
Notes Payable - PayPal Capital 2,454
Notes Payable Shopify Capital 537
Sales Tax Payable 138
Total Liabilities Assumed 5,494
Total identifiable net assets 8,414
Purchase price 592,000
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date $ 583,586
XML 31 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of condensed consolidated results of operations - USD ($)
3 Months Ended 9 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Schedule Of Condensed Consolidated Results Of Operations [Abstract]        
Total revenues $ 6,986 $ 17,022 $ 15,676 $ 52,496
Net (loss) income $ (659,935) $ (1,087,775) $ (2,319,485) $ (1,200,616)
Loss per share (in Dollars per share)
XML 32 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of revenue and earnings of Mango Moi - USD ($)
3 Months Ended 9 Months Ended
Nov. 30, 2022
Nov. 30, 2022
Mango Moi:    
Total revenues $ 1,163 $ (51)
Net income $ (657) $ (9,757)
XML 33 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Details)
9 Months Ended
Nov. 30, 2022
USD ($)
Income Taxes [Abstract]  
Net operating loss $ 4,105,379
Deferred tax asset $ 862,130
Effective statutory rate 21.00%
XML 34 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Details) - USD ($)
1 Months Ended
Oct. 12, 2022
Sep. 17, 2021
Commitments and Contingencies Disclosure [Abstract]    
Option to sell investment   $ 30,500,000
Execution term   36 months
Future securities agreements   $ 15,000
Immediately purchase   $ 250,000
Restricted common stock percentage   15.00%
Outstanding shares common stock percentage   4.99%
Exchange period 12 months 12 months
Additional fees $ 30,000 $ 20,000
Restricted common shares (in Shares) 1,250,000  
XML 35 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Shareholder Equity (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 12, 2022
Jul. 12, 2022
Apr. 12, 2022
Jan. 13, 2022
Jan. 03, 2022
Oct. 11, 2021
Aug. 25, 2021
Aug. 31, 2022
Jul. 27, 2022
May 26, 2022
Feb. 27, 2022
Nov. 17, 2021
Sep. 30, 2021
Aug. 24, 2021
Jul. 19, 2021
Nov. 30, 2022
Aug. 31, 2022
May 31, 2022
Nov. 30, 2021
Aug. 31, 2021
Nov. 30, 2022
Nov. 30, 2021
Feb. 28, 2022
Shareholder Equity (Details) [Line Items]                                              
Preferred stock, shares authorized                               200,000,000         200,000,000   200,000,000
Preferred stock, par value (in Dollars per share)                               $ 0.0001         $ 0.0001   $ 0.0001
Description of preferred stock shares issued and outstanding                                         There were 700,000 and 0 shares issued and outstanding as of November 30, 2022 and February 28, 2022, respectively.    
Common stock, shares authorized                               500,000,000         500,000,000   500,000,000
Common stock, par value (in Dollars per share)                               $ 0.0001         $ 0.0001   $ 0.0001
Common stock, shares issued                               389,995,988         389,995,988   370,747,042
Common stock, shares outstanding                               389,995,988         389,995,988   370,747,042
Closing share price (in Dollars)     $ 6,687                                        
Restricted common stock (in Dollars)               $ 3,750                              
Purchase agreement description                                         On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the "Note"). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, and interest of 12% per year and mature on April 12, 2023 (the "Maturity Date"). The Note is convertible into shares of the Company's common stock at conversion price of $0.037 per share, subject to adjustment as provided therein.    
Commitment shares                                         4,960,000    
Share cancellation and forfeiture agreement description                 On July 27, 2022 the Company filed its Pre-14-C notice and accompanying Information Statement and furnished this information to the holders of shares of common stock, par value $0.0001 per share, of Better For You Wellness, Inc., a Nevada corporation (the “Company”), pursuant to Section 78.320 of the Nevada General Corporation Law, Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulation 14C and Schedule 14C thereunder, in connection with the approval of the following actions taken by the Company’s Board of Directors (the “Board”) and by written consent of the holders of a majority of the voting power of the issued and outstanding capital stock of the Company, to amend our certificate of incorporation, as amended (the “Certificate”), to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (the “Authorized Share Increase” or “Corporate Action”).                             
Issued and outstanding capital                 78.32                            
Issuance of common stock 2,686,667                                            
Extension value (in Dollars)                                         $ 64,211    
Authorized issuance of common shares 760,780                                            
Issuance of common shares 17,500                                            
Holder balance, amount (in Dollars) $ 17,500                                            
Issuance of common stock shares 1,250,000                                            
Consideration amount (in Dollars) $ 30,000                                            
Related party fund (in Dollars) 20,000,000                                            
Number of vested shares                         10,500,000                    
Stock option, description                     7,000,000 shares vest over the next 2 years.                        
Forfeited shares                                         2,500,000    
Exercise price per shares (in Dollars per share)                                         $ 25    
Stock options fair value the grant date (in Dollars per share)                                            
Interest rate                                         98.00%    
Total stock option expense (in Dollars)                                         $ 274,025    
Unamortized stock option expense (in Dollars)                               $ 1,853,540         1,853,540    
additional paid-in capital (in Dollars)                                          
Option vestment/expense (in Dollars)                                      
Common shares issued for debt, amount (in Dollars)                                         $ 17,424    
Common Stock [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Common stock, shares authorized                               500,000,000         500,000,000    
Common stock, par value (in Dollars per share)                               $ 0.0001         $ 0.0001    
Common stock, shares issued                               389,995,988         389,995,988   370,747,042
Common stock, shares outstanding                               389,995,988         389,995,988   370,747,042
Common shares issued for services                               1,350,000 5,060,000 5,085,000 2,977,740 50,000      
Minimum [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Common stock, shares authorized                 500,000,000                            
Maximum [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Common stock, shares authorized                 1,000,000,000                            
Equity Option [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Stock option expire term                                         5 years    
Stock option outstanding intrinsic value (in Dollars)                               $ 0         $ 0    
Stock options fair value the grant date (in Dollars per share)                                         $ 15    
Stock price (in Dollars per share)                               $ 151.08         $ 151.08    
Expected term                                         5 years    
Black-Scholes option [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Stock options fair value the grant date (in Dollars per share)                     $ 2,787,028                        
Mango Moi, LLC [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Closing share price (in Dollars)                   $ 0.05                          
Board of Directors Chairman [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Restricted common stock   100,000 125,000   125,000             125,000                      
Closing share price (in Dollars)   $ 3,990 $ 0.0535   $ 15,000             $ 18,750                      
Closing share price per share (in Dollars per share)   $ 0.0399                                          
Loan amount (in Dollars) $ 35,000                                            
SRAX, Inc [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Common shares issued for services                                         31,815    
Director [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Common shares issued for services                                         274,025    
Option vestment/expense (in Dollars)                                         $ 63,943    
Sauer Energy, Inc. [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Common shares, outstanding                               359,996,332         359,996,332    
Green Ohio Ventures, LLC [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Restricted common stock             24,137,499             17,963,817 250,000,000                
CRS Consulting, LLC [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Restricted common stock           250,000               50,000                  
Closing share price (in Dollars)           $ 45,000               $ 7,000                  
SRAX, Inc [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Restricted common stock           2,602,740                                  
Closing share price (in Dollars)           $ 468,493                                  
Restricted Common Stock [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Restricted common stock       549,097       30,282                              
Restricted common stock (in Dollars)       $ 68,000                                      
Mango Moi, LLC [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Restricted common stock                   11,000,000                          
Closing share price (in Dollars)                   $ 550,000                          
Nevada corporation [Member]                                              
Shareholder Equity (Details) [Line Items]                                              
Common stock, par value (in Dollars per share)                 $ 0.0001                            
XML 36 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Related-Party Transactions (Details) - USD ($)
3 Months Ended 9 Months Ended
Oct. 12, 2022
Nov. 30, 2022
Nov. 30, 2022
Related-Party Transactions (Details) [Line Items]      
Loan received   $ 145,000 $ 39,500
Deferred compensation   $ 284,499 $ 284,499
Deferred compensation percentage     66.00%
Price per share (in Dollars per share)   $ 0.037 $ 0.037
Stock authorized to issue (in Shares) 760,870    
Common stocke per share (in Dollars per share) $ 0.023    
Retire loan amount $ 17,500    
Loan Amount 35,000    
Sale of subsidary $ 17,500    
Mango Moi, LL [Member]      
Related-Party Transactions (Details) [Line Items]      
Loan received     $ 35,000
XML 37 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events (Details) - USD ($)
9 Months Ended
Nov. 30, 2022
Dec. 08, 2022
Feb. 28, 2022
Subsequent Events (Details) [Line Items]      
Common stock, shares issued (in Shares) 389,995,988   370,747,042
Deferred compensation percentage 66.00%    
Restricted common shares, price per share (in Dollars per share) $ 0.037    
Purchase agreement description Aprari Solutions will be paid $25,000 over 12 months for accounting services, and for fractional CFO services, $30,000 in cash and $10,000 in stock over 12 months.    
Subsequent Event [Member]      
Subsequent Events (Details) [Line Items]      
Common stock, shares issued (in Shares)   13,918,999  
Ian James [Member]      
Subsequent Events (Details) [Line Items]      
Deferred amount $ 141,197    
Stephen Letourneau [Member]      
Subsequent Events (Details) [Line Items]      
Deferred amount 106,810    
Jacob Ellman [Member]      
Subsequent Events (Details) [Line Items]      
Deferred amount $ 36,492    
XML 38 f10q1122_betterforyou_htm.xml IDEA: XBRL DOCUMENT 0001852707 2022-03-01 2022-11-30 0001852707 2023-03-03 0001852707 2022-11-30 0001852707 2022-02-28 0001852707 2022-09-01 2022-11-30 0001852707 2021-09-01 2021-11-30 0001852707 2021-03-01 2021-11-30 0001852707 us-gaap:CommonStockMember 2022-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001852707 bfyw:SharesCancelableMember 2022-02-28 0001852707 us-gaap:RetainedEarningsMember 2022-02-28 0001852707 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-03-01 2022-05-31 0001852707 2022-03-01 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001852707 us-gaap:CommonStockMember 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-05-31 0001852707 2022-05-31 0001852707 us-gaap:CommonStockMember 2022-06-01 2022-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-08-31 0001852707 2022-06-01 2022-08-31 0001852707 us-gaap:RetainedEarningsMember 2022-06-01 2022-08-31 0001852707 us-gaap:CommonStockMember 2022-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001852707 bfyw:SharesCancelableMember 2022-08-31 0001852707 us-gaap:RetainedEarningsMember 2022-08-31 0001852707 2022-08-31 0001852707 us-gaap:CommonStockMember 2022-09-01 2022-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-09-01 2022-11-30 0001852707 us-gaap:RetainedEarningsMember 2022-09-01 2022-11-30 0001852707 us-gaap:CommonStockMember 2022-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-11-30 0001852707 bfyw:SharesCancelableMember 2022-11-30 0001852707 us-gaap:RetainedEarningsMember 2022-11-30 0001852707 us-gaap:CommonStockMember 2020-12-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001852707 us-gaap:RetainedEarningsMember 2020-12-31 0001852707 2020-12-31 0001852707 us-gaap:CommonStockMember 2021-01-01 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-01-01 2021-02-28 0001852707 2021-01-01 2021-02-28 0001852707 us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-02-28 0001852707 2021-02-28 0001852707 us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-05-31 0001852707 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-06-01 2021-08-31 0001852707 2021-06-01 2021-08-31 0001852707 us-gaap:CommonStockMember 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-08-31 0001852707 2021-08-31 0001852707 us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-01 2021-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001852707 us-gaap:RetainedEarningsMember 2021-09-01 2021-11-30 0001852707 us-gaap:CommonStockMember 2021-11-30 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-11-30 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001852707 us-gaap:RetainedEarningsMember 2021-11-30 0001852707 2021-11-30 0001852707 bfyw:PredecessorsMember 2022-11-30 0001852707 bfyw:FastTrackSolutionsIncMember 2022-11-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-01 2021-07-30 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-30 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:GreenOhioVenturesLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-30 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 2021-09-01 2021-09-01 0001852707 2022-12-31 0001852707 2021-09-17 0001852707 2021-09-01 2021-09-17 0001852707 2022-10-01 2022-10-12 0001852707 bfyw:SauerEnergyIncMember 2022-11-30 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 srt:BoardOfDirectorsChairmanMember 2021-11-01 2021-11-17 0001852707 srt:BoardOfDirectorsChairmanMember 2022-01-01 2022-01-03 0001852707 us-gaap:MajorityShareholderMember 2022-01-01 2022-01-13 0001852707 srt:BoardOfDirectorsChairmanMember 2022-04-01 2022-04-12 0001852707 2022-04-01 2022-04-12 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 srt:BoardOfDirectorsChairmanMember 2022-07-01 2022-07-12 0001852707 srt:BoardOfDirectorsChairmanMember 2022-07-12 0001852707 2022-07-01 2022-07-27 0001852707 bfyw:NevadaCorporationMember 2022-07-27 0001852707 2022-07-27 0001852707 srt:MinimumMember 2022-07-27 0001852707 srt:MaximumMember 2022-07-27 0001852707 us-gaap:MajorityShareholderMember 2022-08-01 2022-08-31 0001852707 2022-08-01 2022-08-31 0001852707 2022-10-12 0001852707 srt:BoardOfDirectorsChairmanMember 2022-10-12 0001852707 2021-09-01 2021-09-30 0001852707 2022-02-01 2022-02-27 0001852707 us-gaap:StockOptionMember 2022-03-01 2022-11-30 0001852707 us-gaap:StockOptionMember 2022-11-30 0001852707 bfyw:BlackScholesOptionMember 2022-02-01 2022-02-27 0001852707 bfyw:SRAXIncMember 2022-03-01 2022-11-30 0001852707 srt:DirectorMember 2022-03-01 2022-11-30 0001852707 bfyw:MangoMoiLLMember 2022-03-01 2022-11-30 0001852707 2022-10-12 2022-10-12 0001852707 us-gaap:SubsequentEventMember 2022-12-08 0001852707 bfyw:IanJamesMember 2022-03-01 2022-11-30 0001852707 bfyw:StephenLetourneauMember 2022-03-01 2022-11-30 0001852707 bfyw:JacobEllmanMember 2022-03-01 2022-11-30 shares iso4217:USD iso4217:USD shares pure 10-Q true 2022-11-30 false 000-56262 BETTER FOR YOU WELLNESS, INC. NV 87-2903933 1349 East Broad Street Columbus OH 43205 1 (614) 368-9898 Yes Yes Non-accelerated Filer true false false 2023 404014987 3154 9642 1495 108301 23425 1657 78072 216104 9642 1741 583484 801329 9642 311541 375408 284499 895 128 414 202000 799478 375408 2216 166 599111 1400970 375408 0.0001 0.0001 200000000 200000000 700000 700000 700000 700000 70 70 0.0001 0.0001 500000000 500000000 389995988 389995988 370747042 370747042 39001 37075 3319048 1485364 -250000 -3957760 -1638275 -599641 -365766 801329 9642 6986 9008 5823 15381 1163 -6373 346762 532243 1332475 609243 258401 533854 852184 542910 605163 1066097 2184659 1152153 -604000 -1066097 -2191032 -1152153 55935 128453 -55935 -128453 -659936 -1066097 -2319485 -1152153 0 0 -0.01 0 372031446 361664351 372031446 287241405 370747042 37075 700000 70 1485364 -250000 -1638275 -365766 -7048873 -705 -249295 250000 0 325000 33 -33 5085000 509 272226 272735 11000000 1100 548900 550000 411315 411315 78072 78072 13514 13514 49686 49686 -891872 -891872 380108169 38012 700000 70 2609749 -2530147 117684 5060000 506 250192 250698 30282 3 3747 3750 274025 274025 17188 17188 -223060 -223060 -767677 -767677 385198451 38521 700000 70 2931841 -3297824 -327392 1350000 135 31815 31950 274025 274025 2686667 269 63943 64211 760870 76 17424 17500 -659936 -659936 389995988 39001 700000 70 3319048 -3957760 -599641 1185 1185 -4935 -4935 1185 -4935 -3750 359996332 36000 -36000 700000 70 69930 70000 3951 3951 -72051 -72051 359996332 36000 700000 70 39607 -76986 -1850 50000 5 6995 7000 2990 2990 -14005 -14005 360046332 36005 700000 70 49052 -90992 -5865 2977740 298 531945 532243 265946 265946 -1066097 -1066097 363024072 36302 700000 70 846943 -1157088 -273773 -2319485 -1152153 1332475 875189 86810 582 1495 108301 23588 -11440 -63866 113267 41643 284499 -1675 156756 -760961 -6941 2323 -2323 56640 558000 202000 3750 49686 6941 756796 6941 -6488 9642 3154 30702 78072 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 - Organization and Description of Business</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement, on July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2021, Mr. Ian James was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors and Mr. Stephen Letourneau was appointed as a Director.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2021, we filed an amendment to the Company’s Articles of Incorporation with the Nevada Secretary of State to change our name to Better For You Wellness, Inc. On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company. On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. The Directors were officially seated September 12, 2021, after notification to shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has elected February 28th as its year end.</p> 1000 1000 700000 250000000 700000 250000000 0.8962 350000 350000 250000000 335000 0.8962 17963817 0.05 24137499 0.05 On September 1, 2021, we entered into Independent Director Agreements with each of Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, pursuant to which each director will serve two year terms, with the option to renew terms upon completion, and receive cash compensation in the amount of $1,000 per quarter, paid in equal distributions quarterly, 200,000 shares of common stock issued quarterly in 25,000 share distributions, and a non-qualified stock option to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Significant Accounting Policies and Use of Estimates:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no material changes in the Company’s significant accounting policies for the three and nine months ended November 30, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of November 30, 2022, the Company had no deferred revenues. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2022 was $3,154 and $9,642 for February 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basic Earnings (Loss) Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any potentially dilutive instruments as of November 30, 2022 and, thus, anti-dilution issues are not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, “<i>Compensation – Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity – Based Payments to Non-Employees.”</i> Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of November 30, 2022 and February 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Reclassification of Prior Year Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Significant Accounting Policies and Use of Estimates:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no material changes in the Company’s significant accounting policies for the three and nine months ended November 30, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates the valuation allowance associated with the Company’s deferred tax assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of November 30, 2022, the Company had no deferred revenues. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary of significant accounting policies is presented to assist in understanding the Company’s unaudited condensed consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at November 30, 2022 was $3,154 and $9,642 for February 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 3154 9642 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at November 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basic Earnings (Loss) Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any potentially dilutive instruments as of November 30, 2022 and, thus, anti-dilution issues are not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of November 30, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, “<i>Compensation – Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity – Based Payments to Non-Employees.”</i> Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of November 30, 2022 and February 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Reclassification of Prior Year Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Going Concern</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 - Business Combinations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in">Assets acquired:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; padding-left: 0in">Cash </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">913</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0in">Inventory </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,995</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0in"><p style="margin: 0pt 0"><b>Total Assets Acquired</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,908</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Liabilities assumed: </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Clearbanc Debit Card </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,365</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Notes Payable - PayPal Capital </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Notes Payable Shopify Capital </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">537</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Sales Tax Payable </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">138</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0in"><p style="margin: 0pt 0"><b>Total Liabilities Assumed</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,494</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Total identifiable net assets </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,414</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0in">Purchase price </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">592,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0in">Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">583,586</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the Three months ended</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(unaudited)</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(unaudited)</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>November 30, 2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>November 30, 2021</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; padding-bottom: 4pt">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">6,986</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">17,022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left"/></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(659,935</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,087,775</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Loss per share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the Nine months ended</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(unaudited)</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(unaudited)</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>November 30, 2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>November 30, 2021</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; padding-bottom: 4pt">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">15,676</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">52,496</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,319,485</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,200,616</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Loss per share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the <br/> three months ended <br/> November 30,</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the <br/> nine months ended <br/> November 30,</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Mango Moi:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,163</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(51</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(657</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,757</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in">Assets acquired:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; padding-left: 0in">Cash </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">913</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0in">Inventory </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,995</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0in"><p style="margin: 0pt 0"><b>Total Assets Acquired</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,908</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Liabilities assumed: </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Clearbanc Debit Card </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,365</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Notes Payable - PayPal Capital </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Notes Payable Shopify Capital </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">537</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Sales Tax Payable </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">138</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0in"><p style="margin: 0pt 0"><b>Total Liabilities Assumed</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,494</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0in"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Total identifiable net assets </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,414</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0in">Purchase price </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">592,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0in">Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">583,586</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 913 12995 13908 2365 2454 537 138 5494 8414 592000 583586 592000 583586 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the Three months ended</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(unaudited)</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(unaudited)</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>November 30, 2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>November 30, 2021</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; padding-bottom: 4pt">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">6,986</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">17,022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left"/></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(659,935</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,087,775</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Loss per share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the Nine months ended</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(unaudited)</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(unaudited)</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>November 30, 2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>November 30, 2021</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; padding-bottom: 4pt">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">15,676</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">52,496</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,319,485</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,200,616</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Loss per share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 6986 17022 -659935 -1087775 15676 52496 -2319485 -1200616 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the <br/> three months ended <br/> November 30,</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the <br/> nine months ended <br/> November 30,</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>2022</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Mango Moi:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,163</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(51</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(657</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,757</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> 1163 -51 -657 -9757 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of November 30, 2022, the Company has incurred a net loss of approximately $4,105,379 which resulted in a net operating loss for income tax purposes. The loss results in a deferred tax asset of approximately $862,130 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on December 1, 2020, and our fiscal year end of February 28, 2022, we have completed only two taxable fiscal years.</p> 4105379 862130 0.21 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 450-20, <i>Los</i>s <i>Contingencies, </i>to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of November 30, 2022 other than the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, providing WVH the ability to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. Any future proceeds from the sale of shares, pursuant to the aforementioned term sheet, are to go towards the Company to be used for working capital. Pursuant to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, the Company renewed its Agreement with SRAX to retain access to the platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, issued 1,250,000 restricted Common Shares in lieu of the fee of $30,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.</p> 30500000 P36M 15000 250000 0.15 0.0499 P12M 20000 P12M 1250000 30000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 - Shareholder Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 and 0 shares issued and outstanding as of November 30, 2022 and February 28, 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 389,995,988 and 370,747,042 shares of common stock issued and outstanding as of November 30, 2022 and February 28, 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date of $0.0535, as listed on the OTC Markets, which totaled approximately $6,687.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the "Note"). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, and interest of 12% per year and mature on April 12, 2023 (the "Maturity Date"). The Note is convertible into shares of the Company's common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company's common stock (the "Commitment Shares") as a condition to closing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC. The shares were valued at the closing share price on the day prior to close was $0.05, as listed on the OTC Markets, which totaled approximately $550,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 12, 2022, 100,000 shares of Restricted Common Stock were issued to four Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price of on that date of $0.0399, as listed on the OTC Markets, which totaled $3,990.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022 the Company filed its Pre-14-C notice and accompanying Information Statement and furnished this information to the holders of shares of common stock, par value $0.0001 per share, of Better For You Wellness, Inc., a Nevada corporation (the “Company”), pursuant to Section 78.320 of the Nevada General Corporation Law, Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulation 14C and Schedule 14C thereunder, in connection with the approval of the following actions taken by the Company’s Board of Directors (the “Board”) and by written consent of the holders of a majority of the voting power of the issued and outstanding capital stock of the Company, to amend our certificate of incorporation, as amended (the “Certificate”), to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (the “Authorized Share Increase” or “Corporate Action”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended August 31, 2022, a total of 30,282 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $3,750.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of $64,211 for the extension of the April 12, 2022 Registration Rights Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, the Board of Directors authorized the issuance of 760,780 Common Shares to Joseph Gushy to whom the Company had a $35,000 debt in relation to the Mango Moi acquisition. The Issuance of Common Shares retired half of the Debt (i.e., $17,500). The Company shall pay Holder the balance of $17,500 in the First Quarter of 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, the Board of Directors authorized the issuance of 1,250,000 to SRAX pursuant to its Platform Account Contract with an Effective Date of October 12, 2022 for consideration of $30,000.00 for access to the Platform for a 12-month period from the Effective Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shares Cancelable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No shares were cancelled during this period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended November 30, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 10,500,000 fully vested on November 30, 2022. The remaining 7,000,000 shares vest over the next 2 years. During the nine months ended November 30, 2022, 2,500,000 shares were forfeited. The outstanding options have an exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options was zero as of November 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-hidden: hidden-fact-100">The</span> Company fair valued the options on the grant date at $2,787,028 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 per share (based on the quoted trading price on the date of grant), volatility of 151.08%, expected term of 5 years, and a risk-free interest rate range of ..98%. The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ending November 30, 2022 was $274,025. The total unamortized stock option expense for the period ending November 30, 2022 was $1,853,540.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Additional Paid-In Capital</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarterly period ended November 30, 2022, a total of <span style="-sec-ix-hidden: hidden-fact-99">$3,319,048</span> was posted as additional paid-in capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This includes Common Shares issued for services for the Company including $31,815 SRAX, $274,025 of share option vestment/expense for the Board of Directors, $63,943 for Mast Hill notes payable extension, $17,424 in Common shares issued for Debt settlement for purchase of Subsidiary/No subsidiary acquired this quarterly filing.</span></p> 200000000 0.0001 There were 700,000 and 0 shares issued and outstanding as of November 30, 2022 and February 28, 2022, respectively. 500000000 0.0001 389995988 389995988 370747042 370747042 359996332 250000000 17963817 24137499 50000 7000 2602740 468493 250000 45000 125000 18750 125000 15000 549097 68000 125000 0.0535 6687 On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the "Note"). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, and interest of 12% per year and mature on April 12, 2023 (the "Maturity Date"). The Note is convertible into shares of the Company's common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. 4960000 11000000 0.05 550000 100000 0.0399 3990 On July 27, 2022 the Company filed its Pre-14-C notice and accompanying Information Statement and furnished this information to the holders of shares of common stock, par value $0.0001 per share, of Better For You Wellness, Inc., a Nevada corporation (the “Company”), pursuant to Section 78.320 of the Nevada General Corporation Law, Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulation 14C and Schedule 14C thereunder, in connection with the approval of the following actions taken by the Company’s Board of Directors (the “Board”) and by written consent of the holders of a majority of the voting power of the issued and outstanding capital stock of the Company, to amend our certificate of incorporation, as amended (the “Certificate”), to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (the “Authorized Share Increase” or “Corporate Action”).  0.0001 78.32 500000000 1000000000 30282 3750 2686667 64211 760780 35000 17500 17500 1250000 30000 20000000 10500000 7,000,000 shares vest over the next 2 years. 2500000 25 P5Y 0 2787028 15 151.08 P5Y 0.98 274025 1853540 31815 274025 63943 17424 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 - Related-Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Loan to Company</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended November 30, 2022, Mr. James loaned the Company $39,500 last quarter. Our Audit Chairman, David Deming loaned the Company $145,000 in the three months ending November 30, 2022, and Mr. Deming plans to convert his loan into equity. The Company has recognized $284,499 in deferred compensation related to the Employment Agreements for Ian James, Stephen Letourneau and Jacob Ellman. These are non-interest bearing and unsecured and payable on demand. Both James and Letourneau will seek to convert at least 66% of their deferred compensation into restricted Common Shares at a $0.037 per share price to be consistent with the Mast Hill per share pricing. In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary. On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.</p> 39500 145000 284499 0.66 0.037 35000 760870 0.023 17500 35000 17500 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9 - Goodwill</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While changes in circumstances requiring an interim goodwill impairment test have not been identified for the three and nine months ended November 30, 2022. The Company will continue to monitor circumstances, such as disposition activity, stock price declines or changes in forecasted cash flows in future periods. If the fair value of the Company’s reporting unit declines below the carrying value in the future, goodwill impairment charges may be incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10 - Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 30, 2022, Mango Moi founder, Amanda Cayemitte voluntarily agreed to be furloughed as a cost savings measure while the Company focused on the reformulation and re-packaging of the Mango Moi product lines.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 8, 2022, the Company issued 13,918,999 Common Shares to SRAX pursuant to section 4(d) Share Adjustment of the Platform Account Contract, which was executed September 17, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to their Employment Agreements, Ian James, Stephen Letourneau and Jacob Ellman have deferred compensation. Accordingly, the following represents each individual’s deferred compensation since March 1, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ian James has deferred $141,197, Stephen Letourneau has deferred $106,810, and Jacob Ellman has deferred $36,492. Both Mr. James and Mr. Letourneau have stipulated that they will seek to convert at least 66% of their deferred compensation into restricted Common Shares at a $0.037 per share price to be consistent with the Mast Hill per share pricing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2023, Anthony L.G., PLLC <span style="font-size: 10pt">replaced Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case-by-case basis. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel is important to the company’s growth going forward. The Company seeks to retire the debt owed to Carter Ledyard Milburn by August 31, 2023. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2023, the Company appointed Dr. Pratibha Chaurasia, CPA, CA, Ph.D. as Fractional Chief Financial Officer (“CFO”). Pratibha offers over 24 years of diverse professional experience in financial reporting and auditing under GAAP and IFRS, with expertise in PCAOB audits and more. Chaurasia is the founder of Aprari Solutions and was formerly a Professor of International Finance and Management at the Daly College Business School and a Manager of Operations at Max Life Insurance Company Limited, formerly known as Max New York Life Insurance Company Limited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2023, the Company entered into an agreement with Aprari Solutions for accounting and audit-related services (the “Engagement Letter”). Established in 2018, Aprari Solutions is a leading audit and accounting firm in India with a team consisting of qualified CPAs, Chartered Accountants, CFAs, Ph.D. and MBAs from top institutions, and experienced professionals well-trained in US GAAP and PCAOB audit standards and procedures. Aprari Solutions will be paid $25,000 over 12 months for accounting services, and for fractional CFO services, $30,000 in cash and $10,000 in stock over 12 months.</p> 13918999 141197 106810 36492 0.66 0.037 Aprari Solutions will be paid $25,000 over 12 months for accounting services, and for fractional CFO services, $30,000 in cash and $10,000 in stock over 12 months. false --02-28 Q3 0001852707 EXCEL 39 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

\A,X DNCZPL(.0)F)M6?< MUU>"4W%V9 /S6\\<8QM2?[+4Q*(\7,J#@-V>B%T\6WPF]>*BHX5M"8&7GA%*",SWB<1FQ+]?J,%Q6T/%[."(3N]1CA3_R96'EJ0XT"F2*H M. ?N>_&I-#UL2*!1C?+WP,2#$]MV@":^*@THKP]==C_T>U*5-D,A"Y*J]<.+ MF=KT_C2@W-9?2.J&O'BT7L$'8($.)A/L5ZN'"7FP\F>%&QYO\S4!I9AHXGHR M$"G@!UEIF@ %0 &)F>7D(6X!2 M6Z*2S>W7KV1L@L$VQI&QR?13B&/..7J>(^F%O[ZJ"B_??A?L:A<0 PIL*"N="9*G9B#EH:4-@68 M=0DUE3\L\_]*4>E;UN"X5!J-1N\T_@[3$(6,V%2#3#Q0BD4NT!-9IU (/%;. M*5)N %7*-:5:.=ZO'5.Q>.![?U1SWJX<'1V5G+_.7V4HZ$4NME)ZNKEN:7UH M@B+"S )8$PH8.F;.PVNB B]UI1/"I6JL5:Y=V8Z849;HKR M@1(#-F%7<2P_MB8#>%)@R!P8PB#G69_"[DFATYV,N)!JM5*IE86(W\63[_1[ MG6!&#*0+[$^!(9K2ZD-H%10A^J%YZ6M$!UH6I)SC";%'T# P9 Z5)?%R*516 MZ6,*UEYR!S5AR^*?38A?;?"R.&&S?*/K@/7/#3)ZK;5S.25YKB \6K<-2+I= M@.@0&#;_R&RM#QB#%@-8-Q#H( -9"+(VZ C!F[$XY^=@8!WS?I]+-D)P<;%_OX)],O0O\9"+Y3/P M+90-ND]TWJY0':P&';#WI(A),4T'M*!I!:DWL>@%L\P!+!U4#D8_('C$A5.8ER@D?J M*(C"PIN$?%P0HH^084C&?BXVQSB_-#TT $F&Z?5+?IM._!&@X#5CG!NGW8.) M"-*XQ_$GU(9ZZNW81'/FCA2.1E#0&PO,L+'U-8&!*-;R",\MHY>)S%@T[RP-OJ$VJU(35O"3X%^,\6T7[TB<$E,E&@L2:R@_55!:\JN[DY MCB,VC67?( W9AE_A%"VMBZPB$SH3)5J$)Z9)<&K KXC/=-J/!_HJ))*S:U77 MD; 4&/< Z9 8H1[3-4TV[2=+*4!NTA#LK.X& IW86"/@YO4-'LA M,%&QGGJ L%9=?J+E2#A"LL*H='"W&A7T5LAT)[9 EI;V0'[4,'9/25?Z\+0H.6$2Y=8Z9==>YF(SG_\#T/@-591IM+ &^"A\5H>$HG^\V[!0,! './C$Y^[XDNWLJ_(3 M3YRJX?R=IV BD#H%S+\4YRJXA1RZ-AC+CN$W4YZI=X5RZHOJ-T1SW32[85V$ M3R_;[[L__O/DS:PQU_Q M_I$^/1CVOD[P0\,>71S0HX.KZO-#>\*,@Z$V+1N?K)+5@I^F![4?XXIV;96_ MG9]76U>EX?BT_K4\U%OTVZ%UJ));]C?Y4T5X>-C8 \_]AO%4H75ZVZS MO3YL3&YM/#W?0XW>F=V^->_;I7WMX*K>LA_5AYO6I/RHGOY]6WHV6\][3T^H M=OL9-(U1^1P_V.^_V5?3IC6&AZ=E]OFP/>WIC\_JU^8>*DVFW4:O_@/A]N/9 M$ZCUII^:7ZZ.*E?JIPOKB=YE[W$/#B$S'(E.054R68'JL@ZEE_+F7]# M;Q!(JV-G,7FB[\A,:[;VR+$.4U&HTI&[KTACS[?]P,E\4!ER$/Z[:S./3 M5Y$8'UVIQR\;<$"AAF9(\"*[3M^/360Q )9X&#=2V=-ID&PPNJ\RT2IH"@2N0AN\'ED-CT)&4U(D, M5/KF^F,PM"ZA!ZET2J>"X6YSWF;/#-/[IKIG*+@NI8=I]='%+;_^8P.I$QNA M.O.:C51RHS!V^3V2LBKK-Z&RQEZO4;2$=IG(G M4$RE>%:&1"UYM>$UG==45/\SAWEB13"J>"-.WV M&!8%X>K*4O):BK!QZ?;K)@_Q*-+U M/L ]V.2C[UFW"S79D]F6C<]Z#,Z&JZ5=/+&SUQSNT,LM@(%Y56B \@O >,-J MU(Z7[>^I3/ /,Q)FPJIIBTK,P%;*N[7M+=O;E=V]_. MI+/FRKHMNT1>)Z)5T[VK^U(H=V_1\$SW\+P9-_;[0N2QN)QY<1H'JK=A\:_Q M5R;],N[4VX[!.^6JO[Q4%ND1=Q8&U<0^S/_%L7CG/U!+ P04 " "YB&-6 MZP")%FXM IK0( %0 &)F>7)%( M"0 !<""(CE^T?\=K8H#?# :#P5Q^_*^G17CP@$D2Q-&'P]??OCH\P)$7^T$T M^W#X:7PT& _/SP__ZS\/#O[EQW\].CKXB"-,4(K]@[OEP3!>W(^]X&!"4)1, M8[(X^'_IXO\?'!W,T_3^A^/CQ\?';SWZ-XD7$)S$&?%PPGYQ<'1$!ZR&'!+, M!OSAX(P$!Y>('+QZ>_#F]0_?O?WAS;N#3Y/AP9M7;]X6G_S+CV$0_76'$GQ MYQTE'PYKE)[N2/AM3&;';UZ]>GM<_>%A\9<_/+%?-/[^\6W^UZ_?OW]_G/_K MZD^3@/>'=-C7Q[]=7HR].5Z@HR!*4A1YC$ 2_)#DO[R(/93F2+;.ZT#X%^R_ MCJH_.V*_.GK]YNCMZV^?$G\U1?HW?KHB4Q_@N^/B'P\97@<'/Y(XQ+=X>I O M\8=T>8\_'";!XCYD,\]_-R=X^N'P;KI\I-3>O'G]^NTK1NO?V&_^)'\.XRB) MP\!G3#I!(5OS>(YQ>GC AOYT>]Y8[1U.4TRH,"SC[!&'8823G.?'[(^/A6,= MVY[MGS>(X"B=XS3P4)A 3GYS:"MK.:>[SRD: M\SCTJ5(Y_3L+TN6$#O(F)F]-YBP9C4X9'.4A2N9G8?S8%=[5.,>%HH.8YS69 MH2CXFBL8%/DCG'@DN&?_%4]/LB1@LS&9M]*X4&"/L\4"T7E,Q\$L"J9TPT3I MP//B+$KID7-#\?,";+0,Q9$+AL LYF-,1Z9L]S")3*;<^!YN!U9,H\?S71#E M?#5"E#L.H$ 7.FB"GLP87O\<3A!2LJ7MQY.,H MP;Y7,Z?H[3$+TR2>QO?L]KD"N=M"]4A962W!=#=FF**+$8FHV%/"ERB:Q9=Q M +#"]N$A]92*(3G"*0K,KE\ZP\.J7Q7#LL/"] @ RB%/>758AVPX.&.B9O9U MF"MG%$B9D1A^'2:M,"J8%;1E#W81<-%88+,5684=)MTV)-R-N&F9=5(D_*% M)'L4>QD3O4'DGU+!2Y?G$7/YYMO<9++2\5;J A%/=U._RE?@! MIE&3J*UB-$43I,?WDN/R;X^W/2U&P/-=X@8+(>*K%U^O# MP\9DYW0(XF5W^&A%6&^^O %JPFL%X!R8HP5>W&&BB6[C4ZLBB]AU5&=NJ+J# MLAE1.0VB@&VL"TJ[,2O\E&)J'?K5O-C'$/[\%=,H^3#V&C1#]DH2DXIDB.YP M^.$P2XYF"-W_N?))7T_/J!5!3S<4WL1)/OW!79(2JH>W44PJ,*8HN3FY=A]FA+T,#-@5BC]WP;' _7"U>1LL'9#F M=*@$5"1*8="5Y/+K*8D79FQ)8^GZ8T(-@0^'K^B?YV+^@Q?&]!;VX3 E&=;% MN9H?\[C3HX3]#[,QZ 66G8"#=(@(65(SZ5=VHP66&S6:U3;<)==:I8^Q2!.Z M5K89\:V\Z"2WV,.4-+V37N&TG#DPNZ2DCNL::S_Y)(>J9,]K,7N ^%,SC.G% M8U>LXE-=2UU?6"9 K^3>&PGWC-AW0_ ]"OS3IWOFZ;+#+#Z-E1[?3\X(@"GY M\!;T;#J/V'6,FE!7&!K[QM![?](T@2BQ_G?8 V6$IYC.QC_+<#B,$VC MX;? MLP:(S=AX.Z"48)^'\ G\PWA#U1I,N;$!5>%&J[W3,+ M'5[+2$FY88A4\)J*7@93NU%KQISU(S(H(SCORWL)^GKY"F9I!X5C1=,X4.FF MM^Q--%30-H+[8OWX6VE!.[X8":'^L46&FHK%W^G&=H.6[,)!51[]#1W3WYZ- MI5N;"F6W"JQ=G'FW."5$[;A)*C..A=S3"PLJG+D%]:4=;BJ1=+QR2=8+*XBJ,3%/UU$:,HH7)T%:>X$BMHI[8*R;ZP3PT_<)6:6_VW11 - METL"]_W&)PZ\5'HP<]?9Z@HQW0QUIME173P*>\\$*3SMOA*S8R7#DW@7#ET) MH;[H(!E6K3X5.+O;NKW=*]-,8H%)_"W:9\!%',W8\5,CI_6>*_O>A=?6X'B0 M0E!"_@Y8/54T+9I)7!).7MI5!:TA_ER 8*\@^;SJ!*@Q=A],E\D0W0"CL>RO?.X M-Y91 XT2\._A[]!I[/W52 6V%@XF)-0_%Z0,-6LWO!M2NEMRZC9"KW@4'-[P MVF5S(_9@&QZ%ERBCN+AXL8@C:WS8&M[E#M'AP38NUIQ_ ]_/<: ;%@7^><2U MF[H[WP54W-[F])@B1 KV%,]-C#PIA9IPD4>O]*J.O:V/]EWXP&5%XO #ZI%8@V)M#004\2U[ [8E:MZAZI99X^+1[ M_#K>*P:1;YTOK>1<^J8 'MT%&+9N(Y8T<]S,FEEG(>T^FV:SP-0_/KF&;TA3 ME*Y)3L[/3;H;3/*3S^K50TC4M8(SVSRJB-J)\J*WS< M(M:K;"M5 &U%X_'HGB=)MA.FE83ZYYN1H68M/(Q']#I+63%+5O5S!_RJ4WL> M3&O@9\VK5G-9[.BH4Z'82SVI!*7";:LK'RT?<3)*?33MI:28E]4R8Q3O+)'$=>W!5WJQE;.H&VQC'TGU81*5C>*I6 M.-+F-T[/\!;8-^-3->I(F'JQF&KE9O[4$RH3J*)8CE M[CE,'@(/)^,XA#]4A80PJP"]#QTJ4T4<2)\D-B:?@CS/UD=U=\Q2T"Q>* M=D^)44Q7450TFI5U!P11I-UCNH1T]EW5*R#5ZAHQ>J0/\W^GUWIF!9V@I)DK M5,[B"M/=.4%/T&_W>L3=[:96^6V\YFM":BL7>TRM1SKEHG5-R++W_ 6%C4T\ M#1YP.0_H9P\UHFXO#5KL5(713C#LYDQM*TRG_I$N>E+) =F)!<7L+N+$&A-J M%!S&;YAPH8Z-BO]0_[Z7QSH79$J6:UW]))_OM9'6NG:5%"PSKT"*"4[2DF ^ M!7"7 (>$N^#[=@EKUG3BX6.EQF,^MJT#H#&VPSNZ'OH;D-AZW[V*H[BIXNQ8 M36(Z?;FW2)!J=7\;<0:GUL[CYMAN354=%C0A4- B23](PU%;84>G2H^IS]":UT.@4Y9<^5H$QLU9IJ#V[JKH74=/<&C MYQ8OFN';30BV;=.8VK!/Z6F8_]6'PP3/BAZKD"IJ-8MAB)*$[B3VY#IX"JR) MSQ8=>ZJ'V_A!RK"&-'*9M0V3K0>I&J%1V60#]B%JFX!-6VJK8XB4$2)I;#Q* M<1"RY:S=IO7GJ]WPPS(SJE8S%KC!$++S7K6:6'%V,O=]'.7= 2PJ+BXM6QRR MH;KX8-GAT 8M*PJ,3\/6+41/?\D$LW$=X>-DQ4_%I06NQH1.N!!\D>-EL#>7BRB?5#X) P H6*YNC&3]OA0-<$DXOWLI"E/DM!P^\RGSI@4MA8R=SD4*>)Q1+%70!UTD7;.E9^W-O'LKPB\@LM?, M: -()8O:(%:'L+SM'1P2,DHN^2)V1S2#<20X67*4_!/+1*CY%X4E!L!/;-L9 M+H*TEOW&7YBW G46-SA]BWU,)^5?DR$*0^R/,L+:M-,-&?LV2FPI$NW-3E' M3R6%U@K_"E':-0-+JDY+%8&PKX(///*M,8,BG7!+;&Q$9K73Z\VVDZ-F*WI. M0+I4V;OC6)U@/_99"V@*3>7@MUCQZ[.85(E).]QNV[3WH_* \<[C@-D:J@2^ M!1UQ5$1\#\J!F.],,4.!HYUD4G63$6^.$GP]M=(A3XMT7Q6M ,C6&"V5QJ1/M@LJKB5['/0LLVB6X8>']G05%;8Y<* MMD&VOUN1 V'%1J "STJZ8/=,Y-#MM<'#YR'4 TW1\1'Y:Q*S_X_! M&R/KDM]G56&.:<7;W3JM;G&2DL!+RT?2P2,B?EYT@DKI% =I9LGCWV4ZO;XY MJP%>"0.LL^N&Q![&?G)&U\2FQZ)(KJ>?$2$H K\[MQ#K@87>!E?%)" '5A'? MPX0B*(G%T\>26$FTFH5:C)/:4/NL3;4@J=@A<4%!:\]A'#U@PN)^KZ>?*&Z[ M5)7;M'NPI33!K"(5()MU;EMH@VF*R2VF"T=1\#5WH1C:N;R1>F>P" +W#'8$.LP.8 ]H3S8'BLK350JMH %Y'#H0S)%SI.^ M<$2!(58Z@0D.KRO\F/_++BV -MK@?7 MQC5]""BF)\M/":OQOBJQ M-_#2X(';$AQ.V'4GL!]'O83G&UM#&V KJ8#_%(UE+M'M&@V6(PV?[BWVXL@+ M0MR@/(G=[DXK4]P'LU!Q]]IAD;7FU_SX#>BCB$_$IM;P#H6C(+$BS-X5[LR6:8"_(Z;-" MX+7I /-=1NF?L+VE2*OTB#0K>>P13%7*"!?_6YMU^:YKKS>2*N&]\ %K*7-R>PL K= 057AP\6"@.J$32:2E332&7LY2'IQ4;787T+0Z9,^$&$:9@ M'#!V8P*NJYY:YO0FW-:LZ>W)W!!\CP+?3D!Y*SG'33) V;J)9+LFAN'@>?1 MCY*8[&*CUFFY[:P!RKH&A+:2Q\6*X 8M=WI^5O2<5V2WHE97:"IDD8/QD8[H M7P3H+@B#79V8FR2?E2FTA:>5[LS;I$?E ZI%9Y,BT>>U.?FX*B2A ]T_6=+[ M,*,S8,]^N]NF(KK/9Z\*D;62B[Y-_RI.<:7R=WQKD9!^1K:1#.#V]'3;3[C. MGFY[Y4#2P=-2F43!%)CEG;A\E9=-X#F\RDL!ME*"D>J**JFG2-'*CP@Z+S]C M4\!6RA H$MW+=WR%/=#(N5#$UU;(A>(2G&U?IYH9AL4Z*%OS%0HFL7HM=*6Q M91-X#AI;"K"5:W"E4:ZG+ VW2A?*7X,MJ6D>I3W MXOO5'&K&^I+-!YJ5JF2=[DD@QBI#K*"-N_)XG-U1*G0!>76;F*033!:6&2RF M^0QVK1JV*L$2QAE>5>@_TQ>UJBA-CLISNT1#]'C[*2&D\ERCSY>J)?(PCE(2 MW&54'E@\3NX_4>**=("]O(;H,$4.CZ6'%_5Y.S-$GX-7B(NG)4\]H\_^CY6] M?T ASJ,BJNH/[!\&D=_\1>TOB_RH38_EZ9,79JR*._UACJ(9OJ6HG$ZG&/Q^ MLN/)]^INLVO&6GEMZ+2(?1*V?4CMWH7@V"J8>Q5''J6T]K]$_DI+YAF$MCP@ MRG3[PV -+-L+YL)4?JL_<9VR5,P.]2V$PSF]*.G*K[Q8FP OFVV#"MJO@?=7 M8^C>,8@/4*L'PE&2\G6M &*_!%./!+1K7%#-QW=7,TT'12N-&["$G4H=S.")Y0[)Y327\ + M!I^>V_RJ5CFI[RMXUB@FU;G8GN-LL4#TGZ;C8!8%T\!#4;H-UZ%YWE]_MZ@4 M$5L;3Y&H6T^2WGY2Q;%]ESC:(Q_C/$DR\C")#HW*4=='N-@L/R*U-/E?FA05 MJX\TV8X[5Z _64>/VQ \%(9-<6N';F6O4LO4W?L M;2FO=V]V%O&&LG202DEU>*_FC&O?CE4DZO8X56%N?7>H(KG'9F>1[CY!3]CX M\K<:8KUV>^GE0DI=DA4V![6U":2DG.>;M#%Q(TQ= IJ:(\I-I;;%(BC*/J#( M9Z^G]"C#T>IJ9?1*L1YSL#&F]1VA1]L\(4")CJUMHTG2!(:CR^:,._Q MP9*[K(NFZF5/=:,+V]8P>KMX=3O;X)/=WR):X=S7=->L%9'USGF M8R]FDQ3388\@]G6/.MW=JQT-CAK J%1YRH5FJ0=]3@B*$JI,RQN=Z?$F&M+2 MJ=U*SMB8%8UL?Z/H4'9KZJHRN[YOM'#=7_/W8QS[CP$]&8P-P6H$:IZ<1RF* M9@$]%(J,)^O&KAYMV[V_9KXG2J)I=#4H[2HF>5W/Z-?#:!>^9:M\M"9;(]4H[J4"HD6G8+,[#+/"&9WBA' M,5"M.89FG#E%)*)S8UF/^6.*70:U47/GT--C4RMJ*K4)C?AUA@*2-V6\Q(BY M"-?;V"[GU.GVA8<:2+:G IJ\[C?K64K9)WA6EX^P]TI/!87J8@U;2([?=^KZ MOKPW4"W,T@H?,#LQRSE!.W,-9M"7G66$;L5HF ;FU52N\&-M[B2.Z(]>D2.U M"ZVI3;Y/_A5];"L>0_<'NB%!3(JZ#;?8"U&2Y+?^'+E5JZM:SB?XG4&3?)^X MK(]MQ>66(K[[D@N11W89/UH^@Y2(L3?'?A9B5E$N=Y5^Q?ZYSU3T-,!^\29= M%GOUJ?JNU5FG_Y8ML)\C:.W5$WAV#JTBW0P+<,: 5X%,2%J;Y3"F6S/*RSBQ M6^PJ'5E?/NBX-=F@_[66"R.23ITUJFPW ]->[]O55,9%3.LMOF?]&Z/9>43U MZR)?R,FR_$?[VU]O%KW@>&>H6]^O7(4$E0N*IU-ZRWY@M^QXFF3>'.5*"T5^ MN%9616BU04 Z#^813E$0)EH3N-"*JH>G:A*,#S4+]1A^6(H[#OVW)BHK/P8P M0W:;:) ?/=4),Z;7U> 6:TR^)E]WA(_I;>H36+GP6 M)**Q@5;'.!]+2_970>)3E-QC+S<-1_D1!6)HB<:V]XA9\>S(;ZRB8%VKH*X- M*2$JT,WEI>3^?&6?#=89@:H\@W<7FU- MRY-U<-^U?^+NBM'6+E>0$Z_ZQT(_4=B9HY.+63\ELL98E8N>4R&TTE?+P@2= M51WJG?1M=/*";LD'JKJW.H#:;6Z]V[GOE\<:2$-8.\7;10':_M_-,B[B:&:I MU\X.)^XNA.$YB')3!E1J+>^9$.?-(GLEO<6,7U0P!-M5FECMG\SV2EQ?)+4K MLVWE D'.NQ_2N2F6+]CHX'\^ M7_[ZW?_^SV_>??;T>_3=>__KNX?9[\OHTRA[_/B.O'_W\YLOGR;+)'SWX'U] M%?Z4'J=C_-/7=V__>GKM7:2O_C@[>S/^^?CAZ63X^ZL'?TS^^#[]?A!?)?\= M_\<@B!Z^'WV#OLQ'X6^OR9"\._O#^S))OIGCT?(JB[Z>?1.,9J?9Y&IQ,SG^ MSGOW\W"G/SWU?&7Q?C+-[_]%KR]^@7=AH^OSJ)/V;__D?W\ M]39]PM^?O$I^^7[R=>9__C+X_?:;X'CY=3J:#?\*HLGGT]_0V]G7GVY__?G] MZY\'/WV,YC>/OWR\_R8^17$R^?P5A;]]NGQZ/_C[8_CYEXLD>1B9A\\V5V-O\[N4H^_._!<'Q[=.2FJ-Q. M]RW4;K"5N6>H7VKEC?;XR&B=Y8O98L1;M5Q%MX%I7A5?Z:W*LV"?X"2C@A9/ M6<)L+3Q<,SJ-/7N+XC>3(_"A7;2:"8&=>J M,(<6C+K'<[T$= D#NI1EM&M\UDMLUDMLUDML%D1-JX0:"M?3TN;?-^8:XZSX@N"V^L/*=0(O2WBH3>D23:-T;S$E'?IOG;E?6D%;K08\I6-=7:%VAI3.0.Q/XH\XP@2%K%X*_0':#ZY* MU=6;BHPQVLBI1G?O:\/RTB%HJ*DU* A<58+=:S2PMH=#EY1ZHJ/VH!9-&WXV M8Q?6K528/G8 /BS0OBXGR_J_J'JWM"Z0RH2M'55JV8RF&T&ES0L/9E!/&6\" MZFXR0W[NU$G#\9:9"[>(9\H^-!C>J'G/NG/'@?_,%F_4O&I@X146-**(BO-T M;@@%*(30;I9JG5SQQ(JM:+]V>LZ588L0MS%K SU+K37:"(,K1C7&.=23D&Q3 MU9%F-8TJW]^0%;*[GN8=(2VH23$=>^FON].3$A1MA?C7*5E1CAP"SK5AJ[0V M:O5S$+*5Z;9-"USG"?CA4,EUY ;\BVKYMK$*7CJ-TB(2"R;,0SBT)3>W??TE M!PPZ\4-$#2P 1#*X,]6E(I,R5FAH+CA>@,2!M'##411(=UXHZ:U.MEC1BIN5 M"H\C]BQKTQ[CTK+%'P<6&1]+2VE$&\2LV&5\&K9>6O7,,IG@-KJ%\'&RXJ?C MT@*WSH1,PR]VXYY''XX+@65#VO0N4U>S+U7.?=/FV+HIC3%CZ__0\ M\H.'P,]0&"[/%ZSQ'PE0R N=L[(MC*?AOEQ)JW.X8088PPWK*LT%KI'-IK'/ M>-_M054#)4:(%PY[]2_H$.QCCTXM)MQM(\)W^S.W_4C$S[YK2#E+A3\AAK=C MIE"I?<%"YRXNAAJHBK[=>VB%BP:]].6DSE'T$UI@'6'=^,2A'E" 1(6+;G79:>/[D:KUZ'H>Q+]2@S4C6%,+ M2#YW9THH("Q;MH+SP"#@^O;GR?@CB;-[/2.<]]U^*P7N2MN+;.@GZ>3AI&'<'\=C.@QLD4$VJAV+O7RRBYO.&+GV6WKR4" MG( ]_2O?PQ,S%W-*>6Y.1S2 ML:\?H[RA9%U:U R> 1&NWXJ,2>6'(EH1E%B4IO4O7RE>GSA3A M"*[R2.!X(@;'4N'L,WS7B;2U:F#BJK&A/6KQK-J#3\&A=-^8JL^U5%).!M9CB)OC*Y*_:M MQKV1EK5G-&Y;BGWF&MWO87<>4_"%/(TRPBS=O/EX(6=K4ZL(OWQ$Q/](MDJ0 0,&4VB[^PWQ;X4 MA/>@@L"11>8)KAT/18!!=22&?5V@/Z5GX!R 84WE28"-@,II>O'B M'D7+P8R2S&N]U)8*+!/M])X!PQ5 K;@I?3!T4O0F6RP0_:?I.)A%P33P4)26 M38&8AHO#P&-A,ZMB"B9"MST>OY1,9VF3$#+<+ZSO8:WIX2 =(D*6E,"OK+0L M\/1;B#EI#JC.PT;,6@MLBB%5+C8$1WLW:HD '=:VMH"45)?DP.S^OJAD@<)1 MZ5QMQ/) VYBM]-R^S*NPM&$\MN-G*\ZP*DF=-QHZCSR"*<&)+:55Z4A*I"BP/T3W =6=;#:Y M,4&EG]VQH7T;ZG3=Q2QILE$#2BNY;*?3*?;2X &OYGV+4LR:*41>$ :Y+AZD M9YBYT4*6II*QMLZ-/X:.3 "8DHD?QODE M!4?-:ZNI&JH-/M@"-#U-LJZS)Q0+-%SD+#ZM'R,O@I^*S;P,4S769JDU&2ATRS>$,VYHCA4 MGX\#5;2 8Y_*HXAN2SK7XL%7\1QN?-);[;2Y=%NM%*^G4VI$$<95UJT%67B+ MY))P^JABS!HY:FH=!K59]!D'LSE5D(,'>D^EU]^0BV1)I?05\9;5X" M!F_]G6OCOQ3&UV2L6G4M);&U5@7_I0S^2QG\ES+XNRB#SZHA38*4I>RLJ]\ M54+EC^N\Y+VR:I-@ U^1=HO0YR"=YS+ 1&8>W$_BO%*5AFK394\+Q1WL)D%E M5*F "CG5!B!XUV+-&8"43S5AHK.JJC;X:+/LH$"![\XP?$Z6H&JA>T!&6;<" MMVFY49(: JO *;M]0*1$K5J%?&[MHXEHQ#"K'4!&F 0/J(@42>A@[$Y^&R0V MFH!(2?7'>E1#SE*Q@S51YFED+L4)_]&I@*PCLHV-AZ MA]T2FP:>EJIZ;8P/'/NB.!2!4XC0@.ON ,RGEXX;+QTW M7CINZ$2POW3V/%T(EC.0GT! MJ8[R] M!+6Y8FA%49S_**,G?X3);*E7,YG[H=. .Y5ZZMS5 IOL+^74I>748>6WT<2A M0^.*C;X5^XNP:,&6JN#>#G[3U N-+_:_PT)S@:!]%:II7*(O,:'62>VN9<4B M$]/98[VL !)\=L8E/73CRSC04QC;7^VYKN L4^5^KH_G%7Y /AK&Y#XNJB5J MH"KZ=N]5AW#1=LJRLAM+D9)JI]'"UO@NA5OE]6NK?&,3'1M6W4G(V@AZ5#WA M1,P+49<1T<<._0ODN$;.'29$!-LC2.36!OX*776\AYN1RH)^+I H=<"T)/EDJ3M374M*5K#NSD?O" MN2[@60J0JSWD6-:?,DK.NE@8;3PI9N"Q0!RJ.]*;*A1[=NPI@6BI-]"6V%CI M#B.BTA<=V8J6%;_0%C7AP07/H#Z>9&JXM5;9Z,BJO/+P#ODEH-=CIHD0!.W, M(ZX>I5:40O!I/XP&Z>);^]X8/.72$:H"4)RJ\Z)7W*VO>H0N9\GMK6$,H+TA ML8>QGY=Z-F]HVCY*7_2)*BCMG5T,+:I:0Y:J+N"ZO)"]CCW*9'MF'*O#67%4 M&B>AO[^VB!8GD]JV$GWLP!UONI6$ZZ_PEA:[!#@K^!=)U3.C;Y?"-@PJU*&; M\IY0'OOU>G0#0EC\(N/XR7+])S=HR7Z5-\HK7@J3LYA,<9#'A/DB_28KGP5/ M>O=O$ET*<%F OI(2B;O Z)I3="#X1"&U>;D14.F+"=**5L4=235.HZ2-)P\G MB6U?CHA*W[@C1*OBCJ0.IT$EVK1(/>'TGQ-6HFU\TA^+87.M%9Z2D]VF1"K;1M(/4&?ZY-] 8F>Z*XX]+K2\!: M5^4PJ!\[:K_UWF]?^@>?AD$D/]G^E\Z2WR:+4O V]!3J_/HF#!>Y4HB3MOV'@N5OG M1@A?%D2>-_ZG_3BDI(NOL(;JHY$3*QUMV->X66Y^TQ,+C+_>"E68UW=.4';5MM3FNI5GZWYA%B/V-[;*1_IU.J(&Y1D*B#5YV\&L^_8ZM#-N5N(H<6L92R,G MU Y&8&K1>#UC:3,4[RU8H];.3NT9WJ19&>7=WL\Z^2/;'[ MLN.-_29$$9/WR.8]O4ZD9RP6(%7Q!399Z%.$%C%)V;O_"-^EU>NE'?ZT$.O9 M = &7<4PF4/1B&=YHLO ]W-X4&CG'5A I%][2814Q1H+7LGBZ7.4T?.]21_H:5KI$8/_2LT@W:<@DW+F?L.6@K, MF-)>>+!K)HBD] !H6LB^%"GHPE<);M8J#VZE[UJK$2FCU,MM*(6NO+0YL82D7$5_-9I5PDQ:ZTV:.9\2@."-;-XMS[JD6TB6'5K?4"S'W#ZRSUC:%[J9&:X+36^>ON2T!/Y1/'Z72*O?1Z.IPS*^0\&H3Y* %K M@$&5HA^'\0S:M.\RDSXJLD[(MU,<[N$OQWQCK%/K#^L+5W"I-<+OYH M>B\4K8.893\)AE5_D) .8-']P'^,4(5ZG6HF73_$XP.@=S0Y6=;_97=/$3S" MCE\F5 17P6G*A=1*]Q!Q66V*ODW(ZA/$[EZ)#%X= MC'ECLR_ZQFZ?T$\L:#\1%8O;R(ZR$\(%V_--0LZ*AA/3V%3=^,3!S;'=J%E9V)OK@XTG M*.M%X/LYCBYP&F9X W:!5K&3G=@+@UW 1BM9H)$#>L$8;QT2]*)2M;PF+2"M=/@ M#.'[\BJ1[GIJD9<@4^H9XV'88$VIOH2&]%56.H:$[#C3NGJOW2@"D;_E5L)> M==>P4GC4_J1[)6J[8J1*R(N9\5$E^)11 ?::"4E)]>PTDL.FT%;3V?OB*/:* MY*W(/\W;M9]']$\7N=CJ/S+Z./BS&K$VD.!]L2%""?:^G<4/%(*@D![ZPUIH M6@?6?G,4C,AY;NP^S=T_0:HR@@FQ'(E=/SRRV122>(MG09*R0_@*+;KQA#N@ M V>5+EOX0 "WJ*]/BMV$0:0_'VCW%WQ3N2_6#7X=8"2&&;4]H_0L2#P4_HX1 M.8W\D;SX33O,PD'=')RZL(LQ@0VZ7N\APS['JJIE#WL;F^D:I;[&$K-3ESL# M.CV?3?$L1-T8T1S)Q:U!%_&-M;>:B8:2CUD!U)#>9X M?=+S&TBH-"TW@_QT@]E;BCWAT-[!W%C/_Y(ADF(2+@O[%43+;X[9!]B%> #W!6^XZ5AP> X& M(/A;@_9#U8LQ46C]W>$JU=H,3N<>M>[ R1C]\#(U,))J6^X&8,FJ"G[@0M+>4KPK"X;TQVLRB1]E,2.: M#*B-V0?K2(B'0J/O3MCG.O":W)#X(9 W;M=DP.; O>/"%C(*W;X[L>(F3E(4 M_A'< QW9W&%[9#KQ86EO^VVBC]B6&Q",.D/?&&C_/1#-=;&UL[;UI<]PVUC#Z_?T5N'EN3=DUG&V3M(->I)OGJ)GZ#[/M]\^?_[I MTZ"EZ\1J]>OGMF]?? MOOH:?;Q9HEK9ZY=?/F;!%XQN"/TM M32)\A=>(0OYMOM_BOW^1A9MM! #1W]VG>"T&)$K3YS#_>8SO@/2PR5O8Y.5? M8)/_*7Y][MWBZ L$(S]>G4EQ>MM8BTUZ7L$9P;_/"3P-2/%CCN, !R6LL(*" M:'0#RJ)R75@Y\1MK1D#\)"V7I!O__8M=]NS.\[;_N\@RG&?+79KB..^2*"/[ MTCW77G9+-RXF$@!>O7J.HSPK?_,,?D/I)%Z;X5X""5 TP"R_A#ZHYTGN104[ M]-C];W0;45DFH^ SQO&SC]=?_.,&%D'%&.31&7][3A?Z1Q/>1=JDK)?ZY;[D M1PW Q8CG?D(^CFW^+.+!7J?)1L.3/%&A]?P?!_%_$L8#4 ZX+6/SZF9QCA;7 MURFN14#.9]XD9!@ M.?A[Y]:;3BRL?_G_+;+LSW([-=L(&+ MTZ +AE(0^.%_^I]O7KW\^J^(34-/CO$Z],/\*25"2(/__'R!S8 MXC1,@NO<2_/^?'@A8,0[+P([H:;R9T;B%\VO';S$SDA M3T[/EFGN^O:/C@X,2GVJ&HW*X94H M.! $*7]X<1 C./#COTCBI%SO+/:3#2Y6'5DRY/N,KXQH140*C%I4\GN<(C;> M[7FA91HO+FIDG_]CV$ER@7.VV#DYF\:6E<;:+HRR!@02H2!C4$@'/7\2D6'. MS2XA2QJ2T,%J_-.9:"2X%V5%%A:0%DCJ5$WK3\XI#*L'G-XF/4DJLJB I"TQ M_2QH>H@9=7WO$9*O=CD\[,$+Z-@>I,[ZSIP7;4@D9U9A5Z,G88S8'+>FD)1# M#?M:B-S(]H29 T,$B<)%)*3S9T7F%X,5!"*S.=[@.&<&*H06)#'Y9[9X#,=6 M&-1[/?_'N-]DI)(0%222C[)PW]9CT<\P^K]N=4PC_C7=8#K4FYK<,&E:1EZ6 MK=;4 S*E)'7V&?]J-Y*C-AP2&:+#4+)F[P-M 7(I/C*&"45'B.T!)LK2R^XO MT^0A#'#P;O\QP\%97)G/"S\/'Z9X4.RQL7WWB#EP"KO')RN@;;$$1(X]V9%5 MB#GTE'.HU"LYMI9[RT%+(^U#KZ%N&/$N9_$#SES(JFCCVIV%,U%P'XBG:>#;B*0"NSU%:39_[ :K@OH&$RJ@T M4$)A"_@?*)\/7@1ZYQ7Y M+0SW$ ?UC$0?,7W,A+:OR=Q7Z*O0P?8_;?DT<_ MV@74S^[?$[;A*Z*EG*S7V!_[GW^"Z,8[BRB 7*X/G6]6O(*/(R MVK?2?;>WY[4\&'"1A[-D/8X#,=/_?Y9S+T+#,AQ\/]G%H,1?)E'H0^C/+=G+ M&UW]4&PT\EFEQDBS+9'-+='"@UA7VDSM"2J*7!T1TPW7HW4:8 M)74L?"+2*0Z(J/-!:%FVVY!?3I&$,P& ]FW#\9%0QJ:P(:A:'^."Y.:&,. =+WTZO =*4#>,_B+) MIQ(BS6:VGY=5P$ADB0:(L$EERIE8HF:1J2-BI3IKIT."OJZJ (?_>YSX.WC) MOB'C%!*48?_+N^3A.9G"A(?\4,M,9Z&QDR=D49KMC2624 Y!,,9%E(&,TL!@ M(0Z]TX[Y5;[?>2DA6;2_PMLD51T,YFQMKVDO$EE[^W8R\?YU)LK3O!*8R(2#2!T L$&HQ-POI#AKH\"(4O:HM!% ML*?ZT#A@H%)2R-3ATG880O=IM;G!XD#YW%+!\)[?UE\:MT&()QB UT95ZH.%"R7(C4@!. MK7.%[T+0&./\PML<=@L(%QP[=MF WTT(U#ROQR(8[,;MJ.-&D_,"]/K[TNOE MP#1-R9%!72(TCG4);OMTOTR",>1!O;X#\5 "I):6QM0C1">C)$7% @A6<*A2 M]F!H4Z3T)#E$PFZ\Q]+!QHH1CG:SR%:VK6XHH5&+%)F$FK,Z5Y 3*=(PK2D_ M*LR'*R&+(""*3S(]X"4+N] )Q*"HS_BR M/',U";%9[GV@:HXUSWD%Y@<* MJ^; RYE7BI%[J5%SK.WXDF)^D-2 =SY=$OWT+DE5Q4[[/*'4Z[EQ;S5@T+^D MI*@&\PT8U)RG0ZO$!;><%[*B MR?DN9L,Y?[+!Z1VY>=ZGR:?\'JK'>/$8W[YX79M6@P(.M3244Q";@XI)KJU' M):>: B)'>I#-44C=/8ZB\02DL9P+_8$'0',\P$B!&#@Z( 1\:)T/;$0GN-0;-=QIQ]J(4#U(6R0" MMH%WU\3_M4_%1V/[5+6\&XU"!9+&6J4S696PHZ(T(>)F.S]43)C9,EUUQ!BB MDRR(I 946B/O,"%JKF3W=&GL+1&,:@R"0>YT"R'%2TYW$1EX8A0F:GT&C1&_ M*UW4]ND@ T3FJRY<5_QMT@GEM>^ZUK"H P+I+VBD]?-%A : M-8(-1G0T(L/=NBHD+&GI"0($!R8.%DFN$U7C:"YN[900[R_3&MKM2!TV)%56 MT>@B,T!SN%WO/Y7W#5U1S'H81OGY\N7K%Y2G\HD6OW$I$!JU@([]UL67K:4W ML%B-U@%E!!=QNY3/(E]Z:;HG!L4/7K0;NS6.V9[V6W48P:6L#$9T25K>$M?3 MG19,Z,7==B$H,U(,O5%8M9_L"ON8+'\;82B;.4US<]56-BT6$X!DUT\Q!=5S MYE#:20B;DL5JN9.3XX#*=9M=30B&1IF(LPNU&@RZ$2,DB M7F3D& XO00?5R6/RYSTY]486B\;2]G4F?GMI29YBB,OV'"(.-"ONM/ 8J-<< MXS4F$A.<[G"T3+*QN=U9WO;WWP9 _>EG5"5.:!])CUJF+F5 QAM>#H3X#?_P M+U-H19GO+PEU!6O2M?#("$@XZ>3-2DK;QH8BP., !T[>HG7Q_9&MA55.2B:5P!NHI.W '.F2>1(A.YP#;;TH%QZ M>UKN-@[(;])=HZKMM#XVDYU=NG$-X--Y=8LE')]C U@M\K69TF.P0ES::!!H MB^.,5A I]]A/(XM&6[JRQ55 R:)=BJF(G^O4WNK#5)'!KB7"(6W5DS2_P>GF M(HG?>?&OYXD7PVT-]7-+:1]9WHRVM"UO)D!)V_5B+[WU8A\=X]LP1TLO#5Q> MKGU8VNP9;DB"_M) ,K_(#C'18*E<0D;$VQ]N(DV%SF ([(O"3,".^W7IK3 M*+MDC8JYCB\_!=DK5:2XKT0[6'R(%0,C:&NURM%JC:S_98K2X MP[&_[\B$@R-"P:=&MT\)G@BIFG)!<)*X4&2T MW&NH+VJ\!UXCYTE\![<4[UWHXV94S;?L<%2 (BU:$M\]@RF\*>\JJMP"Q?.1P$]&/8:VFX_Z^)!](7!BZC[)]$7G2-# M@LC0-R=K;Z#J5T^[#K*^CYS$P$0\@B[PH5/AZ(GZ/_]\L6+%R_)19.B!YAXA,C&1R_8 M_U#&2A]XN_P^2:&)Y5_1U\6?PBS;D75HJ%Y=2@!Y&7CI+I('#,44T>L7L."K M5W3<*;Y-=UZZ1Z^^8;]]ZE9*%>+1BNT5DO>PT&]N26+"KU)::3B@JU_BE-9H MF%16I9NZB?HS 4TKU!DKV%$),WH2QN@XB2(O);H4$4FXR=Z,Z;*14U(AZ$JGFCI,WJ7 M6)"N8B,'^2\24'J*%+MT71I]>O;IY(A#?"S-KD]!J[%$J57?RKD\Z8M;R80J M$12VFHED27MZV%+4!D'JE:#&TC!D,77OAC.$*O MOWE[]/;MFZ.WWWQ#C8#77[\X^OJKKX]>?/5J%!OB")$=MYB65X[V3UV[WF5" MT\B3%Q%^%#FU9$F8[.A >S, RT#&>]@/;N6KC^U@2IJA6EVGO.!D1H-J)P?5 M/^30&(F:RE1P*UTF9H(.^Z'E9=K+3F(?R'9QX?^0P-)'A%JF@?OK3V<;J' > M_4-^P.EM,I@'+_HQ@5X;;(TYZ2,',.3%..K)U';:;(H0FP#4Y^,6F6AS$2B- MC694>'A8DE$0T&;T7G3IA<%9+(PU.3RA2+*+D^0A,2RR1*%J-(+AB!Q*@O@D M%RE#:L8UTH,4& ]+H69"N/0(E)%QN'QGDBU;7;B[[%V8G17U.*?! S(Z5Z$# M0JP&'P97./?"& C9I!-(PUQ%B$RT+XLEE)5 M+!]V(A3+NE -RLTE#/Z 4_\>E*X,HVLOQ0+_@BHG_' M =5MWWE9,\.\V.L"$ZF]\1['-E3[;6[[:.H'GLK$071R62#4]44VC.<-&[<_ M90XH2X AK_KN/8[)!Q!!N8U@$\8A"#^\H!:;C2R:AINZT)O,0).)(YM\A(KI M](6ZN8#C..Q>W&[$9)O39:12=B^-["G!-/?9&R\_B^R-ESR?58@,O?ZJ2_4L M]I,-/D^4S8D/4IBX':Q[601 :%4D-O3Y$QCL-OY8P22A@M1"L2\VJ^&\?.K&?#SJ\^" MGU_I^?G509I9^2!2QOH1(S/TFUP]6#<3[V';S2"$0EKS)>/".K7)8BZT-27C M>'U-CO? :D ="7PS[!1X,X-3X,UG<0J\T9\";PXZ!7[$X=U]3E9[(+K]';[8 M07C]:MT)RYGB=.BWMP/W=R\ )?)4KH$\M@B*Z2KPP.(785V=>"Y9L*"#PV:0 M?/"'4'\:'E0HX@H'&&]PL$J77D2^DN-=2A9G78RGR-@QW-2)&],(-$W((9-- MGT;D%&DY*(V ZT\J\7[V=07<*8^9U*$V9D&OSNK-V#?0ZV9;/8 MU;JWS!"PT413>)[.44B;8M!+2CF2'5"$@F[#8KP[GP!U%$PAHLK]G)V<*JB, M)+,(_%\G*>OEF]+6D6Y3M8WYVY$]+3D..QR[RQ<:@CVAXS=T4%-2NF2?7)^0BI6AA, MSTPQP0XR>V1?AB/!E6WNI(Z>,7CCR.V<,OV&R8;QN2L79.N9FOWA5"5P=B[3 MDM=S/)0FY6:[$.IH5^KE#J+/,[Q:+V@_7XLW:F?KN6A[0NCZZGW;8CYX&+/= M;18&H>>V9?80,3"]2X74&E]DV1?B1F8E>\]'"Q0#.([:.)C'&2G!&:0=G#0 MKM8_>FGJQ:.?F9K-G-0+54$D>R5D?T;E!+=%]TSXUVI9KT-Y4-01_?+"8L%D M_:E8L%BXW,DH!L%P*>MQ"69PS5AJ!C"J3OZOUQSBT M:H-T]YZ//B<&4-H ]C9'Q&B\"Q]PC+-LKH:&E-FFEH:8((,UM."7748[6&8W MB:2BR0THZ4MX&[H*]IO6F$$ET1LRGII1!T. T3.M5M\[T5K<$KP<7&0H$&$@)CIM[NO,,'1B\/?J8=GX%TM6LGYI2L JL_MZ<%T ME#;FSTPI53!0IC%]_4,++ZO/PN+[^L.FR6(#+7X+G"^]++[RS1Y" ,%#1?0,C3,P\FJ>P\ P,&K7G\H95K5XOJ?Z/1\]>,U.KU:?4"KRY.K MQUOLAV[WZ,D."I^'\5.4 M5)5EO6K;;QT'JD\HJM)XJ#$Y=4BTB##"?FQWHG@3!_Y#(2#*DOVW?,E^QYF5 M2EXUG'YR/ =V'EILDC0OU-75^C2,/2*\\1TT,H$6)L=AYB>[\1,GC+=UH'^8 MPB8[3-ET(EP!/*<%Q7#J@*:_*4/.D0\K.I6\OMQOG'I]R#14VSC&6W(;A703 M*/G/[3FR1*IVLG^@*:"11L+7,QS'&!LPC1&]L7+'/@9$;5/?D7^'9BY._2%,($/)HR2@^X*/1NPZBC_+F0PO[\ MYX6R)YU&D]&%ST[-2Q;;-[EHMO=SD6FAA4K>(Y2.*@,A9R=P$F:JY4R$^^#D M">'RZ0X'Y_6':D/&VEO:CL0U 4HN93 0G<5D%YSE3A6V/OS4BID(_^%]O+I; M'!=.\@DM4,--YW&JB4"3:G/%2XHPHV8NYYN*P6KIDY)BQ)..UN5;,AW%YG$G MV]?]F2>!3-E8AM/HW'KS>C-8H\XI:#'F(7@!J1K%77Z%:>?O2R^U(HB*K:U[ ML_M )VT)SMK!;\FH?3,%QN4KSA"6JT530YD#O,*2MZ*S^($H-@Y?(%4 S.<% M4@&EX0ODV<4/)]>M%\AOG2J4PR7"X U21["1'](K'Z0K,58!,!\Q5D!I*,:G M9Q>+B^5G(,8&$F$@QCJ"#15COG#1%297&7U"7*VY,W\/R2D(I .QFBEY"#FR4>+%1_0-.UFC) WO"$\C%J!6/=$XE>"^PB"K@*6E MVAC2>KV[3=* D)#66PV.X2%'4P=8F;,N'"6?163U-QW.2A 9AY]OA_'S[0SX^?:SX.=;/3_?CLC/ER^&,?3E M"\OI,P((=/QTSLN:N')F%F@,=XM?$*B(85W[@^*@,JK/,;<,I4OYN9J<7$-#IG5Q;7CR.O>_&YX87J19LP"4+SC_02*:AV0 MY2Y=SGFJNPPRV5-T&5@8( LM*NR=*;I. M"K<8T=WQEHE+C._ WZ-^">Y"(A&<E[I"J4M/+)< M--<>TP REX@&#,I@E%G(@9 =O !T\;%_+'=@$#6<6[&N,J!GP8O!\R(;BN;F M'R=1Y*7NFPCVI_:+4>-WRG#<*]K+UFI,-K?E6.9)GV-:#Y8N+CNM1LXO:%;" M5+/8[!8)II4WRU%C6@ <:0U]X32*(A-(Z$P%=$@@F1&)AFHEW>TN4PPU^*;I M[Z;=;KP[]A"I; (E+Y1#BQ66VC[**QH+8ES+( M@6;)3R1JHIU<7(X*>&3W(IL!(7K*2@E.Q4S!2)%LR; ?>!ER 3,?\.9V=#]A M=WW[OHL.#.JJJ=N30R$HKT1EHX?IC-.!8XQU'@ZC]#U0# MD>A3+6F/ZC*LDL_V#\"2X1^SA:]8_OG:CE(W_G YF6G>IDZBS\U$1/6Y#BQM M*6YE.H6,J/=R4&Q2 8ZT:F0Y!\&D9V&,ENV.&F[.&B-&-BLXZM ?VN^ ?4Y+ MT/TC<,"*A$G6-%X\U7+\D!@*56G%#-6CW?6$5]*][@$OQ^X 3],5SKTPQL&) ME\9A?)=-A'^8N[QHUI_@C0H'E0%-^Q56* M7R9QED1A4!;!(W=;AN.\65S1BZ[);V@7L@RB\J(DVZ7X!C_F[\A.OXX=&3(V M> XTH+%QD 6G\(T-X"WG&&=^&K+HBF2-WNTR(CJ98@N2#+??P M+@[)(>/%>?$6"HVR"$@^,2ZF^G ,-W51D\H,--GEOMMLO'0/ LVM@^J%4+F2 M:SGOQ_:&V6E.H,$O M G,B<;$,D_3G:W^>(VV>7O$UH[EZ"6QI,)IOG&#IQ- MQL!)Q)..1<5@YQ+8F\<-*>Q'BX'Z1WDK+9/-+:1IDT-Y>JW"<%,7AZ,9:!+I M*R>/QN(!,#:_WLG18?630$&>CV MB<^.S>E+$)/9-OL(KIG/&G5\/HP-4W"2)] FP_\P^N(V!3?6=-X@ZJ$-)= MM)=BHYANM6&X' Z)W'$30+6&&8X*/1BRH5)R-*@.-B)'O0 ZQ<"G;<9B%_;/ M6PG2H2?3B2+LI;=>[*-C?!OF:.FEP1_HS#:6V,ET)B.^S$2%Z@)[GL1W$U4N MM0BX[=)%]E"3U3ZB56@*"4//X*=++^H$'_WA/FZ1N-K[LCN,&9[U/"V@4Y1/ ML0'Q'^R&5A5V:7[!U_?)-ESO!=&#?[A/6%HTQA8O9GL7?U8?[!_M6Y6][G@1 M^4QOO,?R4_WCWJWVO\F#GG6Z)3I;9>6,:Z2^=%XC558V;D8U4AO5WY1HS$,I MNL!SMF< NL_Z "4(2&3V)LFAK0BW'.TYTJ[J\;F?GYQ\375@EC0>06'A.@ID MET2P[KT,7Z:ACQ<178#\'B*N\&\[ N%/V$NS*[SQ0@CS7@2_[%AQM*D4E)& MT4-H/@)T( M$VFT+)N&GJ&31Q\"%Y,UVC:^-90\X+05U55?9E60#=2%]FIY18&7?XYV@JG< MCG#?&;&L9U!OEN9"GXKT%O(/ OJ.D(BVE]OBM!L ;/-;.$0:0, 'D^Z@I,D''.]P M1CZ U;I50WGD2T.YE0M-2@60TM)(BXE.]2(3SC53*378]M99)";YJX$^D5?. M?2*OYN\3><6S5HG&P!8=(F68B P[A,Z3+#/BKGX5ZUV?M"#)7DV(\O4D(G]_ MBD(ZUEW3#6/>5,)AAO1(#:->#_SP7SO_\%_/_\-_;?#AOQ[)&B]_4S<+TH@94&%Y-M#1&-%&8SD:__7OW7>!6"H M/&B<*WIZC:6*?#7P1/K*^8GTU?Q/I*\,3J2O#E%%NLN]&_ FKW"VR2%=/^S> UG IP/[_;%'Z=/,^T'A8,$BX&@2J3- MV[ 6(+,T/XT'*0:4QH2$O;*C^A, MLIH5T=Y=(D"5=+C,@)"1MSJWA,@,TRD*KXD1!\NQEG-UBVU[>JRL-R]_C&*=083#-R0]COR>;[FH]\,(0,(7/H^WL<-/2MA]7 M&PUM>U#@ +EC>]QXC]-7<5%NY<(65@$D3>*$*1#=Z+Y@E0GK6GU2U.@.?O6' MTNDA"Q]8Q,$RH06P< SEKZ87JYZ;VTY\Z0>>HFE!L0C5>!O+N);#8=QOE][O M2:,#;#@H_'R?1 'A'.3MYWM(+)A>3LWWM2VBQI"I"OBR^8C-=VU\]65QIS^S M,36&RR'756]_DWIQ1C1]>-^87A+[[.SF8=L8/G6_QF=T"<2OX5@R!S"]^0C> MCS*#;W0NVN@LS@EIPRH@:7KY[+FY[>.R'WB:4#K'\CB,S[Q(#J#& 7=W%;]Z M\D![L$U8]%2\CPL?J@P8:JA!X#HFR77-3G"3%O M:.RNH>!8'X4,8[+QH MI+-$O*XE"9$"('L:@K'PYEN/=GZ.*!E3'B)R) <699?<7_8TFMFH,,8Z"S=' M<)[,1X/IJ;(BU+6DBUH>WY I$XB1;!?+$B0!P]#I@F#\#(1'PS*%\Z6! M\&"187G"]$V%M4V$IO8X&%ED9+NX>+V0P*)N?DE31&G7] PFNK9M-%SCI4:% M[N@:H4$3; 4\H@;8\%=HY/G'Y,"+H;'KW)/NZA,$US;[)C<_7U4K6L4:5@-$ M-< 8O&PG=!K:5DVO6W)B.R#1D$7-KK4:"@P+,F52!XUKB+H1^L0L6=(OJ:>H M2%>PF_R@A$5[BJ?5+.EQXD10=.QI-3=6H7_ \YU'H]AAI8L==,(E_^!.K+.8 MLV3'5BK[;&V_[U8/Z!1E%VD++3K/;=6P(7QN:*)]R7%8HW4H5C'LO')_2O4Y MFR0'DJOSR.04&N_L$25R8L*2./?NB+#]D+"$&E97HJJZ,_T;C D0SNH>]H-3 M(H!L]!$D!A*XT&SSXAT%1FJN4/O(5OYSH9C#:>@YU M<*70R4IR>B$K?E9-XJM&S*961!_6:ZKZJ2ETR T 'R:3]^-="I8\3L,D8-]! M;;?188M/7AJ\3SN%C\9)9^@/A'W3:A"!LM%)P=B&-'&[15QG>,M MIUZQ?(Q2I3J+"YT*UVK7],=R?Y!FTI>^-^"2CX!Y#X7Z_#P.[L%"HSG0AQ%P M\-,979D<+ELOWB_NR,(T0>X89WX:;B=PD>GW''W ]W;4^:\;,1A*N'O^A=M7U;KN-J+1ZT7'QZ-2H4#]Z!(EN/QXS9?T<6,/5>UFT< M)3C&"8@.TP^5/!-E&\HQ/;@6"M1;.2500CA4&(1>&A9%IV^\Q]$U+NV&UF5) M#Y.BZ$Y1Q#Z^0U!QV*EHF3.S6R-%B_T!0E:>?&0IEB5;-+"$/>F-NTY2L*C' M#\XUW==V/K4Q9-*XW2(@)_<>69\1Q\I];Q8WHW?[4&/X>^C)>DWL(QHD7)0% MNO)R#)U(8C^,0FKP+O)3# [,"*+G=V2M?6/PR!(Z!D3V'ZU&@%HBU]7*1-\K MIJ'4<9^<$:6F$<(X$A%[9KW04(.S^ &SWE>K3S$.R)G_"X'E)EEM6;%GHIB: M-0TP6LAJT*,)1#(G'QV"\@1E.(I06*WD,'"D#Z>J2!)C&@R+?3QYQ/Z./O#@ M=&,D)LT9UOM(-+:7G3SE&$36VKB,7122M^)M%Y=!]6Y/=_DNQ==DK90E=%>^ M-2.&*J9;_=KE<$C8S":0#[R<4?M*G3SX&S*C8K\&X6$?]-EF@XG*G^-H7SHG MS$Y_P3R[(8$""&15+.N15?L^9PQ7$+P^Q"6H#@R2/$X>21'67R'672%H?;8F&+WAFEN+E4>V2!@/!GE M[%X1$Y?3'3NX#'>FK-9K8D>D(!_0D-";X'5>N(6#9U(1'!))6 0!#93P(K3& M[B-U54SBG1%2#(<^?_Z(P[M[FUM?6WAC[0F>LP M[ Z"X%*VD//8TB'\YP6R-YF&ID-QH22K=3,]E ^R7L0!=S,:75O#5K:N" T" M4_HL4:U%VZ0W\X9+,0WI@C2$)*F7="6QATM!=;\.)^708Y93SNCS<)%#)I/4 M41H/J/=S$66BA4K18J Z/8]DPNBHO8 16]L=!?14&-I326!JFKD*)5.M=UP2 M0='/23 SST#7.:A W)[T9(;!_" M#'(Q=I=EJI#9$2:;;-?M* -#VRS+:3$4(_+79Y(*QX'/7)U;L>Q4/DQOJ69; M/$'4D/109/KTJG>NW[3Y)-=S&I08$OU4=JZG]U_E[ERD*?C&00S?[>LAE]X> M?D4S/EG\3'::I&LFDU,]DTM6L%C0-%P[(IJ-ANQ_C,)_2!R79Q8GG20R++ 9%Z/@DTDT7 M<5N_3,.[9M:<'.FA$84YD6 B?X*T2^FC<&.*[4=A?G/IHW Q"#W *&GI#_N/ MQ")B>S"M$AE38@Q1ULX3+UYLDEV<&\D*-]RV2-1;2S@/ Y!'1\S#C=2E M;<72%C(#F[1P_J7BTJ@><''Z@ .BA+" UE)HIGNN,MS?>CQ ;Q 5NH7N+''\ ME-5/!"1/6SV(=$#&(O28B2$>ANTVLEBV5W?@GFR!(!&J?[(RX+=>!$0]4AY> MCN1+PBE>>D2X#G(L-JJ;];B41//L*JP""!2]"NMR=1J&6_<:R1E0^XLDJ Z/ M=%Q$A+AQT5VFS*P:^4@0[V$[+5D(A::WV);V%EOOB%$K%A,'AX*28_S1($?X M@(KO<#7=ZCTSMVW/S,+W<02"BX,?""C$I&9A;V._FHT.GVTQ'1T#67D'^D?0 MJ$ T((QM#AK59/+5*3 [.HF'=F:A,4W402E]3)8YW,53+8>CB*&0MNV#.(.$ M#IE#_38#%M1>:3FB0R-3"DZ]/A(BUVFG H0& M^@0X$3EYQ*D?%I6P)BI;I=W.0T"NM>#'CGCI:V0E7>..%4""6V!YYZOGYSHL@/?_57#2W S!P$3IE'TV# MJQCAQVV88I?E(68@R:/HB ?R:7"4XH%/YAR\9P2L,,Y"?XHZL=/!:;\2_52H MF'RP_!M[6,Y6/L:Z^I:G%,K.%SL9.PYM\'/ 4?(#M<];I\A[,CL_)I;HJ1>F MDWVH%J!V4KG7#FX&WW&&UF1T\=WF]QC=P2HH(,O,5?.U*\UCWLE]V#:\I[HD MFVB<#Y*O=FW_DU%E&S&I[F09N0_)E3.F(UO-5".K9WTE?8LLVVV8O)X\;C%D MLH!V.'9_J@D!_9RL*BTV4G\%&].VF#ZG ]E8Y$8Y@\TH;=W\$8%U%6:_GJ88 MEZU@)JB-.SV\CMH]3HF3+#JH&-(LINOREK$AB*.8/KTH?[A/_)+P#;[Y>$I/ M.+^)4_\W!XBL^VF2>U&1>UL[XF""\QA*,^Y)W-MMS =*SL?8VR1I#K&WQ_@V M+^/?II$@S68.E!HU1!*1XB;U$"Q'AZ49@WDA,Z#)4!6"UA6I2YQ-$QTIV<3^ M.24&1")47EWX;>N%P3,B0D5>SVS.*37W&N7@Y)@//*= $I=)_$!H'M(VL>0G MHM6>Q5F>[NA=2R/UQC;AC+=U<':9PF92O*BLJ;5.4A20=6<9JMM7!IHM0GH0 M:U!P+V0\7&$?AQ!/3JMDT/A&"![>&P6=*!>P7O=$!8TJ/R4MYC@,1C'A1"-1 M18GGT+NN;$K#FPNL_>GH9Y1T(U=MB;J@Z/H0^=P,I^]I>K:).@])$!X>!"Q: MF#,V?PSS^[,X"!_"8 ?W:W9/;MJ)]$[5VWDTL.QK8V.!WD>2A86\9R/6 MA\B3[B,83-E#@K.*^IB*NBWC.!6%^[ARR8N D16%ZEO6Q95S3\7(CE-.2H"A M-_?)HX^SC"N[6NZWT]Q=FA8(PU!4USIP5MY 1F2N7JX I<%1+;!.=NGMO=MH[&.A ML;3]BX7?7N4[6#3Y[>33%G&!_YP[N R\$'@_PXWW6'C765//U7I)^ZR&$] ME%HC].PV,@JK-_*R0P=3Z5TZ+V0@N8BE'0-PG=O"F\'9.Z;,#'90J.AW6,3J MD.B14EML1=123;($L*R#._;W8@GHSRB*JA=B/;LO'?6MNOLY15X-$N-1PJ_Z MLVQPK;+R=;&P]J:K6Z_^46SD2*BE <@=W[(?;"&>@T3<6<.TR,N%D2Z;4V ^6 M*7)$AMEJO?!]T/C"^(ZM/JUT&6[J0L[,0)-9CW4W"E2O@.ADVAT^#M#'C!J8 M)UD>;H@YYKRI9S\!X(6R!ZD&B^<5?L#Q#E]A/R&DG?[J2(9!]R7W))O\AU/?"P. \7!B_,A\$HD MEBX)YR._J$LC9PSQ$!R:PVDV]!V;W#NK=77KC"RYK<6M.X*;^\LB]6=V\XHY MT@B^[Z)U@!.6!MO$ ?P'HM(>O(A(8#:Q'6&TIWVGCQ%TA2RLE.L,L6;/QI1<]X6Q<%LPUADUJV;#J5 MPFJN4_'KR^1&2>T^U!AZ_YW%?K+!-][CM%(GW<;ZG2B#1)K4"\,1&<_=C X$ M2<E;\@+ULE^+ZL)M6U,SWM2UTQI#)RM]"52>Z .CX MIV'LQ7[H1:C.Z7)ZJO5F."^+_6A32.7?_I]GS]#//W[XX1O\_O7#W4_[^./Q[M/[K].W7W_WZI>/-_LL^OK!__U%]*_\>7Z-__7[UZ]_ M?7SIG^WYWL;BXVES?/W_A??[>\WOVX M^/CA>O_BQ\6[?UX\_V5S_ MO+Q^>/8?CO?_[DO_MGM#Y^]SK\>/F?_#3[Z>SO_T7+ZZMGSP8TE^+B M:XC5KOR0I3&9JA7L-OE0PJ+IXE!,JHP2Y025#3KTLOTD]_]?K)-K1PG#D.N_!;-5\ MRQV*%*!(S?/=_U(H"]8[VNAY4W>WT2 _-,MO>74-86"["*[, M[/Q\V4,V9'.MGP820&0O;5?7J!Y^A,AXD3C8E@8-)^KFD0ID!]==)?<-SE;K M.D4AVI]MX'TX#;WHW2X+8W(<+?S?=F%&@V6$]\7A5N50,*R;E@,!E=F7=#E0 M:O@%4;TB*I=$_)K.+[2QQ*=AC!Y"VH'-^\Z\^%_>!O=1@EI3['K1FIO+GMZ\ M&-%1L[CKQ"2N#C4!1H,;,>+M/8[/<4Z('F-OUX.ILKG6+S0)(-(2&70TJH<+ M6&Z;X1H^<.T8Y:@.TGC?IQC'J_LP^8$82CO"FWY*C6*ZU5H&J[F^OW:;+;]K-R1?/L/1+?/3_TQ@S[]AZ_O>S;)F..9#>^ M]2]:1.'Z4^Z@T]>2R]+\?]\ET/-O?1RFV"*^"M4ARL:', XWN\UHND5S/8NG?V=SV1?/QCAW'TF) M7RH&760&?.-T(>]Q7!8WUK/-8GYSZ:'^.!\6BXA?L;B#S %I=EP#PVF"%#KK M.VU/J90 UB<&L9&N74%:!DG:4![H"GH70=243]1 G,G%0N8BEDVV[!V6@"$S M"V'XLV)\V3G2]2E@Q(S:%ZS"N+\A"*=,:5J.=@&T%K3U/-S=VMP[X-PI(&9" M>1$(T!K[0WO Z6W2A[ O!)0M1SG_J(:0],7 9_3:X!ID ;L(HFCO;F+].N>I MDM@"\_>0^(CJNMW=9OBW'8[SDP?R?],H3L(]K(=NBJ"0N=RKL8@.=AI*8\2J MA@HEQ73@,^J_/#^Y/8DBB0]><@)T9UGV@74 D'";CD-LX#P. 2G!JU- C-LA MY;P@XZ@L,9QLO'#TPM+=#2;PDT6*$Z +@>Q9%0:"_E3XP=E@IQ^_G#V-XEMB M# ??#LR,A.3@)(;LLRGD0KS'R+>#2BR$ *CMZFKP+&1#R:5&%1HII@>4),B] MG&;:WDS06ZJU^-@F@4HJFEM+ ["+0>AG.LRM?B#D1-.WTL'I('];L=IY&.,S M\N/894 %&UB^,;H0Z 4!AB(ZUGUZCI1#0JEH(CG,5GR?A/'=$D!+8\&)((N] M[\P:7544L5F\MRS,'L:A8F#G>W>A)4II74?5"W$;^E3*KR;YY@WXV_B8K7-8 M]R&WN+RXS?+4\W.'#Z-*J@LY/<9WS$50,*W!_&.63+7W18L!4)7X88-1H=W- MX=M6T[\.N).C.CB&LKUDOT]=,=VJ!U .1P]!F,'GKV>'7!C&. C*Q%MB-=R& M,8VXR(YQ[H51=NW?XV 7X62]]L+T 4H*)NML!WD]&%-L\1<]0N16X+V S]%!6L83]$-N05GKFMA0= M>=9?"*<0M/I9<73F##U?QX*DW[$\_JZVM+?1(9>=_^6'LUHCKOPK^= R\D>-8D.FX C88#5JV[O_M)\[:O7M^"T&N! MD#FMRSFHJ+TN=T[9/=V-N5:^7.NQ'Q+H*5LU6WHTS$1VH(XJ18+-;#@U^X%D M<$#6PE;W$B3_N,*0SI7!B-46IX5Z(CHCYR."6ZM8_HCRG&DXB)?C_+4J,%2&?Y29Q3MA8E@[OKIO:@EJ1D$ MG$28^&6H'X9;"-PTU:%5>W6Z^KMM$W,HMRL+FI]V$>83YNI<_AOD]U2'!MK@/MS<)/;-[V 2: M:[COCK9,U)YP2:27KM*LJ>HT3.L 'I?W]Q#"C&*&WJ1>G!'+G6PSN47:WR M;+RJ8)'(53T%E7-F$6AJPD%>G+2H#[)0KPBIA-4\!]V%_&H6;5!N6T5(89CE MH4^N+ZY3G] 79ODV$W"@O*G:> TQ+3MQ#+WM2/4*-JX5/1CF82@*0]!Y-(K2 MZ-/C/[2NHV3A?@:=?A6;[@4M-(,$1F26S45HY":8&2T&N0XS"8C+X^WU6O#:C\[]TIZL:8-=AE3%%QG9>:'DEZKQV@7,6"W>>9%). M$430-DV@3<7&0S'.R\#4)$4PC_:O !YN:=-;Y&4H7--?W);OBWX=;PRS?#[I MX=X+T"UT/B*_W488_/!>SJ;CNS".(8^/"(57+.]0'K04[$B#(W$T\K9]RW$$+IR\.%NL8X-IEF#&!QK<6^W OZ\V^'ZH$.5KMI^#:$%8Z9*0<;14G=<2R?OIU0#M- MTF-\FU_C/(_H^Q?Y1=D[;K4&!9?N0FV1%E M7_;1@FX2D(U15NU,?[0R8K(-H2SQ=%9G)(728ZS2V\/WJ"3 MQYS,5UQY!H=?#.NA+5L0X7+%N4F-$&TS&5!0S!%'0?\H;7_.]).J_GRSGG(> MG^ORI5/GIAHI&8^4-'!@%L3D^R\R&=E7(^<&-Q1Y=*Q#2ZP+N(#B$N1A:5 M#Q1%CQ3J-X6K@KXI56N2?WHYN2? C()UX8AA,UQRQ@3G#KO,">7 ?W>>>!KM M"GBUWL5!AL#-'839[2Z%\A->AF*, _(3L5F(W>SY?I(&5!'^%.;W\/R38B]- M(2PY0%NRYE_1'8Z)TA-%^R/X[4$XSFU!)( RI,R&@W$IAK ,B+GT MZ"64Y>G.+T0IN2-$(L?ZEPB@)DHMWL.**=YZ(8&S>K'BMB63@!U':$7&Q0KAA MPXY*\%,ZH]S+@\>U\*Y\:%MCIT\UM2QT9+@M)M9/&P#@"OLX?" 6) &9#__2 MV-II,8UQ-BTRA[8PT^EC@ HE(0/4^-M76'@S_OH^V8;K?:;1'ND45,Q!Q214 M3'+8 E..28<36JQMNS!J*^/ -S3.6.OWC&:=7X8H=WC7BU0NM-4F@/U?U.!: M\BH7X^?*T!Y/:OT(9OW:NBQT"'9DE\V^.8>;BI&^E]T3!6@=)9]JK<0+ NJ6 M\Z+2Y*XM<= AB)X,PS!-2G;-5 WR FX:DSXL%8HP+5X& MVO*G^]"_YSB%R.K((^HK\Z9@\$\$A4Y,_@VZZ([HCG=) @IIBC*KP-W5R5;WN+J=2LX M*B82.(LI&8XBG!Y1\RV,[XX07J^)&IVAPJ2#P)@G1=U;1'#Q(JA\\[2HC1O! MG\D>Q$ (N^R+_MO++"3XK+%[,V(#Y8&!'+OT=$=[[/LT*YQNFF5*0)N1Y" M<#YD3C4\F=1TY5XI7BXN(DZ_)/RX3*+0W]_@Q_Q=I#BTCL/,CQ+(EZ4V$S$( MR44$K-[2^?1UB]>_0Z?!HDH4.RPR((@;/@E.2>FQ5(]&_!.64V^7& ,!_>6( MVM:XKW!.#B=IRL69U(9=0&@1<@Y<4U?X <=R1WC]DIZR@>PJ MW'CIKSA'@9=[U75V5-Q_]*(B>A(\L:,HW(3L[0+^3$.EF9_I-B$CR&V;@AOR MMQVU6.&"V209OTI? V"N^\2LF%G#\R".[Z8.?G=$C!MNVM%^-V^'D*@A5\M/GEIP!SC6?',0;2)+*A?50T?GN.V M KZC+F/VA)"QUX5/X(TM]$G"X8!\NZ"6TD.;.J=!?DR0O!S MJ!Y-P[Z.M$XI)0XN+:Y^PNH3L+89 R"3WLNFIX8M )DV#_05(4FIZ?4 CQ[T M#<.+]W_RMDGVUZPX(8_0!GMQ(;][^E1#WSQHV3(,5N0M7H-YR(>=%=M\62J# M5/S*O6$)F>')9A#BLP"[$ I.AL4IF;!(Z,0?$IC")JOM'7 M%W*K,L>33_ ,\P0LU-LD#HH-F16W%1+"[7FKX:E8I'4RX$HVLR4]\,RNX>+L M]*LI,V $AX"8\AT,G9&ZRB+4>?I*Q9'=2^3V(9/I%9%\BHGXWX=;^L)*OKB4 M7$S,7XO^67RH7"PIO3YP1-_+(1TO(>(1N_#%T>_L0>BTK+'4+8:9O9Y MR-Y-0ZK6;F :9D5M:B (Q: J5K1'^Q!'Y% I7CQAD8RIXN0D)N=% @<1N11= MWU]-%DCD1< F9_H2 ::7GYBSZ!GWZ5%#C^==G.*[,"-LJ!\ 0'>1BA23/B_% MY3L!/>-+&?'6ZS *@=%'94,KA!^)X$*5.298E9A]B3IPT7?R^%FIMM/W/VI5 M$3T=[@CRAZ#4EC9;LE$52$!5*:(Y7;./)"PV.WGT[T%'H)<7 1@0>')]LGQ* M2'"W*PITNG1L*/DI%46=V]NV4,+V3-4ZUBOAU[S^RJEC3MD@Q*!+?P6BMJUE M"DN97Y^L/]''@SS[D?VWC-&6,:$85L6ENPL1-,-#S I#]*V4MV@W?^":<=4N M;ZUW7-1!$'$N\Y]A!427<%R]U@Q/GF]#*&2QG!91P /L$[C(W527R)088M5( MQ(:Z?AAO02YZ A(3G#:#T:( M@DC(%;A:+UO)&3MJP6:C43U<(-VN[3F)@*L0M57F\0.A9?(A"<_/EVHZTX&( MC$354)(Z&CHH&*YY'DS@&;+W*74 MJN :H^%;Z8ME.9^]I3VIER"6XU/4K+H/ZS@2[;[HBEC5CU16+]-C< 1FY=Z MPN-@ ;'GFL _?LH184T9Y0Z6,C__"%TDG6M"AW+_>N)5Z""1%QP)6E")9(WXV>R0JJY,+VL&ZJ,O:A]^-&JW&%+*HO%1I M\S@XI@_(E_3%F&8]7N!/]"]2M:8N($". S8=L?E'K DZ.:[Q)S; L>)CA*>8 M:\8$LMEUZ +G2R^[OX1(T0 '[_8?:9OAHGER?+<@]^,#.^XT1SM9"<%2J%P+ MW>[1$U@.A?%35*V(ZB7%C9D=<+4_%40L'DI+J^#JQKW%.PEC$!D.MXK9OTKIC4@![URTI1=#NB; ( LAZ M7Y(?5^E-\DGJ(RA$MQA_A)8TN"-%,,>-&J) 0BS-$EPMZOL+&NRFTPG9**&: MYT";:,(LTB=$6-DTHHA)0)3#9IQ<_46)M HV!2U0'3K)K*F?V3RW)JX<'Z&) MI$/?IF%TGL1W-SC=\'GN1NG\U+58!,B[U9V["(AU:!FB@QOXKKB,8ZCQED1A M4+HK+UE,G\=*@YV&L1=#6%/EU.A\GR.YNL:!R:8$C@*QQ%/&KWV$&JM37SF_ M/CC3JAU0O<5LK/=1Q8W_-,;C@.7WK_=)$D#4^0I*[1"M+,5>AH\Q^Z_L%"LG M'2$Z#97SH!$-^^FIZUY62KQ$'#0@A*VG\^75-E45A3$Z"39% 41EM,@S.@L523>(R\DY0L5\Q^^_9D@* M%=X>Y+';A&^U7H<^3C,>'+G='-'ZXN3B^M&[(QI8,1GX4R2\DCLNH\]"<"+0 MD==%DN1U$@4N]301HL++2$H0JQ\4%XZM+-#))]97KSCL_'K1ZC>&/$[H\(!5NY-+QY!#,P1>SFE^3PU"$Z=9=-25R1@ M-OAITYDW-*.[/.U^Q%#6B2#X@%.BU="3<+5FAV-9*2DPT5SY_7GU%1[HA1HN M0'%47QRHA 05H!0W"P39L!NG L>IR-JAN/3&LL1KFRZHP7B=>F%*%2?Z/;(2 M!5=A]NMIBO%9#+F867Y%[(X)Q1= 8'HGXH @1S4! P$W'W!E$,Q7>N1&CF:H5/Z-H)@45>D0S:6EI50=LG9OLA;\\..L<8F7N>.=V MJZM6LG6.^#1NNI1+4ZH/RB*^]B>9+0^IO+:=Z.535L3/;=&Q XOXO;1![&94 M3+HD1_5=DDKKQW.A/BDJ!SN.HFH +H_X:>$VGZ.)ZWJD3!'5GDV(6ZF3/3J[ MXZF-=N_S24PWRUE)M_DRB0ET&7L6)#_E<#-"!PZJ(]&Z02_E*4JW.:H7.$+5 M$JA>XPBQ55Q>-*:(BIC8CTA6^->KB;0P@+>X9:A)7"0KT.FH.?\/VUG[I5GZ^:4V>>%&(,.]56(VM*\WA/++5[=A\D/Y-.$&H+:YVDZ \$4 M5,X1OE';)KH]4IW))LZ:$"6Z+G#5"H"[H/(%$97",S"7OK5^R MFYHLEI_DV,>J/H7[9;*U(V_.XN,BQM/D>5\0B 0%TLHE&@Y" MM\0WPU/$G#X4S$4M++TI?8R1V@@8JK ME+KW%%74VLD2=!ID2Y039Y(QT4)'[!)0H6[/R:5IH"'V==451\#3S*:A^G-Q M7(A]U XB+ZW'V>QN,_S;CJA()U"T/-.?:-4$Q&;,Y^22H2(\J=1XV[/*RQ0$ M_AU?5T@$2NO"G&8XA<#LLU]-1(Y-YV/08FXQ8 $B)%=KB(_,%G%0A$=F$!XI MC_&K8RHS/J@R:T95.@KSDZ$C^A9TR%LO8$5[]1;QMTN63:0HUDA+RQ>CC]#2 M??:1$ $1X168.C=2%KZ?[G!@4)A-8J(4"R!QW;9Y6"A=),WL$QEQ+'.MB/2" M_W#17HM\Z:7I/HSOU$'*9=0=_8&;?P1-M\LE6!2)TP 1(RR%YYHY>6P&:C1S M/-G;SF*7WR7%&U@]TWU8K0HOR?FGI83E ESR0D742YW1QJN' M%'/BEYEO.2<>2JFA;TPH:Q4\SA/?BR[ODUA3P8..0W2@XPH>;8C;QKL8(YO' M%;PU9ZOUHFKERWT"KXD7+/SFW+T*.MMG'H2.;+=_QOSP_N3V)HHT7JU_GZ4#$ M1LZ@P'T'[LZW(L',HO?K8X97ZY,L#S?0VTE&6#(*+O)JG-$][N8S:"(D$G01 MRNY+QA8FT(&61AFY+3$UYF1L=!'N86W(J-7TPO2JWG-&.VE6A4PFJLFZ50K<6DZ MCH]EM/+MHYZA0/H51^LTJ4712+]2ZVAEO,A;(JM(-96G8>\ MZ1&5:J:F-++(NRN<>T2R@K)/G=ID+D>CJBM?IX*J&X5!C(:($2J$73_N,NU[43%[T&%BFKWD\ZA:C/8^+]KKT_ Q9-95MDDIO_7(\JB<@-L-9KJ<, MA;:ZI49U-J^GK>1J6DN!*/2K]6F2KG%(%5M)ZF7A3# 1H(2KO4F;FM= M'$BAOD^QYE2WJ5?X]SC815#C!=^!Z#*!)9"?Q>LDW5#-Y]V^^*,^(+58CN8% MLSFH6A%Q2Q[1HBG%B)]O:(+0;/HM#R2*4" .H>_G6\6,&4#\'\Q>.J>^%J?;AC\Z"6Z":A\J)(GO&(IWU./&D-Z6 M[?1/KM=J5?0]OH/@<0@;AR0O^K5)$T2Y^91+4 NB*@]*EZ&G:;60ZU<%4X1% M!UL_8LWTX>' .F&B!XBYUPE34.&P)PF'=<(^>+\D*;16 XN<)6?J^M>S"8B; M(?0(N6"<%!L1?S2HV_WNN$ :35)+*\*HG=+BY'OI0B_\(&1(6BWM=7V/HPAR MQ[U85]F+#D7%6/U+FZV--K3'?@+KK&_2]F1=I=BUNY%1F,V ]53 M4#W'7==/.1X=!5B'LL4@4:Y04>%5/4U2T*&N<9Y'%"CRB[)>+K']=[?@#LR] M='^1T'\$(?FY-*%N[L/L^S"NGR=T59]*AS3XTICN5F],?U=NC59KQ&V.+A)4 M;U\;S@ (A"TWW]=LQNU?>%_' /]8RA'O')>HT540]D MW2-!(B!?9Y0. 0.M]B<\$I$[3['A7=QN Y]+\Y;F4E$ MD]$_J]2SN=PM5,X75_UP\W1BA*?PI:0'A>SF;7'A<^H>N'SLX%RB-CK "X\[ M,89V@S8A&CC=)BS8B@8%+T$*TOTR"71EH1ISN>)0Q0H(EG!O4"HQ%%N8!D2Q M7>>@EI5++UVE%"CVPJUK"]:,K26S@45L?M$@H]LCS/E7(T-2\QVI:?,'>MFE M'4WG\)Y+ 7%[^UF@M/V76X[!5AV'19&\XC_G!$-IF'*[.&#Q X)):!6[.DV4 MN(C/>RG2EDYYJC9_N/KNYOI]FNRVY/K1>!6JH7 '=U,\;5L& M [5H$4/>NU MM>I&AM>[VR0-X..%%KA)FD,Q-O!%R2-5^E@!=>/1$9HBHZU M'O2Q&56\B'*L0-1O5HYVV:!1@(7\[EJ%KZ5JA3,(P-W)ML MD'OW)@]LQ[W9Q<1J7<7^67&B=+@C<3Z<6S5=F0IG3@&+CTC\\<;Y$FL096Z& MZNB'F0T/,,P%K'.C6Q("HL>4BH=2XB&BLIP11$KBM>X>J [EV@+XJXO M5(B217D_\^)_>1NL27\BHQ =YEZ7; +<(:@(']MA@$% LTR\Z-(+@[-XZ6W# MW(O4%*XG(9CU+(Q1,6\V<45*O(2*BIX0MI,U5[0?Z24A?5%25IU1DZ3H8QSF MB$U#,*^LH^L\';.#BM!_KT#:IGK.W1K4M,CB/#7-Y[?#@ M"BZ:+C9S:)M!$[NNL(_#AX-KS58)P_5ZJHJS,ZDYJR."Y!P<1$J[(77"[[JK MF+YK*Z;,2.7MGS/0CN(L])5-.D8P)(JMCYK=TJOMVPT^W(3P3457J74Q'1,M M7M27:4)4O'P/SH]\$0<0$+P%<,D5HWC$I7..J+\GIP$OU3RJ3+F]A54X25YL M-31PT#)45JM65(_E?4ITOT/*_,IJW]"%75\.P\@A=?8-)*S%;U(0& 4AX5R5 M8M88E1P=F.R=PSU'8Z- C_&)W'IW/4N5P/)\K>>CLL5LN053)-@F-$.CV&9V M@6N]"262D_$88/?@D.225T;\P06!:\?&W L""W 6<;HOQ>P^"<0/.,UH^0=Z M)!WCS$_#K:K7=SV'UK)BCP+WQ=4HJYKK)I\-PF*[4YE]@B#5IB]=> $LZ](LU&ISU](*T6KRY/01UF9HX- M$35L?#U%9R9!K)->]92$?#G7)DUPZG@.C6A@-2RO_(BYP@ +\(I?8;*$%Q>5 MI.31>=6YUBC50)= S37RPJQ]Y;-Y#QP5@#2\_M2ZDE89+3C6\>6R. M:UM=CHWH7-/A;OW28>9<<:HJ4\0JP[AZ@FHG$E_V^\ M1Y;C5;SQPU,F[;"\3E)PPT@5ZNI3("L4>7A'55@@K((:RSCFCC&ZJF_%D%;6 MDX+")&7>M"OL1UZ6T:1XZA4/?MFQ% P#^[4]^8C5U4I96A_DRI6+S:WU:U\* MB#7Q(52TW@XVV6 BA8;=>XO8"S+!L-F?L["++D[R8 L9_A:]Q">//LZR7@W@ MV12C[N\.N*! 2,0(+?XVM;CW21)\"J-(1OGR[TY] R40(FHV$;#?N5AFEQ1_ M=F=R% (#$ .;IM1^AXMRT_-36* :JM7P'C.%TSGB M6.'G;DV C?+U38FXU MR?\*WX40!QGG%]Y&5^6E'HQ@M/.L_B;P/*75"-H,,Z-<#HO*WLF:*+8 2_8C M^V]9\EN:WR:>C8KI5)/#_\I@K;AV4)ZB5#8GJ;,@C M=.J%:3LDSTDV9#_,1=_:,.K9-8BI\ZR&C4M3$::&T 0]CGTN,W/4*(@8HD+6 M5MV])10<2K&G*K"WI,XB,JA=0\^RQL7#VM:TNGC8?"\JZD-335I]7U=5N9GM MX#S!70!Z][U'AI[S=^PJM*CX=G2Y9)(7[3H2J\J"%V:8S>*%6X:SV5NWFF(V M+_,N;%!?*,Z3M']:!C=S=OSB8#-C48<,-ATBK2ZQ\H(G1W-HB*MK@=M%QZ:$ MMWL@+WQ_M]G1E)ECO []4'I.=1M /^$FHV+VTYEU@^[B)^*)*54L^: 61"$. M:)^'R),&JE6#$(QRZ'1J0-O6@02HV*YX(LL'J'IK7./T@6@14G/:),&B^.L: M*@<7R\VQB[ $<^$Y-8!VUA^E^,T MTUC!Y; _>=LD^VO7!G9"Z2;H0B*+L+/?'_T*!]!"*EBE2R^*!#V[U:E@Y71: M:9XN(.R([CJ?TPA3ZIE^4WQ&[Y]3J)=C0+5%NF&*8@.@=5DT0% MBVU;X I4.I:X%NWZOD^:H--""$DJ^1+ K1LRU^ B#J!2#.$OCJ'M!K1&C9)L ME^*VH7E/3DF&?T8(0)%?>]DMI4"Q,*'$JU?/<91GY6^>P6^^?,R"_QFVM_VV M'\:P 0=$WK-Z#9K6&UEP MOW3YW4]$3)%43D6( MHLTCNW)9UZ6Y]+7B&E7*W-I" OB%KX$R-&WU$_X8TW^1#ZTXU%^^D-&Y&HKJ ML>ZB"@6 =S1G*7*6[ZS!I30A$(':6O3@8Y5O(.,$LN:@$8:T,G?ONER$5)<%G_W).G_U+@\_>02^E+A!? M]:#P5W.B\%<&%/YJ#A1^TX/";^9$X3<&%'XS!PJ_ZD'A5W.B\"L#"K^: X5? M]Z#PZSE1^+4!A5]_]BZ#;IO$\R2^TS5MF\B+(&R'"?"(F\!]Y@X&->FG]CF8 M,-Z17'-5U;)&V%Y1"AF*KU4A]S]A+\VN\,8+(1"#"P_6RBZ_S1%JQ3366QTA M+CV![@:27NS'I1\["HZ?AG@JZ1N3/79?0CAA+\1?YRAOG$3E\23TBSM@N1P= M$?MTR%M/YF*5;UO)Z_)PFJ*AD*ATG5WR*S#HJ PJ1&VYQ&B$/O/'%=4]M-TJ M:$I"X7TLYE1:FL,X;SDF'<+KD+9_Q\$.DE6[]S6YG_6W]0WVK-:BZGU%>:LX:)7Q M$QVWW&*0 -B.@VM5 R,")*IT:/MH&$2!SJEQ !WM!WUU0RVI2U88:=FW##A= M21.DZLA#W@=U:3!8/]I9Y>U%$B?-5S1-A4M^0O5D6,QYZII=4FPDD1HJU.T] M)RROKI?$NME% ,GY^5(=E-<8C:KA#A4E,?R=XTZ%IL6@>UI[SH>J7O%^<9=B M^O24&=0&XR>B>J:XOK6C#T"+G.A#,*2(Q5C5=S@G()&3\:=D]R..(G $:*-5 MV21$9B$R#97SYA"PJL2G\Z$88&_95R8JE%GJI/O"ON]7+K2:73DZG*K\)@B* M/AUSPEAU>!S8'HB(WAJ'^8X %1@X3& II(F6>%=$2R!!M$39WPF)]W5UIDY( MRJ[G9D*.63RW.V]6/5X\7SGES6D,7B-,H^=2)W!XI(4.YE>UP.04LDGR+:@JX\FB#$#I+^/3@Q C7 M,[)I(_7L^+O 8!(*^=D[='=/.+>9'7 M(+SYA6WR7E\M_JVU:HM!W;)'#G1A'MZN"MO%9O#5758#7L3!69P3O7] 3XH"5K7I_AD HLPS*-_[5FD]I(?^"!:L'_O:[?B=X MP_I5=0C_ZRMM,"7M]NFL/J*B,$C54!BG#_2!\70'KB&^0+.X>6=]K-1M;(H7 M^'(U^CS+UNO6L7:5?=\+?=$5,9"&SO(,WYHKXF_GI8B_U2OB;ZT_P"9Q%@;T M*3B)%YMDQYSVXJN7&XK86'?'G !PP1TK0O29,5NM(4>G5'R622;/=BFGP#L"3*J-4SK-<3J5 B'18:W% MWYJ7H",.7YO+^M?SDO6O];+^M:NZAK)JHF7:T6K-[+XA(:YE(=8J\8M\(6PU MUR%CO5 7/[?UIMT<>$O->:(/NC"]8O91ZB83U]]FBN4.7=N8SR,L!0>43WH8SD/#VY FJNL+#3% M^"J'/>'7X/S3R/O1Q7CUX3ULE;E87Q&"A'J 0&%= @"@X">$2=!3^G MJGG]B"X]B6WQVV8WN"KY%: OTE[7.4ZO,%G!B\/?/54\!)'%=)QB Q$Y4AWKYAMF#OR+T;*"$,R66V# M[/OP\%U^G6 E^GZZ:Q1#U^0QEDN4AQ:SI-DJ2%2YR>WQU0-C$1][$\SNUSAF M;;JR>:2T%/U$]0>K?9V:_I-04B11$[+,KC]NM]U&5-GVHC+]MU&83FHM<1-1 ME17=K 3H_,% AYS0*C&CB)L3@HLGODR3TR3=>&4;S4N^Q%PAOD06NVL1T;$3-2S?GB+N#N$D%T&UX9,X ->IU/ OBOBR";2@,R)3J#O;84]L&1H\#_3H MVCM=6#<]FM+_*<;!]>[V%^SG-PES:U,=4]H>NYZ+Z&14S$8W25GEERW@U#5L M@F'GF#(GBUVUK*T?&IY<(E7:P#WFQ%#2H"@ZS(RHXK1]AGE4J4.UJ0-UY[.0 MX&6QQB"GDC$=;;'+[Y,4/!UFR7>%TEI/UPA81]2" M1O7[F]2+,_+UP3<@AZT, M6GB;)68$#B&9EZ#& R?3'&$.*BMSG$(]?Q%3!0_HA M"19T >>'LA(]Z;%L0!2KA9+9C5#>#&U')4P/=TAR/(8-,6ZX6!-&G/-5/:D(MH+\;.=BSF[A;\LGGH M1(=O$NZ:U$>'D!DH3QKZP7QB0>3H"+\F#?+-[VI(32;"X "2,@*H39%$ M80!;76%H#9"MUD57=ZG5H"W,U'MY-]69^H)I4**I6A+Q:Z)B41A1+RORY;@L MU#14* 35F@91]L Z8\53Q2(.2C_?:EW&+0Z48Z,E;1E0_< RD-7RG0J*AU6> M7_+[.C)U3F7$^K!7()'&-+-OB34RA@"&5S++JQCY)V^;9'\M$ZD6>9Z&M[N< MQKZ1&Y#<&*Z;.731DEI< N0M1["D299=ILDZE*H6= AB8QR[@3AHA4$E;61L M7JP728[+<-7K^V0;KO=94-?8-XJ? !7T:0NT-?9$VR':LL1B[1<79OU -P%UZ40TEHO?&%O%;)&"5\ MBC(OR@H^\_$W"]'NX7E6D,V6R;&,DJR,*C"@5?K'Q+6YS3'9.,ZO:9G MVD.U()Q^;$E4K5GE/,TM]4%/!A&_#R&HK2/R C]X@;=,TFW"?%KJK%\V'''C M77?&E"#0M7%4B,ZJ($V_0C2NG]=TV(@^##,*6*N.*?A.LPNJ>,F1NM-G GRF5O M&<*?>1Z[W%B>BE%6XZ$]>)&BU_;%#I0H\@\:9L:< &I/-HCEO7L9$4ZG$L0ZJ"$MQ6W@D2W-1 M@ '3K*J&LS?PZ>NK 551&H6>6???_9FN(+EOK3)G",(\VX83S);M7/1,+ZJJ M2:V$:EAQMKGT++9 [FBF0I2L!LX5D9B2\H0_AOG]61R$#V&P\R*^J1IWDFIC M4Z6E)C^1Y5&]_A'?LJY]-SE]@!R#3*(S(5SHB-!DH*Z]18;1RL' M.F^\U8:Y\R6*D;)K(S(%4U?6C Z:BRK0 %DDX0*<+(IJD=?(?2WDQ.7#+TX> M<[ !]*U;&VHR600U8U&J=1RZG\R1[;YO]:23U:R6HG38!99^$]68(_ &.KTI M>'!%WT,7G:&IFP+3=JJT3>56EJ,&5+!(HEA%/A19KN9,7"'*1$TM":SXPJ#> MR''B[S:-@B.GY#=29U8YO%%>AF6"$T.AFHS*V>*OVTFTCSF7FU$^AJ2Q')ZG M"#X:G I#QX._Q.B^.;[ MDPU.[Z!O49I\RN_!8/=B:>P FX+*.8A-0L4LAX7$%+BT[SPMVK8#@Y,TAPK] M%TG\SHM_I<7[%W' 6RGR2& RE[8K@&X%SV[)]**A 3R0-2PYYY^! 9K"S\.8 M/%:3)\&B9+$F+-3DG"BN9^1BDP?TUC/*C"68@^@DA\:U')..,:U#VE[U0_8) MWWB/Y4NG3XT%]ARF.;N@AWMS6O%JZ(8)6G3$QY<2=VMF$H-E$01DT8QH<;D7 M_2?<+I- >F(53"BF0'P'3$)D%H)ISF\0$2YB#LBQMA=P%GG^K]<^^21QQM(@ MU%&7=#PJ)I0U)]M-5QR$ETG0Z!Q :GPMG?^\V7Q#5M;Z!&"0$]==&U*9\5]C M8;F33;LX7_WNH_)8\X4)C^;PB";!0Z3-*%&V2_WJU>T#]B!GH Y ,XSA++XE'$+J/B'>H*;XFV# D]N9?+W97%)5Q6OJIF(3;- ME<]2A8KX#E:A;2MZXVRSP4'HY3C:EUEJTN><>FB5O>?NZ5@ >.?&E2+GJ&R8 M43P!;?T%S28SVE$2!_H^#0-".F@'-;8-*O8Y$O=SF']DAX)BHM-P7&[8# NZ MP)^*AF+@S4R3F/SH4Z"S7G1'KAQ'0GF>@^:#%_-6] MGN[8E-;CG0-S5(J(^@FO@['M+JQ<&]BZZ!5+T+\DF\&'3[/VZ]>?ZD6H3\XO MO\\1:NQ$?9_\7LV7M'H[@^Q@%Z4L1J:@Z"N>ADM6,U6*PA?935+D-M '*7(B M!3L?BD"HLT_*V5 HJIA?E(.M5^@457"19F2$I8C%?>ACVW%+!&4%2 _ M2#\=+BWU":SP%%5KP-=4K(+*99Q^/H:HBA6='E2RR+V3]1I3$6+0W7B/5P0P MR/TBQW04LE,\/\4!0$GM80C*:PR6?FCETB5_X:D$)J#F\D?((^H2VP%56[0G M5<:0:TMH!(J)!&0T1EA[+J"QKAD!BWJR9&[6:A3S[;GS3S3![;@F1-C8? +N MAA8OUN1\O\()IUSUBKZF\U%S 6?U,(S0ZS"E!U$LGIEE#W'6>P(B!LCI;MIE MO9Y$SCW*(;@-/A&M&*-UDJ)EBH,PIR4:A,D+3K(7% B+SC(]@2PGC 0!#0B$ M>S8,SF*NB*205]5P!.,AV]=QZ4P-(D(>J'"V')*$TQ!GJW7MQ(OV9YL-N;%2 M8@F*:GNHWYW9>F"&\RNB>DDDKH#R,UO6J=-L*"U$+#Z,KI8N-\B7/2;VHD_4 ME7I[T256CNKRR7J"J'['P3&^S>%FA/NCJ$6735<4RQ&BO1!V!"!ZN,Z=0D$M4<%UB\FEKC[HU=K4GKHL;X95H\ M'-$ B$IO%Y<%*E_DBGB/(I9^'C'= D2$/C@9OA9T7_YIX/N=EY([)MJSAW+M M4T@UO@@-F,,[2 L'V2N($%6;F3]@^MRV:Q1SCZ/O]O60PD=+7T=9/%NVVN70 MC"@(X[L?<7AWGQ,+Z@&GWAV^PALOC%E7(IHE0]0'B(M^95(F6OJL?;M'PG+2 M -)1$2((S>QJL(Y0"1@J($,5:(B##0%P,Z@[;9<90K7/E4S8[>$AK,X]L(;Y M$>0S^!!AT59U9E.^7,II"0ULACF4O0/(C0_6!JL,J]$VRSDTU9S9:FQ>5]MT MV"E!A)&($WH*-%2??@FNN]L,_[8C8GH".>]3):=+M[%:HTT"A"Q[M1J.V'AA MOJJ+;UC#LW9#0"G.MGL)A']-.+6=LOK X@B/N /I+'5<@!5JWNUH[1(#"PR M?1QEAFG&['AS72C MMOO)132#& MAA((*83:YSG$767D%_4';+ ? ES(GKI_B*A_PA"\G-9 OSF/I1?=K*B@/3YJ=Z/ M_JXR+59KQ.V)+A)4[UJ7;(=]W04334!$@^"7D1AEKTT&5^)A]2FF*1[\-R&3 M&[ZX!9N'6H?&/"I:?UG7"$H>:\PU_6(F<>H>5"7$5L[D4FB^RKSRDH+ BA%.0>QK%/0.J1 MDT%@:'5;J@;1$K^3!\)RETA%NL);(S" M^"FJ+;EZ.35'AD3,8Z6^6!"@5_S;V%U#7 U*8,.-;X%R6N_IFK MI(UX0(GD;5&OC&UL[7UM<]RVDN[W_15:WR_W5LJ17S;K.)6V+9TSZ932\NGOW7OXZ._NW'?W_^ M_.@=#C!!,7:/[K9'TW"]F3G>T9R@(%J$9'WT?^/U_SMZ?K2*X\T/Q\#H^7,Z8#'DE& VX ]'Y\0[>H_(T8O71Z]>_O#=ZQ]> MO3GZ,)\>O7KQZG7VR;_]Z'O!YSL4X2/*=Q#]]*Q$Z?&.^-^&9'G\ZL6+U\?% M+S[+?O.'1_:#RN\_O$Y_^^7;MV^/TW_=_6KD\7Z1#OOR^/?WES-GA=?HN1=$ M,0H<1B#R?HC2'UZ&#HI327;R=23\#?:WY\6O/6<_>O[RU?/7+[]]C-QGF=R. MCGXDH8]O\>(HY?R'>+O!/SV+O/7&9PRE/UL1O/CIV=UB^T '>?7JYIK3C[._'B[9P.\BHDKW5X;AF-L@PNY2F*5N=^^-!7 MO+MQCN'6X359HL#[DMH-%+BG.'*(MV%_"Q0Q;G3XEAH72MBS9+U&E(_% MS%L&WH(NF"">.$Z8!#'=26ZH_!P/:TU#F)P$Q^'BP7RR#WR$_K'*'%6*(IP:EA\#]UYOA=3<:6TM11$G0K@ M5K"G[H2!BX,(NT[)G:*'PL2/HW 1;MBAL@S7CWF MT38ADS#5FP3N&56\>'L1L$ANNLQUF&T=;V.-VG@];FS\OR=$BQ(N-;#) Y%DP\)-5T_/7O!;CWH)!:8_I)[F8E+ MR&3*(56_"*>_61@[9;5BL42Z2-A_F/6DKCE;VY-XB@C9T@W@-^:K ^N5',UB ME1X6VC;]9! JR@T,6RUPZMSNCP%4@NASB5P 0:V%\0_ &>>[9XX:%#,P@RJ>Q MV[X'")] *CE8KZWLEQ%H0&J##WLW:\JA1R0_["SR9WF!,\3[$_# M"!J5QO!#7C%-6>38?&=EL:3\FMJ@*F,/WL.H2B)'Y3\U4 ECY/=U*6X(BS_' MVQL?94=DZL%NV#D&WJBUDK*%6JM^5G>@-D'!.?=Z,.[O$D$AXUPS#A2>O0 M??0>ELZ(B;.RX>A&..KRZ(%+Q=#I8'*YOU(LS+29.%D+H3%BUR8WJ(-2GX/P M#=JRHQPUQ_0G)*'T&PP;.@S+4+9M-+NUGG="EI*IW6!6X=NR=&]Z'LR#]AF7 M6S.X2Y&TN<35P):3(-16JG7)L0I)/,=D?14&)RCX?!FB(*)*>17&N-!1Z$L. M&9+CP5A.@C;,^&V6+L)%47#G4_O$2JQ1#8;Z)*%B53J+J0RY&?O(HS "D%H% M!!?,TMOE$CP/#Q'@;R$T'FO7)BVHR!?,T+?PD0%5/![#(,EFS# M+'&DE)C0]KV=*+X:(JWSSR%Y8\D:%KP9]/^X)"SEE4BH8F4-<:5CYY16YH'Z MH!MOL8VF:./1=2FUBMJ^M[.*),%HG3A86%)G\5S'*TQ2_S]GKY@1\ H2TQG' M,FJ1$UQ>0$\OPIS[,")OKR*/')KO;4269W'H?*Z\&S:6@2DD-,;(E+M5N):)TQ00X/6G5N9JN%Z'@3'$&L/;77 J:#4E8S.F M.W'=U#!0$X$\]R+@>H7]KV@$5&R?BM60$\K*CB.2/JVAWFS@8%\Z:-OX:/@+ MISE/L!Q#K25SRY[6!-@]R]]53APG62=IE.L4+SS'@_8S) B.:+>2$9_E,&]S M0L8]QY&90IZ$>H1T>P0(.<>/2> :1["3G-W@(D!VB4"*/99F%67VQ.^X_L;O M7_:>_M5+>?VS7P+RSQ941->FONL-)NGN;/0\)B1JWV3J+3)9F=K-Z*ER MF3EADR1>A<3[LE]\1A!O$!O92U)9$=K.B^7Q=Q%%R4'@S0F-,5+6)C>;.9@\ MOJZ3F-4@9<5:#P!JF=I30;8B09N!T%+DZ$ ;L0S%D=IF*6$"GD/[(FYX VZC M-,ZC3*OLK#Z\:W!F9,\541FKURR46H_$) WN<&6N0VWE=23@96WW0)D. TA MW%"OO*V_,=1&,A18$%'1V-'RU&NEW+WZ-Y8]C0Z9EQ+,#50/TKVJ2/F!3E#9 M#6O+Z BTJ7K-4$S=^DUX1&TB>PR;AE0QN?<<',U"'W[#%Q*R<123P*A--%:3 M\]Z1,(IN2+@ O\LKCVSS@"QAS+C"@'HRK)DTF17F#99YU1E!+GC_I$DAG>'O M01*R LM7T,HX\=-_QV[J[IV@J/KD,>?V"E/+,$>/T(DH:L1MKM!.7:^DIB@* MU79QC!GUD^G4LDY1/GO8[*Z]P&,3C+U[G/,+?4\F1]3V24H)>%E!VLUUK\_( MM+FV'++J8Z5[A9@AR@_M.,IF<1E&QN J4;":P*2#5UDZ4&%B%;C2=Q$9$[GJ M*)VM6SX?N%O:-G&PL*YV6(:.@Z,X9RQE%3PFPR%AR2OMUL%J64*><#0\D;<9 M9 %>,H^GM[UC?)C:F"ICVW(LU&"JR4/#<1#AHU,;RBF,YX37XNL MP!YO:V&(8V.^1'5LVZZ["EA5H?2XZ*@[?5H8%=G8Q=TW/4)Z#C!6?!H#=S-'["U7U,9.[NFR7^*K9'V'R?6B<9%F DTUVN.QHHHRS17@+<3! MVLH%94N;W1X/*':7P0=\C2M#4WNI[8:?FRAS5AU<=Z/=#4-U!%_0/T+OMAP" MMK=<)56K/F&I JH?(?-[1T,+5J8^BJ)\(I-'SQA\#3I#2>*K+"XN6DT1@0"G M%\0F[)U,-6?T/6;[!7CD6DQI(-EY(M6M!JM;! 9U):%U1U]B_C1<(R^ OIMO M$AB,X91!CB>@TKKK\]0RYR(SV.S2*@PP:]9DT/QQ:5E^0BMM /F"TK_2]7N= M[4OI>T8L7W/\@=B[-GT5Y#="6SK=-7> #4N\4XT(NM9]"N#1%F"]#B,@MM,: MAKV4Q;)#;E8R8NJ%+7@@2I;Q&)=M%$W<:N^P>ET*(TM*0&0DN'6)RO9SJ1K_ M1CQY/HU!O'64A4\@IM+E^2"FT^T*E\)<^J;#[W-P_&=6BA%%&24KQ&@XOAM, MO)#Z88C$O0[ZII]H"=YE#1TKX<,K#2^7!Y5^=( JT2UV,9V#>TVFR/>Q>YH0 MRN)-2L9$;4%)HB-:AA(2M-UCMY//3$Z6T:5[VX_.0%"_W#KAZ MF[2'$EW47L@<<8*5-@!?T9:P%Q$?Q(%5?Z&+H8>I? "Z[&\2XJQ0A*\71OKJ M*I$>KX47B!(JGQ!\P=M!74![S+9>)$[(1$)#CW*A[Y?DB([#19>58!%8L9+G MTF:+)L[?B9?5ZSFD2:^0'?.ZY@BQP-K277&K 3H\W!RZ(W?;^&A#Q-!4X,XS M3*J.Y"F^BV".V@3 M=(=MZXU(NE"; W>S,#"77[V %Z4]G/KL&1CRK8M9R1?JU#\0J)>>]"F)8C:% M:!Z*!BAK0!$31$7FB,G5CC#0D=C-WHG,Z=38.EAETO/B)"4 >:^@@ M-HI#2)? "C@/'#],-O$A\ X:[VW2'L7B5!1G 7[_T%_/$\!D0<>[Q90$"KPOJ5PU77G> M2./RR;FR*+)D^C_=T 0*#*=6F(8/D@1&!VVGNG\J K"ZN7.&']%\.Z:;L:0YYCU.47@&RM8RR?T[9*#G< M^!6C7MD+\52R^_]Z86+!-5\^#!PDOF *K#2"*UDZ_5G0LXY>(\4?'J_AMJ1I M1XPGF0(PC?!)$[ AM)Z9HFAU[H%&.9JK[?2JK?AL+&NR'AO4>E M>K+]$+&>/+N2OA,G]NZSWL=F)J;!P%!<_!;4:WN4LHC!RB%\=3+:H-37_FXG M1 .[>TSNPOY'@:Z99U>= MY*PW3P/%ORY+C:U ;!. \+X([JE40G*(]5^F9;OK&BC0%2%J5#F!;%LD-D,W M:'O0W;Z@9SO\:,JL[^0)6 %#'&24!8\=.?YWJ'V]CK))^;B-20*UO(/!O33 MG .#84%)HD]MP?,E"U8A!>Q4SVKV3!-"TGOGPRU]$=VGM/Z%L@4KE@*C U=A MC(N-Z<"GNQ;23\K9:Q,Q7$\VTWD&UO(+1A;J4Y&HY?;9 E;9X22RF632QL#3 M2#)I%3'8Z4#K=2/:%H]WLT?;Z49&^7<3QBHV4E%)DJAM-U%_O52>0TI*V'I M6'ZZULR"Y;T!1B%4Y-SCAKBR8P#JP^Y"V]9VT<; T]@N6D5L-:I0&+/K!:L* M4CP23E,;#.T1/$J#M (2ZX*W+7 E";D7]*UY<(LW.U9+QYDM8QL:UQWU35 MY(/K\9#4 /QGOKSC_%0)4>I&N4".,4$-!TGL+ MH8SM0ZB!N]OFT]?UIB*4TG3'9$\4I G6,D 1>&ZAXO+%^QFK3]"C2IQP.,LA M!U5%%U9U%@@+\ UCS_))+X'7:F7H$:+(%Q%8:-!6)9#K4ODN%+BG.'*(MV%_ M"Q2QWWZF_P8_2\5EE:1"WW,,OJ07$]*\?BL+9E\N)7L_>%,"9/?$%/D[ M0Q^Q1Z9^&"4$SRD^)Y329^ )@[-G^W5PIZ:4%R$\.,"/QZVLY5FR7B/Z3XN9 MMPR\A>>@(&[*]9G>>ACQ4FX5AZD%*DG4=DA7;=W)2A)N-=E:2^_"M&9 X& 2 M/--/^.QEJ PM,!B>5&-498'.F^^#YE?*E^KE(2[KY=ZDB>^_M'F4!%4G MMK YJ.B[M'XM>'E 0FUJS[)D@8 3%1K-TKN6#W!F&)S&B9W\>0N3.(*_Z9V M)'G"=LYGK2NUL@TIB!#V1&UE+RK.8=-P?<>2$]*F2G)RO(IG(^RHD)S](A[A#1V@^S%9*X\CY!2GXH2]4%- MK9A64K;7B02,M6=F+6)[ GL,"U)[624N%+@L18?NICC( P;:UXK[42>U48TO M'S7:/:Y.9>B86F.*Q&V>7;1TH7)3JBCHI[!EI;=&6='XO-*]_F)L%J!GEU#& M*G6W$E-?;@U)R <1!)^JM["KCZ,63FCYW.[UM(Q:I"WK!!! 1 P./_]VA>+. M%R1X8*+%!D/,_&8C3]>&/G>OSO9N'$(9CC^877[2,B */*BZT5M0ENSV$H2'1?*LI*T MVRKE%E,CG6#6(&09>.:7<3>]<:$L(3^X-A@]%G0YA8DZKU;R-GNQ,JHDZGY" MAZJNH.N0?(CP]>(LBKTUBL$?Y=<&MUH?50W4NE@LEU7('S#6WU6;=<*D:%IN M?*7FB\E)T6YI,A)N,(FW-SZS'('+&-VPRUJS8$N3'95IEA;_,1%]P7V_/\>L]T^YQTZ9J_!P7B6IY9\"Y4 >;JO46[NH31'$@;T MCT[V3.L01EJ9_+CB7>K2+;3!5AO8&^*%)"LW=HL='T51&H-));SKD5PJS@!^ MBE(D/RY]4)=NH0\0X:TA/1M+%W<3'K-)S&@__@MT+E^T0 M"P^[69I$WBK"I;M'J9L4_;=DC=U4AL9NUX&YL^J[J3Y& X<&ZII21<\B$IO:.VQE>,N9N M\28D;*^Z"*BM7J=S/=GF_VC>D*AQ,1*UZ"ULL M/:QEO^?2D[M>['!3NN+8.DD;LPLY?X8NP!*=JW"CS@K+!/@31!CNI2WP:KI$G M%0SH]!Y%8]NY)^]4Q+UK*!1*R?FWY-084S(#1E[?'^I5#8DSD^;9#^W>+[2> M_O(T"7,U[0TS:^6L;LQ?Z*@R XJRC7.^B;FQDL0!)05]_V.&QY%;U8-I; E5 MR'K15C752&-B PS:<5]&IZ*U+L@Z41&(1DR@^T1"&#SE?\@NC8JR^P-6WF[> MAQ;7!S(DQIR&;F4 ?@4[,-V_#(.EH5ZA!V2W+LS\N?W\?>3\"KZ[_ _)UYP__WI M-^C3ZM3__269DC?G?SJ?YM$W*WRZO4J"+^??>*?+LV1^M;Z9'W_GO/EE.DL^ M3CZ\GVU??)R<_/?5\:?U[-,WO__NO;[Z%=WZ#R_.@P_)?_R9_/+E-G[$WY^\ MB'[]?OYEZ7[\-/GC]AOO>/ME<;JSW]'KY9>?;W_[Y>W+7R8_OPM6 M-P^_OMM\$YZA,)I__(+\WS^\?WP[^?N=__'7RRBZGYR]_6;VWG&_Q._?;Q]/ M)X_'CZOW%Z\>/\S>=_XZ_G-Q]OF;^/-/_WLTG=T^?VXQJ^T2?DT93R#FQGXS+J654$""/7T^K+4L56H;L-7L MY/+K]JX.+.##;?L9B$Z1ENOLJD9AEU).J#J&"_:6O?3\H$<:XB[]=UJB:E##T#2_[[F_PD3S*26H5I.W]>DOB>?U*>L.2K&$R +KT^%O8BZ)M>+ MBX!N^CB*SQ[98VKH>_)64D,T!^)-CE-C3R!!6Y?+O',6Y3";X648J67WBT<9 M'VX2DAG$[5Z)OQL2GK,G3?6Z,ZR0GP.\2I7)CT\#]"4-?#=F^?!&,LM%#\4X MGVZX>(^"9?@^](H#F]YQ+;>)+%LW'_EZ-[+F$4UJ2,43CA9+8J)6CB(JHF;* MW_PW6UM4SKF4T(O?M>._MLES-PN;J>B5_2N/H&)W'K[# 3V*^JPZ$OT#=-Q; MEJJ5PWH;9LIB WQ5;L7F7Y?:QU-S7ZIX$BZ*73"/H&KVL1EAFP %H<@_ E8> M5,-P*M 0A.?Z,U\-Q0V]'I ZU# A.-#>9"?;\K_(!N>4#NC2A.V KKMB9?J3 M\:0+H 1]%4 ^)J@)=#DP.,!6#BNP MGIS/QBE5WOQMU-69WL[8_4KB,_,>75Y.%< 0?3M.1(22@ I(J,!R@8*?T1JK M+(W:)U;36O40J$\:+*U4*< 2X\T*!Y1LW?+S&,H2%K&1 V8W/=MN1X=R=Z%9$UXM.46K>"@F[ W>XB)PO7O/ M39#O;R_6K)D7\9#/N[3FV#>$W8 M@A%WKG;[4^XR"J:L>/SU8A:'SF<#NZ"8CJ5D-XAML$5X^L=GW0S7@JDR+T;V M/@X!VYM=IQ97>@YR!"1(OM39X28W!=PI!8.;&)^2W>LJ)21:!::_'=UC'0-OR+/D:P74[Z8:H^&?X\?L"2SEL&MYPBV*JK M;5B)S)^*W,]1%,\)?$:;O7PH;*0R4<8>AV4XR46"B +Y6T'&R4=N9B MO%PE;).C?RDM^HN@=$4*[6^KD!XE]'I"MI.QE&NI[H)],LN4MSA[)REI+D[> MNT=,6*]LM*0*]5N8=='+7C+O*MN8OR*686*42M!7\&")4UJFW)RKV_1O1PLM MUZ6%J/$$596,1>P\-R],DVX,&5Z[V3*>9H0YM:G M/=$SI=U[D-EMU ,B[CO2*!$!$ C58F+4.J(K^%Q;OA]*?7F6;UW:M;)85[%3 M7>SRH?:[F7FKHL[2V",H,+CDJO76QCOUE#,G7&]0L)TL*6-IL8Z20(#5IIO> MV'5"0J)%R*9_@0=K)4N2]1K1?UK,O&7@+3P'!7'SX>_^ ;N>V1OA$_;=G0** M5J6^B)-XB@C94@)I*V/H&YAV8I;[R,L]")<5''!M%"NKIZ5<[C/0(X:I]=)* MJL+>=DO0=G>UHB!SVMWF(G ( MIKR=XNR_P "WTQI$^K4LLAUB&WM!G*SLSQP]EMT&/8\V'^C4BQP_C!*"#5G! M-DK:5]K[\D?G5%U8Q7W/]1!+.TW+65)J1F;12M#J.I' L^I^=\O/M@4L##-E M)JM5/T4;CS6*H5RG[@Y=)"ST !WOD:=K,W-*$7 %85JM(GJV6& G]N[Q;GZW M*,:L@T'@>+Z723@^QRQ8Z;,"P!'=E.]%%4%! +0YT]6MEIV M\^EE[5I0P KFL[,9#FHG=MU4PWSD27UDT[NQ&FWUNUK6.CYK)NP"HU)8M'P^RH72)@ZP_47)N*W7F+K) M,?:W1;1 SI9QOK-Z6M"W73P)V&I5RDTA%%WE"0LTMX\QRH73*1BP1"ZE\J]) M',74E:*3R.Z1]5&3'&JTVY&LJ"Q5ICI[I"N?SB1+"I#T$RJ?C-/ZU>=M.UWJ M>K&@SB)AVL':MB #-]%<$I:ORK3Q:Y<;6*:3'I@?L;=<49,]N:?GZB6N9D;7 M4FZ 058B/RD(^X/H/7,@#/:I5+Y^^Y1;#M"\C%0^AK>?L!EK>76E46:]E_+68O MN4R'5,Q^AA*J3@$FRZU:X1'NAY8]5LUBT5P1V*E \K56]!X7B5K1AWZ_6BFT MWZ/C0*WAP,B $4G!5H!R=COY7=%X5;X8YWY0F[6-RO;%!-ZC3R&A#DG)0S%2 MW$5,9Y0;CX3XH"*/2@7Q\]9X:O:M^=4831MG[K:BCU?X'KEH&I)-F#T85 !# M].TX+9U0$E"A1-5"B7,O9J45]D6B@:I;\L>U!9KT>;-%)(>N:,]EY:,7KU+] M8JJV\C;S\(S5)%0X;ZKBUD'12FRW4W&%4';)3__TR_[U0M/G'J;0&W.S4V*>\5J #K84 M:@/:B E(*WY]\OJGRWX5K3M\E\-%HI] Z!FNNC\@@L;#SDU:0VQ%)1-OYDBM M1V^;QF%+B#+ZS(>3)S>(OEWL2CY[]"!QJ#' D!DS4>5+TL=6=7A8,\=3MG7UN608H4%QM/Y:- M$X]2'*TT;9 >"9J"!SMQED>SV>>EH4X5@=?47:N3"QOLO1=XZV0-)KWJ>)8N MN5K%5YNQG:R)E!'T""OZRGB#%'UUQ@/IA/C/;)FC?(Z0ZX_3KXG%UP8Y7QOD M?&V0HQ8:'J[ED$ABU[\/[YVV76T$DKWSF"3Q*B3>%_#"X!W$+&W6TJ\,RMK< M)3? ZD#]8;U!Y)JD"]9-"R#>8))R;!1>(=&AQ0P5RR M#,4Q[;U2$K3A?D8ZK8BHC,(0=XK*:G^Q='MJ7)" \O([HEG M6OSV@* *Z(T569'XK+3"X=;RD7L7+OAT!#Z.:-*@]1CD']?Y8514XN'45Q>] MJVM\-0+!8W)'0P=M/RQ%QMD,*@>Y11V"@)8< U2]&]9]FW."DJ MP^V+M9CKE"--=DS^O[PL"]@A#KVS#E%N6HH\'%>CF+T7AO LH>@=0 M>FU-_!.V[!8UJM-RR]P++"PT#3ZARN&6"XM-"&$7Y4Q53K;[7[E!6_:CM'E> MEMH4G8=D@;VTHH K,IAM)8#@20\I*XFK Z9$7B@00'1%ZRR7%>?_$'BQR1.< M@,HH?*).4140 A3'U$I7>'1P%)F.CXFHC I"H:@*"#4"*LVG5:HE3F-J3:C M.)WHA"5.*Y\,WY>IS[$0]T&?K>]O+>8KS(!'@8-W?>?E?4J9<<;@U4C)HT#J ML'UV+T,43-:L2Z$4(J5?'X/@R[,KY-L_Z-$SDIOO;KORI)C<8YD/W];UD&UQ,6XMU061.BC-^H7-::J./8:D*)5- =?!PR"YR8\[5 M:_IWXP")Z]*]THB2<%PZI5 )/>YYK&=5*BCY;8SWW?#M'7>VA?"MI(5,?#I& MD#_Z*CH@ :\1/HW!1S$Z1%3 9J6$7CJ1N^X(RUT]PC)Q'.PS!<3N;W0J]$R> M%5LW819!^1N-NAB IE"U@];U*SVU%5X4B>*>_$]'L#V*)ET@ %'63P6$/!** M784S=_V;,?B.C7D6 C]L6@?GF?G9(R:.ES<@-]3INY/<"%:.O.@*: \;)NEM MGO.[B5(TN]:UY!:S1UWTYT5MB 3YK''AJZ'LK3UF, 8;8A7A0JD!$G)ZZ'6/ M.[?2K"_HY#QZ4'$X4788[37"Y_"/?P? JGAB8"LLUG?Q,<\7N[5U]XY^'9]2 MQ_@<><284AZ ZU%= !X,RD)G#UP&HC)/3@8IC%:5DDS'A'LUS?0UQ/NSP]J3 MG7Y-HBA99QIY]KC!+$>3[=DOAV)"NAD=G?(8PJM0QH-W#.F];_,FQRIKG1., MZ0Z.*:CQ+36*0_&UI/D=T\'4/'B%@AZV@S/GY'WCHX MGL!DJ*),9$QZ(!!3 M 9Z==W\? K0.2K4U24YY<75( M1KY!N]1 B@D*'6,V-+P/@_O!+*UC597*WNO+H ?3O/UKBQPU/%56EFJGG.% M^;57CO5>.5H]68?;!%S<(\=8/X@!6P7Y+1"BLZ;ZNZ1;[&"/O=](2V3L>952 MQ]8!;)V45)V.X@V36!)0)5OU#DT9N7)$/#LF@!^3A(1L&!D=%&5D9KDY5Y.Q MTO4&:\NZ;Z$X1=$JO=V(TAMY*@M,'";])72P&8RM03IJRJJBAXCE;@VET%Q+ M/1/0QU2#J'S2!_P6H=FL ]MXUF^LHF\;I?&MY5:YP55]U5J>B+7'S0K3FER= M(C)6CER]EJ908&"U7Y4#;;%'L.)3_L9'8W&EFK,%J]&JMX(8*]$-VC;CF;U7 M367H\9F]JF3 :JWV#S*AQ_SJZ6RQP$Y\O9BNF%]U$4S\=!2/=26D%MH-_7 ) M?9SIP\GHK&4OLZ%]+:K6NC&;H,$I)1KI_' MG[W\W4_K !I[I6 \M?N>SD$LM[GJ4)+TK6HK,"!W 9"7GB?;\K\<[I*'1]A2 M8I3$2I*X'N!*$@#NOF ;O^P92--P=047@=J_#> %"GY&:QPIW/+4/AGB?5F' M*.N3MA)UG<5XL\+!)8[#A 08)0H0B+X=IV8+)0$5M%2!Y6?DA'=GOK]&*OW8 MFU_9W?[U@.#,'2K2J'NPKFUY<_J)B0Z_ BK6TBD5-WJAE"!N;8%@,[*[B^E8 M3K/JT-L.\ 0)'"!8&.GRRZ=A,_U#'P!3O>4':#^Z3\+Z]K_G*? ?VHA.,C2A MTH=.(S$$YMF#TNWU[I'D]<(@WB LC4DY8#" ,H5?LU*&DI5B7)<.E(URX'?X MQ45OK2A)>@E<+)JBEY"12L'FF1Z//AX*1=MGX/U+JCSGP%S?M5928]KWVF4& ME6YCZT+Q-'2R9W2!>Q;$7KR]".BOKE-:BK>*;4/Q;Q8%(3"I@11] !=[NW%+ MPW&N#BN:'V'GVV5X?TP_SY2>_F&OZZV#:BQ3P7B"Z\3^C-J^8E31&+8DVT$L MN9:60C8R2M8RC^9A>3\793W*!'J+EQZ38Q!?H74_1><.:.7*1G:9%*+FBP+J ML4./-WK07;N^9A,Z6ZYI =M *2J MXXUK$ZK)PDZF?IGUK*H7A)/''W$D]DX@#N"\>"V$]D[G.?T)3*"C/N8XK)Q0 M(CE,A^TXVN0H4QYHE,JCCB*FT"*4XE0+58A,8S>:K9'OGR21QX*] +M1=;QQ M[48U613HP!5E407G;(W)DGHN[TCX$*_8A1,*(%P&_KACB JURJ4 K'_T07,M MK;#OPZ%4&6X<6Q)/#@4J%F()!>N_)HC0L?QM=A8 V8WJ8XX#(*%$"I0.7 V@ M$NEE.>-I*65 F!J#CF5+$DNE@ HB[*!_A.WLP*IR?MVW2QT#-$TA%)#TCBGH MX7$1."&ARI&RS<(<>,HJ%)#M-'0AKO+:QQ^%%RXEJ )&@ "$[M*:H\<+E\[) M6WC9PW2P=28:>2P&L4,^!780P0D]Z":N2Z47Y?]A\VBKVRT+&V_4$:TXKE * MK [>=[+!UY3^\9K,PX>VI#9%J$ICCL,I%$JDN,T%B$_T0BFUU-?DAH3W7M#: M\4X1JOK (\2K(9L"M ,W)FPP=A-&,?+_]#9 3@AWV%%YC'S!%'@=],5QFL7! M6"(8]<:G,M 8HDC5F1< ] ]0J")P&;*(\"H,($Y3C<%&LC::0B@ @4B5UCI- MT5'8V_5[?(IBE%\C@QRCN ./:=,1R:: #" F(M_,;[L.O'8CO'L9I\W*0&- M449(K"3L83_]/OYI-6^OK\_^7]7TN?_*Q3(+]2@ENK0'NE,R+4Y'+6[&GFU M5,/NF]:0G#K#,U(@ \<977SZ]/'Q<=Z%9^RN9E';'%M=:N,'I% 0RUU;%!>[ M('>61KZJ%BF624FYJ)8O2@WR[?6:E(JE,G]\X, F8:.&?=%SK)]/?._XT;'T M<]-Z^P1_^.1,1O03?*U8*"J%DG(BOJ/]<(*_HQFZ9M#_?'EY^.2XYU =@(18 MI%102KY%"C;MSBP$OY^_F>^AZRC50K%1*'N;@2>_!^^F5"R6/^&?.ZI-W<=[ M5/.>9D^Z[X0_X"ZG^[/-2DFIARPMGG"_T.E//F:>[E#'H1;L?6*./ZBN&]1F M*&.O491RT?TF+JN%OF<0=.!](X@NIF!>MK!2]L'9VXH]NY&/LKL- MY=-_OCZTNP,Z5 OS&QK;!205V_MJ7[4[[(ON7V9 :UO.XI/PX!TZ _G$_LBDQ@% M^N=8>__YY)K_O? *2#@AGV#13WS5SQVS-[GZW-/>B>U,=/KS21\>O2!*<>20 M5VU(;?)(/\B+.50-F7\@DS:UM/X)^Q;NX!/^^WFT[@*79*A:;YIQ0?#1XB7! MO1=477N#C[JP6VK!.SZ-YMZ#,NY.HSI(N)>Q3@O/ZAM%<>8_ U^XX)@CMKC[ MID+'=!QS*#[[T'K. #=:_.ED 0(%6_N+PA_QP8YI]:C%5_NBJ]WOI 0;MDU= MZWE_=%?F?U?-O2JUX*?:^<()/"T=8"M!&(O!TMS,/U92P9X]48P:L M?76HZ9.+56O[40#KPTJ=JV^/]Z^W-U+[M?5ZV_[\J0/@Q.4#2&0/#M.^O?[V MM]OW3X_[?L+?57L UHYC&K)T,9PF,ZX4HJ%?W_^-//=J^TA\W]CV]'ZDQR;+C9/ MP;+_+CT9]&S;1P@G'VZB_WP"9OU%7_M!>P7'&M,@LOKW6+5@17WR0D>FQ3#2 MK%=JEPM$EAC,I']_:[V\WKX\_$%>;I^?7E[)\[>7]K?6XRMY?2(@D5]![!*E M3)Y>B%(][9V1ISOR^NLMF0KKJ:!N7;_BGY5FN;*'1'0(+'!G6I(SH.1/EY#( M")XT>^!H]\"97H-0>^ P%X;PP #)M-!3)X4)5:T"-8((]YF]Y=;HW<#73JX> MS7(7FL*U[ZJFX'RA<60=$P6C C8"HI"ACR^M)Z M;-\S,9)+F,.1,(Y'2JZ(Z5OFD/QWYG_$,><^V<-S'P+6KLWA4+,Q\"K=:3HE MP.<@GB]6*82I!+DU',V9X'?Y5T^NBL5BH5HKU78EVW=G_BZBBJ^USI%"XS K M1?X\7E[HFV8C1SJ/\)< D%P0 [6$'FF'['Q>TGYQ#>/M#[3J,6XC9)Y;')42UB3VB7:VO@56L&41S;-(=,)LYP'D\$ 'F MJ!T0_5VJZR.UQV_=0);@[_"%KOO[VD?T,8?' %U3U]61#1MS?P)+\+-CK;_Z M.[4IX&#SE.O6H4]QE$KSITTM<;R_N[ =\(9&EOF.%#CK M.'&Y?6]T30L,<7:!U\:GK\VQX5B3:[,7),9C<\(C?5=[ZE(![?1F0"K(PX,I M@V8,.)9^2I'B^<'F2'[N(!FBC7G4OZH_[GOP51!!789^UZY*#C:->J'4+):; MY7(8XN$_5EJ\&4]9I1 99+Q%3(N8X+M80(B69O>T+G-?S/[GCO7I"M2 CQG9 ML]:;:FA_L=_/EI%85HX8S@A9V>7I_?G+>?NGULSY]?7C?T(M9FBNS)>@:C4L/4FJNG7\/B+P=KV,0P 9@:U($@>T$90+D(VB$B'S^U3R0Q^],"[0 TQLR"Z'#+ZJPXE2CYW[4 MUVQ0)P23D(#E^WA=8[Q1,(G0#R(Z^IT62VHY MZ/N7WV7X6Q0,K.6QOL;4MS M-&I+_-:-6H"JT=BRQWC]YICP31Y]54JGG3.TUC&II-5U+@XU?6#'L3Z))./Y M<2EPPFMOT@WZE>>C#*DD@+]BT1 [#1 A5;L#T@5A8L_D<3N]A?.F%4E)Y8PN M:88?:7]1:*F("W:>]F38,?53]/!S!.X+ C%K:88%Z0^NW@EHB(^!!I],U<@\ M%%BX(2GQ!E8/B%& VYMECHT>BE+3NB#66^>T5*S(I7)#+E6K9XOR+RLA&4XI MC^ ?A5'*1EE$Z<:YL@I8!&E:N]U#P#(*2W&W'EV+#S4#+]-!+27L MIMT;/;R?IU)G JX7!<4"6_H.PIFRC JTWGWY=:?*&1FH-CAM.MC]JJX+W\R& M?_\<:^@,@ _0H>(!6-/S!\J8>L$+ 817,'4FR*W0"Q)X"OAG+ 0@/?BK\<8> M'5FT2UDH2"D15KUBDU-8#WQ(8H]!C=@#$Y/\W)QU9Z Z\WO_4&=WB5OD7Q9G M.).97WI:.I/PC!U* <3CSO_@!/@\>Q2^A+L0ZV#MAFQ9L!JOWX!7X(7@V#ZY^H,NW#%R*G3_RPK)R*.Y\&GE4 @U9STD7R1) MH,:AYF#[%*H#55JF@3:./B$4[)T)N4<1KG;9A=B-ZJB$U03,<>9T#;_;CL$O MJ5*L(O.]T+>QKC*N;1=>R2F"OGY9*I?.Q0/.0&-IM2-,JTV83:5Y-N7[];B/ MVF=K\Y8/+@@6P6HY;^6\)7@+R%DE.NR9$K7;!=[B/8J0W"Q4"H&?$B";0N ? M["$P);S%"'@C'\Z B#^?PW$HVUN/]C6#56&Q M&V^\)"D5+Y?MD/U9N70?6_J )!Y8V)^[ 6\EU(/BX25[=9_4#"8[@.$[A9*K MV5UUCH&_\P.AJSV(!>X\!T1LM%I,/XWH(9@7PB1U[&2++1ZKM>:!LI?[DP)0 MUBS/H$SI,^BA"G@SK4E0D08:1]:U>( YOHO2?*5YD 1YI7UGLTS:^P^S<:L+ M#E/VKB]C6\/&;\O;7!P; :>1]97"-F^7J?H-Z&2A9P$G%/=5O[ W7?,7+6]; ML,,LM-ST7M?T[DO+35S,ZN&6.9FUS+5^D,/+W%P0QH;)O-2QS@ WOTC Y!(KMUOS!U"LX[6\_/#_77KR\.M]/3X\ >VR;EO MM[_=OK3)_>-O3P^_W=[ #^1+Z_%?+]^>7Z__V-N3/K\\7=_>WMP__M*6;KZ] MP+^L\\_SR^TU^Y3GH1U!.]J'AR7\1K(1OD MIAQP-R0%W T1_]V0/>[8L#3EJIF%S'!;6F&PY3$1G-/2[KQ2[%?EY_?3R_/32>KUU)6DN3K(H3I _>58_X\R! M:L$ZYMAA%C>:WFY^D+"?--L>8^A+E :PQ#W*(N%@@@U-W)W9_2YCNQ?Q#1U> M8SM@N.,U3Y>%8;'3X3EIL4>^JA:L7EZC.M-MK7?'TI/_H*IU!Y_8)U:QH?$70/N'K MD[8 +PCR>K$H%XM%WS.(;?BI19XMVJ<6"G?V/,=:CWW+A]OTXO_[PWR9;6(U M"N_M[O5^CU4\(06=%9^Y!""A[N[BSJ9?8'E,_ M+8*"4 H!0\YUM:8JDO\N M#S4S3>*]5R_;2L>BZO="AP++PLY'["3^[=4"=H=;CO]R/X@3*TU)@8G"$EH/ MHYP%SG;_>'/[GU1;U:<8<]Z&2,M4*43@[#M2&Z(UTP3PD'Y%S._P6S'0#&*(0\FEJ9K[UY%C8\ M@6_X^:1TLEQL) TAE0PL-)[^IOZW6%3@T*V75W)/0!3?/[8>K^];#P1,MZ>7 MKZU7-KQ"78!%5-((&UNR!DBG NBSS@TF]#&UL%UDH['Z^U7H@0A),F.R1XQ ML#$M7V\?7]LL:491+LFWQ]:W&YSADA15)$D/"7++#*N43JZNGQ[;3P_W-P"0 M&_)%U7%.%&D/*,6X$',?%GK(DU,/6&?,>;BC'6NL6A-2:KA=YM7$N"O!ODAI M"[\POG6KG'3:!RU:/%=*5,,PLMS"&==C'@0$##]-*)<>4Q3 MI%_ARY0A^1&4#/G*4T3Y7=YJPIA_0LDF893B$,8^H;UR4]WA'?QQVL, MD(5/U__Z]>GAYO:E+0(XY/;?W^Y?_R"G-[=W]]?WKV2%0VIHJV%6G ,+.":Y-I%:,'<"?F)N"\N2N_,2 M*7RRWX>:))%0W2H'[=!J3L\F+J5L$\_23_WDZFOKL?4+4Q1"&;3)S7W[^AL; M^T=P'" \\/!'^Y[ID:E)#>+BA@V7:;.'7F[;WQZXKGEZOGUA?E<[FPRN5%.7 M]PD317FK1-$XN?HW3@FZ!PL"LP 0O?#!@_L[DL?#4_L;H)RTOCQ]>R5?6R__ MNGTE+_?M?V43Y:7ZAD(]8816MHK0)E/NKR]/#YQ76?+'#>+OD+!U$.ID]^$T MI>B&TS">]O3ZZ^U+QF)I!X'H?8NES=*(O3RT%A\4"L=*5\7VE_OVZ^T+.N>MAUMF:8NPC6]> M(ZKW;^U;_*-@S8/"Z-$8X4KEY.KF]J[%?*IOS^")M6\?[Y]>?+@^)+P>B*6M M5,&?OG^\!0Z]NP7&]'E*AX2M77)A=:OXK)U<+;& #P.3Z>&IME4\U4^N;O_S MZ_V7^]?C9;2L>CI^ES8U FB<7+7O?WELO<[)6K+QVP5-HW+'VA#BPJW9D6^<,WQ M$Z2RP&ZY86\2V/N@VMO P2WJO41?OMZM4;*[\8N0S !D>WC?TH7=;@\9P=G+ MV6Z[;.=J,[XK4&F9@/2K/QYF/-TS4G:Q&#J==^"B#Q676"7]PX@(7?PQ)U M:ZCJJ<6_F$;6PWMU%3R=VHJ1NK3-+8+;ZHZND!2:QD]_.=V2F,MYUJU M+&Q+RVX\ ]LUC6V@J[*L5"L+79IBD.AN""#40L\YZG@YJKPSCFK*M4KIH#@J MNE*/JK(S"Y&Q@1)V"6E*0X_4 M<4=_+944BEQI5J-*BKU$<\XA*7((SI\I:#\* ZW7H_ ,_Q>VW74*1;&'I,]0 MV#OJW(5'FA%HO%#L5-MC>WY6+6>2Z[ALZSA!7TA:&K57J[MB0RX7E5SA MY>R2O,)32,>"",&*8Q M*UO6F'O'#]OQ^U9HU679T0E"Z>3JU714G6W0S9SF&GI7XB'[7)]MK9KB/1NC MB]6!2:4F*\7(J9L[$ V[UH YB:=*XAMD6$8D\;4R*;-"X =[_8:YL".W=_?7] MZUE.8UFEL1P9&4+&=L.Y6TFA$??%;"\/FMK1= WKCK?2?# GPEPB[#DR#C8Q M8::+T[,ZR=M;Q-SH,C_]T&]97 (2M-,R>O")-:8]GY99F:Q45A2YFJ80&RJHB,59P@>N@-YK5/5ZJA&E^WZAG8T MAURKUK)9@#EOYGILB1YK#TS+>:76\-$TOJC&]P=3-6RPD!]-A[H&3-'18(]=AN;MVK^N:86JV4'(CU7*P\H:8??)"WZDQIGGP-$/\O!=ZK].? M?%P(ZEFIWI32 <1[J-&=Y)KK RQ MZ%YH+-=3\WMD*P.,%25R@=5>XC9GBQUI+B6?TY*I5E"9TGF+XUN8T%JA\_+& MZ@59<)R.NWFS*E7KD"&E6JD)S$C\ $M\@ M&S3%I,^LD#A76X=52_5@PALQ46&^FBJOWTGF17DQU4$CXV O6EB(R5])10KX MT[.JDVMUI('EFP>5,Q!4WJO@$"H;GA07)0NN))>46G[=DG-&"M#YU,A,^:[9 M2#7(4PP.^/XUF12#L %:E6)1;M:SG&NW:]674W>VLPL.,ZU@3>\TOU ^U OE M'!D90D:Z!F:ZDL;7/[W]C[\U2DK]4O109_OP^JCG;9,S2WXY,C*$C"2#R&"I MH"O)-JP9X/'#IX7E'N8VW.MG2[3>(VW'!*OQE/P]NJM269SO*U9CBSVKUI/5 M=C#8_)NJC^DSM=H#U5J:^P%_M_'O]CH&97I[."\6BT%1Q;D/P ^QR#NN+9/H MH+M_O%MSQ8SNJ@?(N0V"*NJMZ5%*,0*P:0PV!MQ)S^GJBVMAJ MZ=%\I\,.M4BY*)-2L51BS]W1CC56K0DI-?BG\V-N\GOV*!O=ZY;<&P0!9RF? MZ;F00J/(4<",8#5//$F<(?8A]G=T1+W=:ZT,^B+7YG!HXBN8([*)'\)7VJ$3 MDLP&,N6!^(Z4$?6P7R3NW\A=U$-:?+C:;<;%;E9B/H6F8>PF@! M;Y%*=NK+Q0=IO2C7*W6Y&#@Y. T?1";PXA&%%=^I/LD]DBQD_NZ56^*C]17F M6[DI!VNZ/3/AL:IA6G]>1 M';5HV&02I4=/2$KWQLHRLK)<5D!W5O+.ZCF#[ V#;#)\1*HRJ7:P?0 MP#D3)=O;.#MWC'F'/=7H4CUO\9X161%:MU+-"T]S\CP\57::M"YC30.XC)N* M-[\&L^& P&L+C7&JRT+666:/LR/Q!*>%U6+ 5E_K:I%KJW.Q<%AB80,?\(4Z MJF;0WJUJ&4#NMH^R!%%%D!5EN5FMR_7:?DN+G&&.AF$V\ D381A%KJ%KM'?1 MUKCJ]7 JHUD@?0"OI9;M%;S\.=:<"3D5^(\L58ZQJ#3+#4E25+-^LN'D$D%* M8*N16B7+K4;64*$YL>\7L6^@(F,1>[E6!0LR+38@E(F,TWNKB;[Y&!P^.IS3WO'T5F?\-_/(_]+8(]% MP.X*?W*H6F\:[!0?+6[LEVI_4?Y:6*GC;;\S!>HHX1W/@KM+L7-EDJ=X'5!) M[7;-(2PXP419WCI3M2B!-V"CS#=+U3'/WL$$6F= ;0IDIHY[&G;2[&N&:G0U M>,+&//\A[,\^3PT821Y\CO2\K;I[_;]"@=QI5.]=D&?UC5["0G^.J=&%!(3E_=J M^-DJ@782"YZ+U.2]G>VG&+ =3NX^@+B@N"2ODQ&DD<07!Q!+@'F&6 ZEA4_5[H4)"6L.Z(H<&_V5K 9A&@?M#X"&B*]*4O M]^\7SS%%9;H,[=O8S-O8?U2B]7X^4?];+);A9)_4JSV1+2 AOU '%I7N3(O\ M88[)[U37#6K#=^Z-[OE>"TXXW+6)U6,V[4GP$^-)UEVX[4E"E)A/(VJI3%B0 MTV^NW#S;]Z,#0B70!: /+$I9$86A&90,X=&!32C I;>DV )^4'9P^F4,QJP, M>$K7A0'$["C\';;7=7^?M3&[IJZK(QO@X?YT23ZTGC/ W19_XA 3.[^&?70L M32:_4OV=HD<.NU8-NR LH"A.^Z++'G;" )]A'41'\B]\[_*V!K! C/Y\4CM) MZ.5!NFJU5GQE)/F54^(M4N(ZIF[;P=^'_B()@M^"/&@W;&6.MP& I/0SB M$)BI6$[O4#FD.IMA11$T6UH1%[9,;$[B&NY!#/:?S (;X# M&H^O(3;@U?5Z!FCDQ"?MVG;Z>;KB:"$=723^N1S/)K?Y[XUD16 M^DJM[@"[:MB4M%4=IW+,TJX;"EGKY<$LNLF*01=5?U^RU^8&*[OWAF'7?Y5- M'-*R3ZEA!= ;F#V+1%:2RH?:W*YGAWI=9:38]8%EY(IP;5Q&6R2 M&Q.9W\8;N?TQPCQQ[Z8LC.*B2N8 I*U^,&C!?#-[L)DMS.6-2/H!P6/6T8U\ M46W:(Y23>ORLCE!QG(;WG=$8;TO7S2[6DS#H,N!>FT,$KHKO$2+ED3I/_5?U M1TB?Y$I-KM>"RD"3 4,RH#THK%=WC_5JN227*JLMN1SK60C-)H5U12X#WBN! MK;QRO*>$]]KN\5XK-K?,[?MPI]VFN@X?R>07:E L8L?RPU9OJ!F:[:!E_KY@ MIN2W"QFR@ 3^!/9:1F\6=X([EG-%J=J0*X&SE?+;JX.AKPULK4WIJUHNRXUJ MT'B%G+X.AKXVL.HVI:]&M20KC9R^#IJ^-K >-Y9?E9+<5(+Z9.=7_S'"O:PO M+UD>]#VF.XQM<-INQ>>.>;V8O-'(;K M-G7:[HVN.:2?3A],VS[*[+/L"/SPC,@D7#>.;$1UE,Q(H-3@&81Y;F1.G2EX M<&M19_:(]M)*GMN/?)QY-UFUH MP 6I@"@3'R%I$E6Y64X[HWK!&CU3XZ,-7,'U^$@I->1* M! ,[9Z2D&:F\!4;*_$5 )&7++"XN7=S%9I+T>RJI,-$C=8@F+N#U*+G3FV]C?>$+[R0]<]S1:0H0B-:V,Z4MI.[K M4&>]9.EJ$QREQCCYT;GY'@LY+B)U[0F.9;DLM*4 M*XWUPS\Y.1X+.6Z0_[R^=(R;^9PJ.>:>6+Z9#&YF9PWF3ZZ0G\F(PHNQ66@F MTYP6!.OV,D!+:PG)6]4R0)39S]1R6Z]JW66I:_ 0 [E]H@);-O% M;#7'[(%BMI@B9@,-G%D4KVX&FZ-X4Q37#IEY<[,TWTP&-Y.M"X*3J]_9;[1' M5-B'^D8),'X'3%>S#[)B. 21P5F7F&/'=E0#-Y"PN[F]F,-&][!)O'3M5I?W MCW=KR647G2V.S4>&S*<^D]'VTQ2%R^6U*ZG+]9)<+"MRI;*%RX&XZ2LYI6U" M:=6,4%I-D6NUBERNKC\!(*>TO:"T8D8H+9=IATYIM6Q06JE1ETL5H+3B%BZ/ MHEFM.,@F..+DCQDHA?W3T5IVN.W"7F5\ M M7Q"E")A>L6&^.*P*CQ9G]]^E6*H*2+9'JA$['FMK?U&^E9.KUP&5U"X8L[#@ M!#L'&J8#"^ @1'B#!J][PY%#(]5RT.IU!M2F@%!UW-/0+NYKAFIT-7@"L._0 M(>S//O_\";=WM7_ <)&XW>U/W^.^Z/\*!7*G4;UW09Z!TRYAM3_'U.C"1BN7 MY#=5'^.62:$@OLCD&O^J+U_13[-*"=EFCFQK^-FJK,J36.=>/*CW=LY# =MA M*/"?W3WU)7F=C.#$+4OM:-U+\@ABB4/FT40@E/Q?^N1^BX$'8>L!9AF@.A95 MOQ8HG)?6.5SQSMEYVHI MQ[#_J$3K_7RB_K=8K""UJU?[<\0OU(%%I3O3(G^88_([U76#VO"=>Z-[_KEC M?;J2KDVCA[GE/0(_,8[!07BD[8I#E)K7 ]5X@W=K!GQN=K\/3!UXSO['WQHE MI7Y);O\<:\Z$G-[0OM;5G#-R^LT5L&?\);@!$+WP?XM2-O_-T Q*AK#E@4TH M[*!''LUWRH(3Y:),2L52B3T'/RCD=#Q=+PQ=FV(D&>C7(XABIJT!Y[HN[ -F M:.#O\(6N^_NLR=4U=5T=V? &]Z=+\J'UG &>M/@3WT.44Y]$BE$M#8O.@&+7$O^:Q+6[9K9//OC199B^._:Q:7+F2(P4 M4C>0?8L\6[1/+0OEV)&!8$H#.3"N6K +=,K O']6M5X!]->U.M(<53\>&'"< MP[G!I-11ZQS/T5O=[G@XUID](VR3XSD\JW]/YKA1;[66I%H%6$4!0 Q^:B6H MO*\%!I/6?E^^JWQ7^:[R707L*MW.:L*1*S5^"LS/7B*XV<$T=.#AR4+Q7"E5 M-6.^HYKX^.3JBZJC%0!NX!WM6&/5FL#[9'Y&=+CGH>$ZEVML*?2^PK=>Q%KH M>(76XCVU)-X3Y5:BOLFMQ,+UPXH[KJ)I4/:>[*N M51W.>C.V "[/U-+,'O=&P@G%\T7D8J4A-^JK>QN$"(,, #$&6X6!D-W31F"U M>H0TT^T#;N^+M79%4IM*ZB1(JE1IRJ5F%LDJ''8;]$Y;'W;Q;..< U8A<8.> M8YLB<5/TI7L)E*R%HMGV&%/<30N,%7O CS&RZ+MFCFU] D9+EVKOM+=36MC< M2+EGQUPT39:/P?(N4TK5+'-TNH;)(M@8ZZP8'E:.8\(=G_S+U&92-D>B$M(R M/S*+3D&F\)>IS41M*%XN+FTHGI2&W:+^M*GUKG6GJ;.[E_B)JDK^^9UIM<4Y M0]4F*,U&KCCGY5TT&/*I,\5F5D&7*5F3JDDNE5;'8W-<9FPS MZ?K*R1!6/<*0K(-TG$=CJSM0;8I5D/:X8VL]3;72CNOOR@QX%H=]ZK=LFSKA M5H"BH F0FP%SC!4)AF[#Y^S"+E,2,E.;V8D=$)VJJI6&W,SI:O\VLQ,S8 VZ M2N3V8Y?./8,#,4<,NG1VM/PQ$%B^F;W83&KZI:7K9A=K8=V6OK2':2K !BJ^ M*&#$Y*P$J(#%5U8V]0.. XF9VDQJFB4;%)5MS_)WU;)4PR&H@#%C[)@(+]_, M7FPF-8WS;)E=2GOVG64.7?I_Z@N."+$UZPVY6%]=WYCC+F.;24W1[)20=NFS MY-HCWTS&-Y.X]NCT)Q\\:*$)JC?['X+5!3^X[! 27"W+565UA5N.P(QM)G$5 MDAUJRK:?[&9G=R\7)L&L*D-[WOJ?P.A$&)M M5IIRK9$G8.S=9G9R\[)MNMIX8&IX@69"':H>J4-TTX[6HO0DC!Y6%]U&I9CU M5@HE\# 81=A)#H4<"CD4G.VB.WA30NZ66GR6Y5FS*]4JNE-/"&5I57P.^12:(I:VW2NS M)%?+8 )7ZJERVH)[?12H#L?TIO5\4;LG*W6YUEB="Y 4.^?M,)8AO)R==ABU M_:V#+>V^UC;"8U+;)I[X%2O2(72WDWB[W;3&K*)!L4 ME6W',*]'SC>3\N+RJ/ZM:[]ZX5D>:H^I?5>O[ MJXG_I4[('5)=5AJ;1I". YN9VDQZJB=;I+5+O^;.M/I4<\86;[G+O)RN3PT? M$[WEF]F+S:Q(04DI5/9";^O\QDL M>[29%0274D M*P2W];J51966USJOYHUCJ^;+H9!#(8="#H4<"C'2M+=8ZURO MU>5:/79^=H@=?*C(V6*M3D5;K6*N2HK MS8917S0:-W:U7,33"2&I5CE]B[ MKV(NY57,R4(^W ,K;[N*N2R7FG6Y44JWS/4XJYA7H#JU,N9EJ"[5Y7*$.KD$ M$)WMU+9,%SN7LU+LK,CE1 9!9@&,.RD?5#:>I'T<=]R9VDPX4>V^V!G-XGPR MX_YM)I2N,D%6S;Q(:H_I*]_,7FPF-?62C9*6XT!BIC:3EF+)!D'MJ2-IF Y\ M,%(G:D>GH(X<@%7Z&>V[\BM;W3_'FLTJ&<)=RA).MY%KM339 M+ST-?F;$8-'>ZT"S_ZV)]<(3,FI%N1'AQCZ+'!5'Z:<%[9!TB+RMYMYM)G'; M8/MDI]3E2H2;XQS;&=M,TC;$3BBONO'-9%Y>F+'JA."ECJV )H="#H4<"CD4 M7KAY="HKN$FYNK 2O[;PT7RGPPZU2+D8N[JP M$H>ZX$ND9XX[.DV^#&F-M2-YU;5M5A8"!3:K+Z%2H'@]P=\O$6*X3C5A,>#)IWP\-;J@N.44>8(W8CQ&ZI0+0L MEQ60SY5<^2:/WZBU@^7(M8,YS#'FCZY6+4.>];6_J(7I.XG M+%P/MCURMYK<3A?69" A7:KK LP,8_@[;*+K_CY+AEU3U]61#;MV?[HD'UK/ M&>">BC_Q2/)S( 8S8$CTD&@8'1R3]?%(Z"5G03Y%=V"RU+LFJ ML)>7)<2]B(CQI(67[]^QGU6+OY)EA)$CA0+R!3!,BSQ;M$\MB_:.#@1SA)!# MY&K:QO]SQ_IT1;"9/\@__HOHZ9\T-#8[>KQSQE2DWJX6OLYU*RHB6+QSU>IV MQ\.QCD4GY(;VM:[F?/[4N?(4KOAG74 <.-1>32 OX@/4G)FR-KBBWG$DJ_A7 M(2'D\?S;._CV%BJS(E)2H+>QA,[%;9DM\Z/+34K%43%;[1+Y3 MS4(?OZCAG4K>&FI'D*]N$?)[EX,0&8JU=:&8$VL<,-*J4-^XZK"R$[-,G,0W2H0-5[^,87F? M[O;@5!.B&CV6@F!IG3'&Y!V3=(-O,]SKY9]"#5;OJ>B&LOA*[:= "[.P=!]K MOV';6X]L'"M+C>/].>PQX&EYH_P].FQHDMFFF9M+FLL\T@_VE[!J;UEIK.XD MMT=PCDI4RS,H]^BP8415W31S,3-$M:T00^0N @?4%V!!?QQ;T6MD@;'VG=S! M@BRGF:@TL_9M8@ZRU*X.]PYD*PH3-I@7MF[)=T5N1ABXD1?C)V!Y90,U68JW MQ,A (G>T8XU5:T)*#5:QK^P]Q466GVOG!&1+?FXW :"26@+ X1+8VI?YV0+9 M=@FLNO8%_$%"*U1;;MK[/6+988+5-AL^;1;66]*/7.T[U"(6-:TWU=#^8L-8O,O9$#J)*AS6EHRQ>BK- M=XSE8=P6GNUEYFCA/9:PRU>S)I?+JZ>:KCK_[F&W4:_=J*#CK%++\ES/A[4(LJ7)9?5V81W[48URR)<4@" M[J18/@\HNK+ J?.,HFH>PZ[!"XZ2S W:-[^88UDOR<4(>C[K]]];P\TF%EE&<+.] ,#:.90R^:I.2%G99?;D%G*/0!)N M;VK1&C?J>R&&MXZ?%$=:1+LVW0NT)&E0A.*FE/U)09E$T#;X)K6)!AO/^#E: ME&PIS;7HZ6R';DMO-M.YTVL).X^V9C18,C[_YKWSO3:HMSAEH@U?W-)*EM.K1SR=U%- #R M@4=9!=R^W9+6LI<>&4IZ*=V2KD%Z-1P5G%7RBXSVN+FENT%[/:7;TC707M^C M!)V\66#"&\N!DP,G!TX.G!PX.7"R#IQL!P?R/.&$#?E*U@SYO8/@GA4I["Y/ MN 2>;W8C5E'1G;G$^IUXOEM"=]YI-<_H3"^;("K+[WD+LYQF=D S>2.WM4&6 M)]M'O(7>8A:P4I&+Q?WO@K4UW&QB;V4$-UD* 0T[)@V56V-W\:VLY 4O)Z9 MO9 VLK:%O.'@ MNX_8J5;)2L9B26[6ZW*]DMT0<'0P[B2%J-1L9!5T^W9I4U]>I)U)XMM]VF(5 MW*QF);N&=53$9ZZ!:WC!=P;P7I)+E?(!]WLYN6*@(N8(#V83RE,,.PCN6<[T!CJGI>MF5W5$0\,OJDU[: D#6[$^AB*))\32J55!V:RN2CM1>KQ"$X^!+I MF>..3N-WKUBV1A3KOE'<9IY"62Z6*G*QOGYKL;UQ&TGEC74;(%7MI1&%*.1V!$B8TO9.(U*36Y&N(,X"HR$FY.-U-* MEAJ52K4N%QNKKZ8C8F>EP;^GB-EV E*I7I;K]<289L[2_^2H ?FK5])DB0< M\9&[*!KAX#84 6*OVI#:Y)%^D!=SJ!HR_T F;6II_4LR5*TW#=Z"CQ:#JI7[ MZE#3)Q>KUEE1V3QRMYK03F=!U 77A%K)[!ZW8@F]W0:J7A%UXPZ%(H2"^R.0%_ZHOV,1/ M5'#,$3Q<0B80G[B,4^I+\CH9P8E; MEMK1NI?D$60)A\RCB4 H^[_TR?T6 P_"U@/,,D!U+*I^+W0H"#!8=\0@[M]L M+6"S"% _:'SD,\7OTI?[]XOGF*(R70KV;6SF;>P_*M%Z/Y^H_RT6JW"R3^I5 MYIF)2Y;/G:LOU(%%I3O3(G^88_([U76#VO"=>Z,+4J)SM8>2PCO2Y*V*P=17%ZK]H#:'34Z_N4+S;-]/#OB4,.G4T Q*AO# P"84 M@-%;B'"56(,,'NK:^IF7<55*$%YX#[-G2_*A]9P![K/X$\='E#V?1(J33F.@2YR5Z/,3@@QE. -B_.>3TDG( M@D%*:;7Z3RAP($0?7K$2"E%#[HOA]("% MKUOM7\G=P]/O;7+W\O25/#W?OK1>[Q]_(:WKU_O?[E_O;]NAF2D^6(8DLFSX M[71O&00[UVL_!=XA+'I$F-IQBKD="QZK*QF"5@IU7<.^&,EO%0LT5R\0R6G= M8C%K22XK3;G26)UAO"Z0#A<]&Y0DK']WJ%1+\/_5\828Z-DD=RO2>UJ]_XUM MAWG"6)UC40!E5P-+ /D8H8"?&O!S%XW#D66^:V@Z=2;D= S6)/C<9\0<44MU MT!W'P[]KCD;MBY13]E8_N,7\P3B;25=L+VE@R^Y?8$'$G$CHWFG?^$VN^ )3 M*I='RQ4L#YS6:J0DT]8%5*->E95&*4#&U/_3L>PS3>KO%(+:-W(TX=4JW2J,D- M);L%AE%SV^+.HMZ)J+VA(U"F&L/:GA*>_PA :'XZ#*F,:FR[##YY0EO>J,8;CG\!)(\M"^-VJFU3L-U0Y.F:VM'TW/S*J$P(U&!=+KO1\*;: M.\;@4@96:JXM.$X6!3/CAO)_[PWW<"_>V<+,LTJL^1\Q^T(D+C,:<4NGMV(H MO5"=A?OQ8G1R)+0FSOP,1];"2GF58D,N%U>/#^,=+"73VFG#F43) MR#W1G&!;%J4$Y9KA_C)1*2INH7A&I)QGZHW4R6'JWF=^L @462O+C5JI@A[0"5.3: MQIUA=B]M*_LM;6]HGUH6Q5OT:=#[8.C1/5VTB'ZI40'O>M.(_NY),NY(F:W( MOB?FK_A"<(>CW]G1KGF\<8D(7'H_7HMUX9:VFM_;B.'25*[9" ]/BY\S-$,S MJ[)<*IXWS-B:5?J(A"-,TL@!M&I-KE=76_.QL);RE4IHAZ*0E)(H+C'N/ET.D]*?!0Z^3+X! D AN="? C^",JK7BG*SMCK0 M&S7S-%)674X$223E)4<$6#*[%1)(UUR(=EL\E[]\__C;;7LN?SF_*,Z"\W"G M_0#%TMKKRPZP&E@:Z:O9ZOXYUBS*W ;@VMX8&93RTX4-1BR7XH1-,G/C$7<$ M9B8<"Y_%(XP<@I<,]A(;9]^(TI=WB1NU_E-Q>!0K4H"P3#B'9J@Z'S;C)8#O:9S?/?0=G/F%CCQ* M\P5B)DAU(816;>Q@?EGR"FJ/,KU#J)<3K[40F=U2!L VR+0]QO !L"!K MIZV%7X.6Y7HULV2WYMB.3 BZI:',6S>1$_%M:9TQRC_'!/=RI#FJ?MCW,7') MV@7:]11FK^8UAUCHX,E:(Z6[ET/%4(Q8] 88VBCBO&-_// 6S*M 7.?N*Y18 M-KB]B'8WL>6PD@>AX+#2W+447I\V5[-PDD#*,#:2ORA:"QO1N'5M$*6CK[,; M@\K49G:90\ K-C&N9%5<-FC8+BA8 M_$/+Z,U^X'N2CV^<3V2Y_='5QPA9^($AX 4[,VJR,9 MK$=UAYO+ZQ]3-FUR@9DI@;G$=UQ"\ZSEI.J0#GW3# -M2K-/1HRG+_::;<)D MY0;-R#>2E\]#9#8F]-WJSX.9-B+6YDGLQJ%_I0 M?MQ@7D-*_%B6E6HE'^RP%B\IO]W084\_Z3'&I=01!Z&RI%,N_S2 MU6:7K@?1C="[=Z4])22HW8@TY3#KY%G9D#QGY@%M8WQ 8H,3W-/LZ=R'?%!0 M!%Q&F!14RR<%+4P*JN23@G8QQ\4]I3>9Q7?LL#E$M6W,(8HT/6A+PE+=!?,%?]<, M,$):8+;\]\EZ4PW1FG9Z4MZV]AFL;#C@;/MD59^>'!T-W;3'%GV%-WS1P;XI M=(O_Q3?\%TP<"C;."#6^-:;SQE#2[XTG_>:'!7("0(E-_!MDUND-',?21NQW M4'Q?QK:&9.IA?//7^Z71# X#V-2/;(%1U;-6MX#>T@D3$VG23VI\PP4."18X MY/2#RF0,OYEC2T;[1OK'WQJE4O'RFMM$[#?EDL"W<3B6^.,+?=-L!UT:\?GX#IU#6MD6DQ.?*A.0/V=>0*8S"3 M@.P>Z;O:4]&SOZ%=/H-+82.XBN>)4.%J4?-ICN(R2)SEM(FSE!YQ/AFD-;(T MG91J#*\*HT$BB(\P5<6J#$%)J89+FZTWB_)I="BJGG65R:BOU'K#F5&,(&7R M,:!XQT\T> J?Q\Q2F7W!'G=L9HTY0*AHVFM=;<0(58-#J"[5XCD&$$JTBSWR4?<&;25L? *+<&P&/BLKEX5?OV\0\?2XM/ M@3K BP>A8+K@.Y/#V-1;;=R=^Y:$9_1]D^.$M,>=N:]._S ][]/88A$&^+RG M6;3KF""2_DG[?8M.0 \CHV_-$ A2AHD$B!PZCWXR>SWM2Y\$PB!JMV!M 1P MKHB9A5LN33QFKZ0M3A54WR)B@1)_"NE9<^S9 "%('!_+,KDRY:=H1]T@?3+!HX:?,0R=PR'M:4!N M^D0"_8'6B1G$UZ1E@[CO#F3_-\C,-X8,"8/1T[4)<7( N+53(-2MX!X3UTB-CJ M,NF/=69U:OQ-( X+V+S>MMF5I;?+Y6R/\%#JE_:B%69[SIC_7+F<\-BXEK:< MJ.["M@&68$I.T#0C-$L"(EW41?(4THR*+;5'78OXZ?4:>-[Z3AUPJ+IXR]&C MW.D?6?1=,\=@=6O=[_"9/1EV3)T$N!1C6%SGGCZLI!%=:K:KL\7M#$AFX121>3YN':NGQD)]2.E37Z#N& MOP>J$V ZRE(/8PR]$*6(Q&:8#I :AL)L86?S:T+B3$;@G;(H:H?W20*[;J1: MZINEC@;D5#W#)U_&(/252M7';:"JQQ:K/L*Z.;0IE6:YS)2%(P("X^%0];]K M/@B@Z3K;6 =WP X!K*09[Z;^SNXU!2N"R^R+E_@_Q.=MJNON'Z69/R*[V&#J M+P82_)^B5A>B94A5-V>[33F42J?E,W?[LR/)@DERR$@3 =0UFR9 M=PQF,Z5NV**AC$^X>&J3<3?&=JAEGX-4))C$P3 NA)WYKMDLQ((!R&E@!\SS M'H.JJ'&45/]2TF]=X@RCS27D)VU,?F*A7/*[@KF1MN2OIQIG MGO5G^HX0MQC=U:E?FO[*X[Z2RX%S>H%\P)

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end

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�MA]($ MBF9KJG$]/+?M<57.E9B8<6XT57I]_7L9)21,XUCJ;-L\Y',WL;7 H X(E$9K MVNB!OH)@^.@^"8-FY5":0-'L.>2-$>*[C9 KK:9J8DIGJIV=.C>FK:B@M!!* MHU :@](XE"90-%MZC??A[]W[\*'>!Y060FD42F-0&H?2!(IFJ[3Q/OQ=O8_G M# \WJ+7XH(8'E$:A- :E7.QJ;[D_^7\TE)IS\](<*=I+3FHOP&E42B-06D<2A,HFBW-QM_P]^YO^%!_ M TH+H30*I3$HC4-I D6S5=KX&[[;WVA1E:$>!Y060FG4?_P[FR]@!&&^;-@C-*E T6V*-0>(_\[L0&2OWC\G=@-9R@OHA4!KU M'__R8IL �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�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end XML 40 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 144 236 1 false 33 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.betterforyouwellness.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheet (unaudited) Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheet (unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheet (unaudited) (Parentheticals) Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheet (unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Deficit) (Unaudited) Sheet http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statement of Changes in Stockholders??? Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://www.betterforyouwellness.com/role/ConsolidatedCashFlow Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Organization and Description of Business Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Going Concern Sheet http://www.betterforyouwellness.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 009 - Disclosure - Business Combinations Sheet http://www.betterforyouwellness.com/role/BusinessCombinations Business Combinations Notes 10 false false R11.htm 010 - Disclosure - Income Taxes Sheet http://www.betterforyouwellness.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 011 - Disclosure - Commitments and Contingencies Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Shareholder Equity Sheet http://www.betterforyouwellness.com/role/ShareholderEquity Shareholder Equity Notes 13 false false R14.htm 013 - Disclosure - Related-Party Transactions Sheet http://www.betterforyouwellness.com/role/RelatedPartyTransactions Related-Party Transactions Notes 14 false false R15.htm 014 - Disclosure - Goodwill Sheet http://www.betterforyouwellness.com/role/Goodwill Goodwill Notes 15 false false R16.htm 015 - Disclosure - Subsequent Events Sheet http://www.betterforyouwellness.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 016 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies 17 false false R18.htm 017 - Disclosure - Business Combinations (Tables) Sheet http://www.betterforyouwellness.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.betterforyouwellness.com/role/BusinessCombinations 18 false false R19.htm 018 - Disclosure - Organization and Description of Business (Details) Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness 19 false false R20.htm 019 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 20 false false R21.htm 020 - Disclosure - Business Combinations (Details) Sheet http://www.betterforyouwellness.com/role/BusinessCombinationsDetails Business Combinations (Details) Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 21 false false R22.htm 021 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities Sheet http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable Business Combinations (Details) - Schedule of fair value of such assets and liabilities Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 22 false false R23.htm 022 - Disclosure - Business Combinations (Details) - Schedule of condensed consolidated results of operations Sheet http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable Business Combinations (Details) - Schedule of condensed consolidated results of operations Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 23 false false R24.htm 023 - Disclosure - Business Combinations (Details) - Schedule of revenue and earnings of Mango Moi Sheet http://www.betterforyouwellness.com/role/ScheduleofrevenueandearningsofMangoMoiTable Business Combinations (Details) - Schedule of revenue and earnings of Mango Moi Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 24 false false R25.htm 024 - Disclosure - Income Taxes (Details) Sheet http://www.betterforyouwellness.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.betterforyouwellness.com/role/IncomeTaxes 25 false false R26.htm 025 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.betterforyouwellness.com/role/CommitmentsandContingencies 26 false false R27.htm 026 - Disclosure - Shareholder Equity (Details) Sheet http://www.betterforyouwellness.com/role/ShareholderEquityDetails Shareholder Equity (Details) Details http://www.betterforyouwellness.com/role/ShareholderEquity 27 false false R28.htm 027 - Disclosure - Related-Party Transactions (Details) Sheet http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://www.betterforyouwellness.com/role/RelatedPartyTransactions 28 false false R29.htm 028 - Disclosure - Subsequent Events (Details) Sheet http://www.betterforyouwellness.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.betterforyouwellness.com/role/SubsequentEvents 29 false false All Reports Book All Reports f10q1122_betterforyou.htm bfyw-20221130.xsd bfyw-20221130_cal.xml bfyw-20221130_def.xml bfyw-20221130_lab.xml bfyw-20221130_pre.xml f10q1122ex31_betterforyou.htm f10q1122ex32_betterforyou.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 44 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q1122_betterforyou.htm": { "axisCustom": 0, "axisStandard": 10, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 455, "http://xbrl.sec.gov/dei/2022": 26 }, "contextCount": 144, "dts": { "calculationLink": { "local": [ "bfyw-20221130_cal.xml" ] }, "definitionLink": { "local": [ "bfyw-20221130_def.xml" ] }, "inline": { "local": [ "f10q1122_betterforyou.htm" ] }, "labelLink": { "local": [ "bfyw-20221130_lab.xml" ] }, "presentationLink": { "local": [ "bfyw-20221130_pre.xml" ] }, "schema": { "local": [ "bfyw-20221130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 340, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 92, "http://www.betterforyouwellness.com/20221130": 9, "http://xbrl.sec.gov/dei/2022": 4, "total": 105 }, "keyCustom": 41, "keyStandard": 195, "memberCustom": 18, "memberStandard": 13, "nsprefix": "bfyw", "nsuri": "http://www.betterforyouwellness.com/20221130", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Business Combinations", "menuCat": "Notes", "order": "10", "role": "http://www.betterforyouwellness.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "11", "role": "http://www.betterforyouwellness.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "12", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Shareholder Equity", "menuCat": "Notes", "order": "13", "role": "http://www.betterforyouwellness.com/role/ShareholderEquity", "shortName": "Shareholder Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Related-Party Transactions", "menuCat": "Notes", "order": "14", "role": "http://www.betterforyouwellness.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Goodwill", "menuCat": "Notes", "order": "15", "role": "http://www.betterforyouwellness.com/role/Goodwill", "shortName": "Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "16", "role": "http://www.betterforyouwellness.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "17", "role": "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Business Combinations (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.betterforyouwellness.com/role/BusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c129", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Organization and Description of Business (Details)", "menuCat": "Details", "order": "19", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c101", "decimals": null, "lang": "en-US", "name": "us-gaap:IntercompanyAgreementsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheet (unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheet (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "20", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SupplementalDeferredPurchasePrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Business Combinations (Details)", "menuCat": "Details", "order": "21", "role": "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails", "shortName": "Business Combinations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SupplementalDeferredPurchasePrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c102", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities", "menuCat": "Details", "order": "22", "role": "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable", "shortName": "Business Combinations (Details) - Schedule of fair value of such assets and liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c102", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenuesNetOfInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Business Combinations (Details) - Schedule of condensed consolidated results of operations", "menuCat": "Details", "order": "23", "role": "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable", "shortName": "Business Combinations (Details) - Schedule of condensed consolidated results of operations", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenuesNetOfInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "bfyw:Revenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Business Combinations (Details) - Schedule of revenue and earnings of Mango Moi", "menuCat": "Details", "order": "24", "role": "http://www.betterforyouwellness.com/role/ScheduleofrevenueandearningsofMangoMoiTable", "shortName": "Business Combinations (Details) - Schedule of revenue and earnings of Mango Moi", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "bfyw:Revenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromSubsidiariesNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "25", "role": "http://www.betterforyouwellness.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromSubsidiariesNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c103", "decimals": "0", "first": true, "lang": null, "name": "bfyw:InvestmentOwnedSubjectToOptionPrices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "26", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c103", "decimals": "0", "first": true, "lang": null, "name": "bfyw:InvestmentOwnedSubjectToOptionPrices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Shareholder Equity (Details)", "menuCat": "Details", "order": "27", "role": "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "shortName": "Shareholder Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "bfyw:DescriptionOfPreferredStockSharesIssuedAndOutstanding", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "bfyw:LoanReceivedFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Related-Party Transactions (Details)", "menuCat": "Details", "order": "28", "role": "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "bfyw:LoanReceivedFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "29", "role": "http://www.betterforyouwellness.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheet (unaudited) (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheet (unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c2", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c48", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit) (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c48", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "7", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Going Concern", "menuCat": "Notes", "order": "9", "role": "http://www.betterforyouwellness.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q1122_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 33, "tag": { "bfyw_AuthorizedTheIssuanceOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized the issuance of common shares.", "label": "Authorized The Issuance Of Common Shares", "terseLabel": "Authorized issuance of common shares" } } }, "localname": "AuthorizedTheIssuanceOfCommonShares", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_BetterForYouWellnessIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Better For You Wellness Inc Member", "terseLabel": "Better for You Wellness, Inc. [Member]" } } }, "localname": "BetterForYouWellnessIncMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_BlackScholesOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Black Scholes Option Member", "terseLabel": "Black-Scholes option [Member]" } } }, "localname": "BlackScholesOptionMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_BusinessAcquisitionsNetIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisitions Net Income Loss", "terseLabel": "Net (loss) income" } } }, "localname": "BusinessAcquisitionsNetIncomeLoss", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "bfyw_BusinessCombinationsDetailsScheduleoffairvalueofsuchassetsandliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Such Assets And Liabilities [Abstract]" } } }, "localname": "BusinessCombinationsDetailsScheduleoffairvalueofsuchassetsandliabilitiesLineItems", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "bfyw_BusinessCombinationsDetailsScheduleoffairvalueofsuchassetsandliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations (Details) - Schedule of fair value of such assets and liabilities [Table]" } } }, "localname": "BusinessCombinationsDetailsScheduleoffairvalueofsuchassetsandliabilitiesTable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "bfyw_CRSConsultingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsulting LLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingLLCMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_CRSConsultingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsultings LLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingsLLCMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_ClosingSharePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Closing share price.", "label": "Closing Share Price", "terseLabel": "Closing share price (in Dollars)" } } }, "localname": "ClosingSharePrice", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_ClosingSharePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Closing share price.", "label": "Closing Share Price Per Share", "terseLabel": "Closing share price per share (in Dollars per share)" } } }, "localname": "ClosingSharePricePerShare", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "bfyw_CommonShareIssuedAfterReorganization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common shares issued after reorganization.", "label": "Common Share Issued After Reorganization", "terseLabel": "Common shares issued after reorganization (in Shares)" } } }, "localname": "CommonShareIssuedAfterReorganization", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_CommonSharesIssuedAfterReorganization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued common shares issued after reorganization.", "label": "Common Shares Issued After Reorganization", "terseLabel": "Common shares issued after reorganization" } } }, "localname": "CommonSharesIssuedAfterReorganization", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_CommonSharesIssuedForDebtSettlementForPurchaseOfSubsititaryNoSubsidiaryAcquiredThis": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of common shares issued for debt settlement for purchase of subsititary/No subsidiary acquired this Q.", "label": "Common Shares Issued For Debt Settlement For Purchase Of Subsititary No Subsidiary Acquired This", "terseLabel": "Common shares issued for Debt settlement" } } }, "localname": "CommonSharesIssuedForDebtSettlementForPurchaseOfSubsititaryNoSubsidiaryAcquiredThis", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_CommonSharesIssuedForDebtSettlementForPurchaseOfSubsititaryNoSubsidiaryAcquiredThisQinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares in common shares issued for debt settlement for purchase of subsititary/No subsidiary acquired this Q.", "label": "Common Shares Issued For Debt Settlement For Purchase Of Subsititary No Subsidiary Acquired This Qin Shares", "terseLabel": "Common shares issued for Debt settlement (in Shares)" } } }, "localname": "CommonSharesIssuedForDebtSettlementForPurchaseOfSubsititaryNoSubsidiaryAcquiredThisQinShares", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_CommonSharesIssuedForNotesPayableExtention": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of common shares issued for notes payable extention.", "label": "Common Shares Issued For Notes Payable Extention", "terseLabel": "Discount on notes payable for warrants" } } }, "localname": "CommonSharesIssuedForNotesPayableExtention", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_CommonStockIssuanceAcquisition": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common Stock Issuance Acquisition.", "label": "Common Stock Issuance Acquisition", "terseLabel": "Proceeds from Common Stock Issuance" } } }, "localname": "CommonStockIssuanceAcquisition", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_ConsiderationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration amount.", "label": "Consideration Amount", "terseLabel": "Consideration amount (in Dollars)" } } }, "localname": "ConsiderationAmount", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_CurrentAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Asset Abstract", "terseLabel": "Current Asset:" } } }, "localname": "CurrentAssetAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "bfyw_DescriptionOfPreferredStockSharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of preferred stock shares issued and outstanding.", "label": "Description Of Preferred Stock Shares Issued And Outstanding", "terseLabel": "Description of preferred stock shares issued and outstanding" } } }, "localname": "DescriptionOfPreferredStockSharesIssuedAndOutstanding", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "xbrltype": "stringItemType" }, "bfyw_ExchangePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exchange Period", "terseLabel": "Exchange period" } } }, "localname": "ExchangePeriod", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "bfyw_ExecutionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Execution Term", "terseLabel": "Execution term" } } }, "localname": "ExecutionTerm", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "bfyw_ExpensesContributedToCapital": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses contributed to capital.", "label": "Expenses Contributed To Capital", "terseLabel": "Expenses contributed to capital" } } }, "localname": "ExpensesContributedToCapital", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_ExtensionValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Extension value.", "label": "Extension Value", "terseLabel": "Extension value (in Dollars)" } } }, "localname": "ExtensionValue", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_FastTrackSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fast Track Solutions Inc Member", "terseLabel": "Fast Track Solutions, Inc. [Member]" } } }, "localname": "FastTrackSolutionsIncMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_ForfeitedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forfeited shares.", "label": "Forfeited Shares", "terseLabel": "Forfeited shares" } } }, "localname": "ForfeitedShares", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_FutureSecuritiesAgreements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Future Securities Agreements", "terseLabel": "Future securities agreements" } } }, "localname": "FutureSecuritiesAgreements", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_GoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernLineItems", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "bfyw_GoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Table]" } } }, "localname": "GoingConcernTable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "bfyw_GreenOhioVenturesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Green Ohio Ventures LLCMember", "terseLabel": "Green Ohio Ventures, LLC [Member]" } } }, "localname": "GreenOhioVenturesLLCMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_IanJamesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ian James Member", "terseLabel": "Ian James [Member]" } } }, "localname": "IanJamesMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "bfyw_ImmediatelyPurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Immediately Purchase", "terseLabel": "Immediately purchase" } } }, "localname": "ImmediatelyPurchase", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_InvestmentOwnedSubjectToOptionPrices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The option price of the investment that is subject to option.", "label": "Investment Owned Subject To Option Prices", "terseLabel": "Option to sell investment" } } }, "localname": "InvestmentOwnedSubjectToOptionPrices", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_JacobEllmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jacob Ellman Member", "terseLabel": "Jacob Ellman [Member]" } } }, "localname": "JacobEllmanMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "bfyw_LoanAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee.", "label": "Loan Amount", "terseLabel": "Loan amount (in Dollars)" } } }, "localname": "LoanAmount", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_LoanReceivedFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received from related party.", "label": "Loan Received From Related Party", "terseLabel": "Loan received" } } }, "localname": "LoanReceivedFromRelatedParty", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_LongTermLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Liabilities Abstract", "terseLabel": "Long-Term Liabilities" } } }, "localname": "LongTermLiabilitiesAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "bfyw_MRKTSGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MRKTSGroup Inc Member", "terseLabel": "MRKTS Group Inc [Member]" } } }, "localname": "MRKTSGroupIncMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_MangoMoiAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mango Moi Abstract", "terseLabel": "Mango Moi:" } } }, "localname": "MangoMoiAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofrevenueandearningsofMangoMoiTable" ], "xbrltype": "stringItemType" }, "bfyw_MangoMoiLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mango Moi LLCMember", "terseLabel": "Mango Moi, LLC [Member]" } } }, "localname": "MangoMoiLLCMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_MangoMoiLLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mango Moi LLMember", "terseLabel": "Mango Moi, LL [Member]" } } }, "localname": "MangoMoiLLMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "bfyw_NevadaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nevada Corporation Member", "terseLabel": "Nevada corporation [Member]" } } }, "localname": "NevadaCorporationMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_NotesPayableShopifysCapital": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes Payable Shopify Capital", "label": "Notes Payable Shopifys Capital", "terseLabel": "Notes Payable Shopify Capital" } } }, "localname": "NotesPayableShopifysCapital", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Line Items]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_OtherIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income Expense Abstract", "terseLabel": "Other Income/(Expense)" } } }, "localname": "OtherIncomeExpenseAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "bfyw_OutstandingSharesCommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Shares Common Stock Percentage", "terseLabel": "Outstanding shares common stock percentage" } } }, "localname": "OutstandingSharesCommonStockPercentage", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "bfyw_PredecessorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Predecessors Member", "terseLabel": "Predecessor [Member]" } } }, "localname": "PredecessorsMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_PreferredShareIssuedAfterReorganization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of preferred shares issued after reorganization.", "label": "Preferred Share Issued After Reorganization", "terseLabel": "Preferred shares issued after reorganization (in Shares)" } } }, "localname": "PreferredShareIssuedAfterReorganization", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_PreferredSharesIssuedAfterReorganization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred shares issued after reorganization.", "label": "Preferred Shares Issued After Reorganization", "terseLabel": "Preferred shares issued after reorganization" } } }, "localname": "PreferredSharesIssuedAfterReorganization", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_ProceedsFromRestrictedCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Restricted Common Stock", "terseLabel": "Restricted common stock (in Dollars)" } } }, "localname": "ProceedsFromRestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_PurchaseCommitmentShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.", "label": "Purchase Commitment Shares", "terseLabel": "Commitment shares" } } }, "localname": "PurchaseCommitmentShares", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_PurchasePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Price Member", "terseLabel": "Purchase Price [Member]" } } }, "localname": "PurchasePriceMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for related parties.", "label": "Related Parties Policy Text Block", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "bfyw_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "bfyw_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "bfyw_RestrictedCommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Common Stock Percentage", "terseLabel": "Restricted common stock percentage" } } }, "localname": "RestrictedCommonStockPercentage", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "bfyw_RestrictedCommonStocks": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Common Stocks.", "label": "Restricted Common Stocks", "terseLabel": "Restricted common stock" } } }, "localname": "RestrictedCommonStocks", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_RetireLoanAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The retire loan amount.", "label": "Retire Loan Amount", "terseLabel": "Retire loan amount" } } }, "localname": "RetireLoanAmount", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_Revenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue from market data services, including, but not limited to, information about current quotes and most recent prices for a specific security.", "label": "Revenue", "terseLabel": "Total revenues" } } }, "localname": "Revenue", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofrevenueandearningsofMangoMoiTable" ], "xbrltype": "monetaryItemType" }, "bfyw_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Abstract", "terseLabel": "Revenue" } } }, "localname": "RevenueAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "bfyw_RevenuePayable": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Revenue Payable", "terseLabel": "Illinois Department of Revenue Payable" } } }, "localname": "RevenuePayable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "bfyw_SRAXIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SRAXInc Member", "terseLabel": "SRAX, Inc [Member]" } } }, "localname": "SRAXIncMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_SauerEnergyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sauer Energy Inc Member", "terseLabel": "Sauer Energy, Inc. [Member]" } } }, "localname": "SauerEnergyIncMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_ScheduleOfCondensedConsolidatedResultsOfOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Condensed Consolidated Results Of Operations Abstract" } } }, "localname": "ScheduleOfCondensedConsolidatedResultsOfOperationsAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "xbrltype": "stringItemType" }, "bfyw_ScheduleOfFairValueOfSuchAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Such Assets And Liabilities Abstract" } } }, "localname": "ScheduleOfFairValueOfSuchAssetsAndLiabilitiesAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "xbrltype": "stringItemType" }, "bfyw_ScheduleOfRevenueAndEarningsOfMangoMoiAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Revenue And Earnings Of Mango Moi Abstract" } } }, "localname": "ScheduleOfRevenueAndEarningsOfMangoMoiAbstract", "nsuri": "http://www.betterforyouwellness.com/20221130", "xbrltype": "stringItemType" }, "bfyw_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresdescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeituresdescription", "terseLabel": "Share cancellation and forfeiture agreement description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresdescription", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Line Items]" } } }, "localname": "ShareholderEquityDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Table]" } } }, "localname": "ShareholderEquityDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity Line Items", "terseLabel": "Shareholder Equity [Abstract]" } } }, "localname": "ShareholderEquityLineItems", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity [Table]" } } }, "localname": "ShareholderEquityTable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderOwningPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shareholders have priority over a company's income, meaning they are paid dividends before common shareholders. Common stockholders are last in line when it comes to company assets, which means they will be paid out after creditors, bondholders, and preferred shareholders.", "label": "Shareholder Owning Preferred Stock", "terseLabel": "Shareholder owning preferred stock" } } }, "localname": "ShareholderOwningPreferredStock", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SharesCancelable": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of shares cancelable.", "label": "Shares Cancelable", "terseLabel": "Shares Cancelable" } } }, "localname": "SharesCancelable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "bfyw_SharesCancelableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Cancelable Member", "terseLabel": "Shares Cancelable" } } }, "localname": "SharesCancelableMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "bfyw_SharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The security that represents ownership in a corporation. Holders of common stock elect the board of directors and vote on corporate policies. This form of equity ownership typically yields higher rates of return long term.", "label": "Shares Of Common Stock", "terseLabel": "Shares of common stock" } } }, "localname": "SharesOfCommonStock", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SharesOfRestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock refers to unregistered shares of ownership in a corporation that are issued to corporate affiliates, such as executives and directors. Restricted stock is non-transferable and must be traded in compliance with special Securities and Exchange Commission (SEC) regulations.", "label": "Shares Of Restricted Common Stock", "terseLabel": "Shares of restricted common stock" } } }, "localname": "SharesOfRestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StephenLetourneauMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stephen Letourneau Member", "terseLabel": "Stephen Letourneau [Member]" } } }, "localname": "StephenLetourneauMember", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "bfyw_StockOptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option description.", "label": "Stock Option Description", "terseLabel": "Stock option, description" } } }, "localname": "StockOptionDescription", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StockissuanceofwarrantsWarrantIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Issuance.", "label": "Stockissuanceofwarrants Warrant Issuance", "terseLabel": "Warrant Issuance" } } }, "localname": "StockissuanceofwarrantsWarrantIssuance", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20221130", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Leader of board of directors.", "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors Chairman [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CondensedIncomeStatementTable": { "auth_ref": [ "r133", "r320", "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table]" } } }, "localname": "CondensedIncomeStatementTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "stringItemType" }, "srt_CondensedIncomeStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Condensed Consolidated Results Of Operations [Abstract]" } } }, "localname": "CondensedIncomeStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r133", "r256", "r257", "r258", "r259", "r282", "r315", "r319", "r370", "r373", "r374", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r133", "r256", "r257", "r258", "r259", "r282", "r315", "r319", "r370", "r373", "r374", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]", "terseLabel": "Board of Directors [Member]", "verboseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r187", "r188", "r189", "r190", "r221", "r287", "r306", "r316", "r317", "r334", "r337", "r339", "r375", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r187", "r188", "r189", "r190", "r221", "r287", "r306", "r316", "r317", "r334", "r337", "r339", "r375", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r187", "r188", "r189", "r190", "r219", "r221", "r227", "r228", "r229", "r286", "r287", "r306", "r316", "r317", "r334", "r337", "r339", "r368", "r375", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r187", "r188", "r189", "r190", "r219", "r221", "r227", "r228", "r229", "r286", "r287", "r306", "r316", "r317", "r334", "r337", "r339", "r368", "r375", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r147", "r222", "r345", "r362" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable", "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "auth_ref": [ "r358", "r392" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table Text Block]", "terseLabel": "Schedule of condensed consolidated results of operations" } } }, "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r147", "r222", "r345", "r347", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable", "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r364", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r177", "r178" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r87", "r89", "r116", "r357" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Related Party Receivable" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r5", "r338" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r232", "r233", "r234", "r359", "r360", "r361", "r380" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": { "auth_ref": [ "r59", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.", "label": "Adjustments to Additional Paid in Capital, Fair Value", "terseLabel": "Warrant Issuance" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile Net Loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock option expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "terseLabel": "Share Based expense" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestment": { "auth_ref": [ "r264", "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.", "label": "Alternative Investment", "terseLabel": "Related party fund (in Dollars)" } } }, "localname": "AlternativeInvestment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r202", "r274", "r332", "r333", "r354" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortized debt discount and debt issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r96", "r112", "r131", "r165", "r168", "r172", "r179", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r256", "r258", "r266", "r338", "r371", "r372", "r384" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r108", "r119", "r131", "r179", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r256", "r258", "r266", "r338", "r371", "r372", "r384" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Significant Accounting Policies and Use of Estimates" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r254", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r71", "r72", "r254", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Voting, percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Loss per share (in Dollars per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity.", "label": "Business Acquisitions, Purchase Price Allocation, Subsequent Years, Remaining Adjustments", "terseLabel": "Purchase price" } } }, "localname": "BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r76", "r77", "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Paid consideration (in Dollars)" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r79", "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total Assets Acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r74" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "terseLabel": "Sales Tax Payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r74" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Clearbanc Debit Card" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r74" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt", "terseLabel": "Notes Payable - PayPal Capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r74" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "terseLabel": "Notes Payable Shopify Capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r73", "r74" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total Liabilities Assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r73", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Owning, percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CapitalUnitsOutstanding": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Number of capital units or capital shares outstanding. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital Units, Outstanding", "terseLabel": "Issued and outstanding capital" } } }, "localname": "CapitalUnitsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r37", "r110", "r321" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r32", "r37", "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of period:", "periodStartLabel": "Cash at beginning of period:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r32", "r86" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net Change in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r113", "r114", "r115", "r131", "r149", "r150", "r152", "r154", "r157", "r158", "r179", "r191", "r194", "r195", "r196", "r200", "r201", "r203", "r204", "r206", "r210", "r216", "r266", "r318", "r344", "r355", "r363" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r58", "r185", "r186", "r312", "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Issuance of common shares" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r359", "r360", "r380" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "terseLabel": "Common shares, outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, shares issued (in Shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r59" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r338" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($.0001 par value, 500,000,000 shares authorized, 389,995,988 and 370,747,042 issued and outstanding as of November 30, 2022 and February 28, 2022, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r80", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r39", "r40", "r41" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Description", "terseLabel": "Purchase agreement description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r23", "r288" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Good Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r39", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Common shares issued for debt, amount (in Dollars)" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage", "terseLabel": "Deferred compensation percentage" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total fair value of shares issued during the period under a deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued", "terseLabel": "Deferred amount" } } }, "localname": "DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r20", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Deferred Compensation Equity", "terseLabel": "Deferred compensation" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r63", "r64" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current", "terseLabel": "Deferred Compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFuelCost": { "auth_ref": [ "r104" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of capitalized fuel costs of a regulated entity that are expected to be recoverable through rate adjustments within one year or the normal operating cycle, if longer.", "label": "Deferred Fuel Cost", "terseLabel": "Prepaids and other assets" } } }, "localname": "DeferredFuelCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r69", "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Deferred Tax Assets, Capital Loss Carryforwards", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r35", "r56" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r82", "r83", "r84", "r85", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r11", "r193", "r194", "r195", "r199", "r200", "r201", "r279", "r357" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Related Party Notes Payable" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r127", "r139", "r140", "r141", "r142", "r143", "r148", "r149", "r152", "r153", "r154", "r155", "r262", "r263", "r302", "r305", "r328" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Loss per share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r132", "r239", "r249" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r59", "r106", "r123", "r124", "r125", "r134", "r135", "r136", "r138", "r144", "r146", "r156", "r180", "r218", "r232", "r233", "r234", "r246", "r247", "r261", "r267", "r268", "r269", "r270", "r271", "r272", "r275", "r307", "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of excess stock shares permitted to be issued.", "label": "Excess Stock, Shares Authorized", "terseLabel": "Stock authorized to issue (in Shares)" } } }, "localname": "ExcessStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares of common stock", "verboseLabel": "Issuance of common stock" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r111", "r183", "r301", "r331", "r338", "r366", "r367" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/Goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillOtherIncreaseDecrease": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Other Increase (Decrease)", "terseLabel": "Goodwill" } } }, "localname": "GoodwillOtherIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r22", "r131", "r165", "r167", "r171", "r173", "r179", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r266", "r330", "r371" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromSubsidiariesNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity.", "label": "Income (Loss) from Subsidiaries, Net of Tax", "terseLabel": "Net operating loss" } } }, "localname": "IncomeLossFromSubsidiariesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r132", "r240", "r241", "r244", "r248", "r250", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r122", "r237", "r238", "r241", "r242", "r243", "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Related party receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued Interest" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesPayableRelatedParties": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount owed by the reporting entry in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Notes Payable, Related Parties", "terseLabel": "Related party notes payable" } } }, "localname": "IncreaseDecreaseInNotesPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r353" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntercompanyAgreementsDescription": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Description of product support, consulting, business, or other advisory service agreements entered into between the managing member or general partner and the LLC or LP, affiliate of the managing member or general partner, or affiliate of the LLC or LP. Includes a description of the key provisions of such agreements and the amount of compensation for such services during the accounting period.", "label": "Intercompany Agreements, Description", "terseLabel": "Director agreement, description" } } }, "localname": "IntercompanyAgreementsDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest Expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r117", "r322", "r338" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r131", "r179", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r257", "r258", "r259", "r266", "r329", "r371", "r384", "r385" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r92", "r98", "r338", "r356", "r365", "r381" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES & EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r109", "r131", "r179", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r257", "r258", "r259", "r266", "r338", "r371", "r384", "r385" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r2", "r91", "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable", "terseLabel": "Loan Amount" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r15" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Notes Payable - PayPal Capital" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorityShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.", "label": "Majority Shareholder [Member]", "terseLabel": "Restricted Common Stock [Member]" } } }, "localname": "MajorityShareholderMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r128" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r128" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r32", "r33", "r36" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r21", "r36", "r94", "r101", "r107", "r120", "r121", "r125", "r131", "r137", "r139", "r140", "r141", "r142", "r145", "r146", "r151", "r165", "r167", "r171", "r173", "r179", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r263", "r266", "r330", "r371" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net income/(loss)", "verboseLabel": "Net (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAllocatedToGeneralPartners": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of net income allocated to general partners.", "label": "Net Income (Loss) Allocated to General Partners", "terseLabel": "Net income" } } }, "localname": "NetIncomeLossAllocatedToGeneralPartners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofrevenueandearningsofMangoMoiTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "NON-CASH FINANCING TRANSACTIONS:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r26" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Out Of Scope Agency Payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold", "terseLabel": "Additional fees" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r165", "r167", "r171", "r173", "r330" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income/(Loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r81" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r19", "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Other Additional Capital", "terseLabel": "additional paid-in capital (in Dollars)" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r25", "r102" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "negatedLabel": "Other Expense", "terseLabel": "Option vestment/expense (in Dollars)" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLoansPayableLongTerm": { "auth_ref": [ "r15" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term loans classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Loans Payable, Long-Term, Noncurrent", "terseLabel": "Convertible notes payable, net accumulated interest" } } }, "localname": "OtherLoansPayableLongTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapital": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of ownership interest of different classes of partners in limited partnership.", "label": "Partners' Capital", "terseLabel": "Holder balance, amount (in Dollars)" } } }, "localname": "PartnersCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r31" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r28" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Fixed Assets" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r3", "r203" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r3", "r203" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r3", "r338" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock ( $.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of November 30, 2022 and February 28, 2022)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r118", "r181", "r182", "r323" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification of Prior Year Presentation" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Warrant Issuance" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Proceeds from Convertible loan, net of original issue discount" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSubordinatedShortTermDebt": { "auth_ref": [ "r30" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer.", "label": "Proceeds from Subordinated Short-Term Debt", "terseLabel": "Proceed from related party note payable" } } }, "localname": "ProceedsFromSubordinatedShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r57", "r99", "r304", "r338" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r57", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r220", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology": { "auth_ref": [ "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in tax expense resulting from change in methodology used to allocate tax expense to members of a group for which a consolidated tax return is filed.", "label": "Related Party Tax Expense Effect of Change in Allocation Methodology", "terseLabel": "Sale of subsidary" } } }, "localname": "RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r105", "r278", "r279", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r220", "r278", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r276", "r277", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r60", "r97", "r310", "r311", "r338" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r106", "r134", "r135", "r136", "r138", "r144", "r146", "r180", "r232", "r233", "r234", "r246", "r247", "r261", "r307", "r309" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r126", "r131", "r163", "r164", "r166", "r169", "r170", "r174", "r175", "r176", "r179", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r266", "r303", "r371" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Merchandise Sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesNetOfInterestExpense": { "auth_ref": [ "r163", "r164", "r166", "r169", "r170", "r174", "r175", "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues, Net of Interest Expense", "terseLabel": "Total revenues" } } }, "localname": "RevenuesNetOfInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stocke per share (in Dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of fair value of such assets and liabilities" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r50", "r51", "r52", "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "amounts of revenue and earnings of Mango Moi" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r24" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r350", "r351", "r376" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A", "verboseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share based expenses" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Stock option outstanding intrinsic value (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Restricted common shares, price per share (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r230", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "terseLabel": "Number of vested shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock option expire term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Stock options fair value the grant date (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Transfer of shares", "verboseLabel": "Issuance of common stock shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Price per share (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermNonBankLoansAndNotesPayable": { "auth_ref": [ "r10" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer.", "label": "Short-Term Non-bank Loans and Notes Payable", "terseLabel": "Clearbanc Debit Card" } } }, "localname": "ShortTermNonBankLoansAndNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r43", "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantPurchaseCommitmentDescription": { "auth_ref": [ "r16", "r93", "r100" ], "lang": { "en-us": { "role": { "documentation": "Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.", "label": "Purchase Commitment, Description", "terseLabel": "Purchase agreement description" } } }, "localname": "SignificantPurchaseCommitmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r113", "r114", "r115", "r131", "r149", "r150", "r152", "r154", "r157", "r158", "r179", "r191", "r194", "r195", "r196", "r200", "r201", "r203", "r204", "r206", "r210", "r216", "r266", "r318", "r344", "r355", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r59", "r106", "r123", "r124", "r125", "r134", "r135", "r136", "r138", "r144", "r146", "r156", "r180", "r218", "r232", "r233", "r234", "r246", "r247", "r261", "r267", "r268", "r269", "r270", "r271", "r272", "r275", "r307", "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r134", "r135", "r136", "r156", "r288" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r39", "r40", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Warrants issued and extended for common stock issuance costs" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r3", "r4", "r60" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Common shares issued for notes payable extension (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Common share issued for services to the Company (in Shares)", "verboseLabel": "Common shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Common shares issued for cash received (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Common shares issued for purchase of subsidiary (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r59", "r60" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r18", "r59", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common shares issued for notes payable extension" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r18", "r59", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "terseLabel": "Debt Forgiveness" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common share issued for services to the Company" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r3", "r4", "r59", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Expenses paid on behalf of the Company and contributed to capital" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Common shares issued for cash received" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Common shares issued for purchase of subsidiary" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r59", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Forfeiture of stock compensation" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionExercisePriceDecrease": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.", "label": "Stock Option, Exercise Price, Decrease", "terseLabel": "Exercise price per shares (in Dollars per share)" } } }, "localname": "StockOptionExercisePriceDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "Total stock option expense (in Dollars)" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Shares", "terseLabel": "Common shares canceled and returned to the Company (in Shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Value", "terseLabel": "Common shares canceled and returned to the Company" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r53", "r338", "r356", "r365", "r381" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r62", "r130", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r218", "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholder Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r273", "r284" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r273", "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r273", "r284" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r283", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r39", "r40", "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Supplemental Deferred Purchase Price", "terseLabel": "Purchase price of stock" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized stock option expense (in Dollars)" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r47", "r48", "r49", "r159", "r160", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r148", "r154" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "terseLabel": "Restricted common shares (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "340", "Topic": "980", "URI": "https://asc.fasb.org/extlink&oid=123417213&loc=d3e43603-110378", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868742-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "a", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r341": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r342": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r343": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 45 0001213900-23-017302-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-017302-xbrl.zip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